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Abstract  
Recent findings suggest that oxidative stress (OS) has an important role in the 
pathophysiology of major depressive disorder (MDD), however the underlying 
molecular mechanisms are still poorly understood. In this project, I set up an 
experimental in vitro OS model, using a human hippocampal progenitor cell line 
HPC0A07/03C capable of neurogenesis, to study molecular mechanisms potentially 
involved in the pathogenesis of this disorder and to evaluate the possible antioxidative 
properties of compounds with antidepressant properties.  
Alterations of redox homeostasis were induced by treatment of the cells with a range 
of concentrations of tert-butyl hydroperoxide (t-BHP); higher doses were cytotoxic 
and lower doses led to major changes in neurogenesis and activation of the 
transcription factors Nrf2 and NF-κB in a dose-dependent manner. Potential redox-
signalling pathways involved in regulating neurogenesis were studied. Inhibition of 
the t-BHP–induced ERK1/2 activation abrogated the increased differentiation of 
progenitor cells into mature neurons observed upon oxidative stimulus. I tested 
various compounds for their antioxidative properties and found that the omega-3 fatty 
acid eicosapentaenoic acid (EPA), as well as the conventional antioxidants N-acetyl-
cysteine (NAC) and glutathione (GSH) prevented the oxidative damage inflicted by t-
BHP, with no effects observed for sertraline, venlafaxine, ketamine or 
docosahexaenoic acid (DHA). Both EPA and GSH differentially regulated the 
expression of genes involved in the OS response, including Keap1, HMOX1, SLC7A11 
and SLC1A1. 
Data obtained in this research project indicate that depending on the dose ROS can 
have detrimental effects on the viability and molecular profile of human hippocampal 
progenitor cells or facilitate neurobiological processes that are essential for normal 
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cellular functioning and adaptation of the organism to environmental stimuli. 
Remarkably, EPA, known to exhibit antidepressant properties, elicited favourable 
effects in my OS in vitro model and appears to be a promising compound for further 
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1   Introduction 
In the introduction I will present major depressive disorder (MDD) in the context of 
the neuroprogressive concept, resembling similar clinical, structural and molecular 
abnormalities observed in neurodegenerative disorders. Hippocampus and adult 
hippocampal neurogenesis that are known to be affected in MDD are then discussed 
to provide a rational for using the cell line utilised in this thesis. Oxidative stress 
(OS), various aspects of redox biology and molecular mechanisms that have been 
implicated in the pathogenesis MDD are summarised, including sections on specific 
redox-relevant molecular aspects that have been further investigated in this project. 
Evidence of the involvement of OS in the pathogenesis of MDD, which is the major 
focus of this thesis, is critically reviewed covering clinical and animal studies. This is 
followed by a discussion of antidepressant and antioxidative properties of various 
compounds with a particular emphasis of omega-3 fatty acids, which have been 
examined in this project.  
 
 
1.1   Major depressive disorder 
 
1.1.1   Definition of depression 
MDD is a multifactorial complex disorder characterised primarily by persistent low 
mood or loss of interest or pleasure in usual activities. These are core symptoms that 
are often accompanied by diminished ability to think or concentrate, weight changes, 
insomnia or hypersomnia, fatigue or loss of energy, psychomotor agitation or 
retardation, feelings of worthlessness or excessive or inappropriate guilt and recurrent 
suicidal ideation in most severe cases. The symptoms cause significant distress and 
 24 
impairment in patient’s everyday life and are not due to any general medical condition 
or physiological effects of medication or other substances. These are the diagnostic 
criteria of depression that are formulated in the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5, 2013) published by the American 
Psychiatric Association and in the International Classification of Diseases, (ICD-10, 
2007) published by the World Health Organisation (WHO) and used across its 
member states. 
Depressive symptoms are normally assessed by a psychiatrist, psychologist or a 
general practitioner using a variety of scales including the Hamilton Depression 
Rating Scale (HAM-D) that has been used for the last 40 years as a golden standard 
(Bagby et al., 2004). Despite a huge range of instruments for identifying depression 
being available, there is still no biological test that can confirm the presence of this 
disorder. This obstacle raises a great concern about the objectification of the 
diagnosis. Clinicians aim at justifying the predominant symptomatology and possible 
biological, psychological and social factors, which may impact on a patient’s mood 
and the course of the disease, in order to suggest the most relevant treatment option.  
Notably, despite all the psychological and biological treatments being administered to 
patients, major challenges such as achieving only partial therapeutic response, high 
levels of relapses and recurrence and treatment resistant cases are to be addressed 
(Richards, 2011).  
Additionally, the fact that the first line treatment of depression remains to be 
antidepressants, which is a biological treatment, and the absence of a clinically valid 
biological confirmation of the disorder brings up the importance of delineating 
molecular mechanisms of depression. Moreover, there is currently no way to 
determine which antidepressant will work best for a given patient and there is lack of 
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guidance in the medical literature for clinicians to decide which drug to try next if one 
does not show a desirable effect. Furthermore, the fact that in other areas of medicine 
the diagnostic is defined by validated biomarkers and the absence of such a biomarker 
in depression creates stigma around individuals suffering from depression as the 
society often doubts that the disorder is “real”, which also hinders patient’s recovery. 
The validated biomarkers are measurable ‘objective physiological indicators of 
normal biological processes, pathogenic processes or response to a specific 
therapeutic intervention’ (Colburn et al., 2001). The benefits of having and 
identifying an aetiologically-sound and objective panel of biomarkers for depression 
are significant. Biomarkers can be used to confirm the presence of the disorder, to 
predict probability of its onset, to indicate the disease prognosis, to classify the 
disorder according to severity and symptomatology, to predict response and track 
progress following a therapeutic intervention (Colburn et al., 2001; Gururajan et al., 
2016), and finally, to combat stigma surrounding depressive disorder. 
Realistically, in most patients the complex and heterogeneous nature of depression 
has contributions from multiple pathways that are likely to be dependent of one 
another; therefore, identifying a single biomarker might not be sufficient. In any case, 
this information gap can be addressed by research that is aimed at identifying 
particular molecular mechanisms thought to be involved in the pathogenesis of 
depression. This would help to identify potential biomarkers which could be used as a 
diagnostic marker of depression and antidepressant treatment outcome along with 
new targets for designing efficient pharmacological treatments. 
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1.1.2   Prevalence of major depressive disorder and associated risks with the 
disease 
According to the WHO depression is the leading cause of disability worldwide, and is 
a major contributor to the global burden of disease with an estimated 350 million 
people affected globally (who.org). WHO projects that the disability adjusted life-
years (the sum of life-years lost due to premature death and years lived with disability 
adjusted for severity) will be the highest for depression by 2030 (Lepine and Briley, 
2011). That means dramatic economic consequences for the modern society due to 
decreased workplace productivity and absenteeism resulting in lowered income or 
unemployment. Over 75% of patients with major depression experience repeated 
episodes and exacerbations throughout life. More than 50% of patients who recover 
from a first depressive episode have a second within six months unless they are given 
maintenance antidepressant treatment (Gold et al., 2015). Moreover, only partial 
response to treatment is often achieved. The mortality risk for suicide in depressed 
patients is more than 20-fold greater than in the general population (Bostwick and 
Pankratz, 2000) and as many as 15% of patients who never receive any treatment 
attempt suicide (Gold et al., 2015). The problem of MDD extends far beyond the 
illness itself affecting not only the quality of life but also the life expectancy and 
general health condition of an affected individual. A great number of studies reported 
increased mortality and morbidity rates associated with depression (Maurya et al., 
2016). In particular, evidence supports an association between both late-life as well as 
early-life depression and dementia (Bennett and Thomas, 2014; Byers and Yaffe, 
2011; Cherbuin et al., 2015; Geerlings et al., 2008). As such, subjects with an early 
onset of  depression showed increased risk for Alzheimer’s disease (Geerlings et al., 
2008), while  individuals with late-life depression have been consistently associated 
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with a two-fold increased risk of different types of dementia, as reported by a recent 
meta-analysis that included a sample size of 66535 participants (Cherbuin et al., 
2015). It is clear that depression presents a major challenge for society that will 
benefit from further research. 
 
 
1.1.3   Etiological factors of depression 
Risks factors for depression fall into two larger categories - genetic and 
environmental, either on their own or most commonly interacting with each other. 
Inherited risk factors include a family history of depression, female gender and certain 
personality traits. Genetic preconditions also encompass variants in particular genes, 
such as the serotonin transporter (SLC6A4) and brain-derived neurotrophic factor 
(BDNF) genes. Environmental determinants include early life stress or trauma, 
maternal depression, unhealthy lifestyle choices and stressful life events later in life 
(Heim and Binder, 2012). Both risks will be described in further detail. 
 
 
1.1.3.1   Genetic vulnerability to depression 
Genetic heritability for MDD is estimated to be around 35-40% (Jansen et al., 2015). 
A family history of depression is widely known to be a major risk factor for 
developing depression at some point of an individual’s life (Monroe et al., 2014). 
Family studies have shown that the risk of MDD manifestation in the offspring of 
parents with MDD is more than 3-fold. A three-generation study identified that almost 
60% of the grandchildren who had a family history of depression in two previous 
generations already had some psychiatric disorders at the mean age of 12 years. 
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Additionally, increased familial prevalence of MDD has been associated with an early 
age at onset and recurrence of the disease (Weissman et al., 2005). 
Several genome-wide association studies (GWAS) have not yet yielded replicable 
findings for MDD (Bosker et al., 2011). This is explained by the small number of 
MDD cases evaluated for such studies, the clinical heterogeneity of the disorder, a 
modest heritability, the complexity of the genetic architecture for depression and 
interactions of genetic vulnerability with environmental susceptibility factors. 
However, a recent GWAS pathway analysis of over 60000 cases found significant 
associations between immune, neuronal signalling, synaptic density, histone cascades 
and psychiatric disorders, including MDD, suggesting a clustering of risk variants in 
these disorders (The Network and Pathway Analysis Subgroup of the Psychiatric 
Genomics Consortium, 2015). 
The underlying genetic factors most explored have been the gene variants in the 
SLC6A4 and BDNF genes. Results from studies that investigated the Val66Met 
polymorphism in the BDNF gene, coding for the protein with the same name being 
involved in a wide repertoire of neuronal functions, are mostly mixed (Lohoff, 
2010). Findings in the meta-analysis that included 22 studies with a pooled total of 
14233 participants suggest that the Met allele of  BDNF Val66Met significantly 
moderates the relationship between stressful life events and depression (Hosang et al., 
2014). A polymorphism in the serotonin-transporter-linked polymorphic region (5-
HTTLPR) of the gene that codes for the serotonin transporter (SERT) has been found 
to affect the transcription rate of the gene, with the short (s) allele transcriptionally 
less efficient in removing serotonin from the synapse and returning it to the 
presynaptic neuron than the alternate long (l) allele (Karg et al., 2011). The pioneer 
epidemiological study of Caspi and colleagues in 2003 (Caspi et al., 2003) that was 
 29 
numerously replicated afterwards (Eley et al., 2004; Zalsman et al., 2006) provided 
evidence that the less functional s allele is associated with increased stress sensitivity 
and therefore with higher vulnerability to depression. Interestingly, another study 
demonstrated that the responses of males and females carrying the short 5-HTTLPR 
allele to environmental stress factors go in opposite direction; females tended to 
develop depressive symptoms, whereas males did not (Sjöberg et al., 2006).  
This brings up another predisposing factor for depression, which is being female, with 
a female:male prevalence ratio of MDD of around 2:1 (Angst and Merikangas, 1997; 
Kessler et al., 2003). Clinical data indicate that gonadal hormones have a significant 
impact on mood in women (Altemus et al., 2014). Interestingly, women are more 
likely to suffer from depression during episodes of marked hormonal fluctuations 
including the premenstrual, postpartum (Buttner et al., 2013) and perimenopausal 
periods (Tangen and Mykletun, 2008), that are concomitant with a decline in 17-β 
estradiol. These observations together with numerous data from animal models, where 
rats exhibit depressive-like behaviours upon withdrawal of 17-β estradiol (Stoffel and 
Craft, 2004) which is reversed by 17-β estradiol treatment (Galea et al., 2001), 
suggest that this hormone is necessary for mood regulation. However, some studies 
failed to reproduce these findings (Galea et al., 2002), likely due to differences in the 
dosage and duration of treatment. The biological effects of 17-β estradiol on 
emotional regulation are not surprising, since two intracellular oestrogen 
receptors (ERα and ERβ) are prevalent throughout brain areas implicated in 
maintenance of mood, including the hippocampus. The activation of intracellular 
oestrogen receptors results in changes in gene transcription, whereas binding to 
membrane oestrogen receptors triggers activation of different signalling cascades 
(Solomon and Herman, 2009). While animal data indicate that the distribution of 
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central ERα and ERβ is similar between females and males, mRNA and protein 
expression levels in some brain regions are higher in females (Orikasa and Sakuma, 
2004). Presumably, the higher incidence of depression in women could be associated 
with frequent changes in female sex hormones profile. 
Additionally, personality traits such as neuroticism, which is the tendency to 
experience diverse and relatively more intense negative emotions, have also been 
implicated as a risk factor for depression already a long time ago (Nolan and 
O’Malley, 1988) and reconfirmed later (De Moor et al., 2015).  
 
 
1.1.3.2   Environmental risk factors for depression 
Early life stress (ELS) is a broad term that encompasses such experiences in 
childhood as natural disasters, war, maltreatment, sexual or physical abuse, severe 
neglect as well as adverse family environment, such as maternal depression, parental 
loss or divorce (Nugent et al., 2011). ELS is an established predictor of a wide range 
of adverse life experiences across the lifespan, including depression. Preclinical 
models of ELS in laboratory animals have become increasingly popular in studies on 
the pathogenesis of affective disorders and the development of novel pharmacological 
approaches to these conditions (Molet et al., 2014). Maternal depression in pregnancy 
is another important risk factor for offspring depression in early adulthood. A 
prospective study identified that adult offspring exposed to maternal depression in 
pregnancy was 3.4 times more likely to have a depressive disorder (Plant et al., 2015). 
The evidence for the effects of maternal stress, depression and substance use on 
adverse neurodevelopmental outcomes for the child is substantial, and known as 
“foetal programming” (Dunkel Schetter and Tanner, 2012; Glover, 2014; Moisiadis 
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and Matthews, 2014). However, the number of longitudinal studies that have 
investigated the effects of various antenatal factors on the development of depression 
in adolescent or adult offspring is limited. Major findings on prenatal environmental 
exposures and foetal origins of depression from human studies are summarized in 
Table 1. Psychological stress at any time in life has been repeatedly linked to the 
onset of depression, being recognised now as a major risk and trigger factor for this 
condition (Cohen et al., 2007).  
It is well established that all of the above aspects are important risk factors for 
depression, however one does not invariably lead to psychopathology. Partially, this 
is explained by gene-environment interactions where genetic differences influence the 
likelihood that exposure to different factors will eventually result in a mood disorder. 
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exhibited by children 
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major depressive disorder 
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35% met criteria for 









exposure and child 
depressive symptoms, 
and the mediating 
effects of maternal and 
child characteristics 
42 mother-child 
(4–5 years old) 
dyads 
Structural equation 
modelling indicated that 
prenatal alcohol exposure 
was associated with higher 










anxiety is associated 
with disturbances in 
HPA-axis regulation 
and whether the HPA-
axis dysregulation 
mediates the association 
between antenatal 
maternal anxiety and 
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associated with a high, 
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adolescents only, was 
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31 adults Healthy young adults 
whose mothers 
experienced severe stress 
during their pregnancy had 
significantly higher ACTH 
(adrenocorticotropic 
hormone) in response to 
the Trier Social Stress Test 
and lower cortisol in 
response to a 1µg ACTH 
stimulation test in 
comparison with control 
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to ACTH stimulation are 
indicative of HPA axis 
dysregulation, constantly 






predicts depression in 
adolescent offspring 
125 mother-
child (16 years) 
dyads 
 
The risk of depression for 
the 16-year-olds exposed 
to antenatal depression was 
4.7 times greater than for 







symptoms of antenatal 
and postnatal parental 
depression with 
offspring depression at 







age 18 years 
 
Offspring were 1.28 times 
more likely to have 
depression at age 18 years 
for each standard deviation 
increase in maternal 
depression score 
antenatally, independent of 





whether there is an 
association between 
offspring exposure to 
maternal depression in 
pregnancy and 





Adult offspring exposed to 
maternal depression in 
pregnancy were 3.4 times 






Table 1. The evidence for foetal programming of depression. 
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1.1.4   Neuroprogressive nature of depression: introduction of the concept 
Ultimately, the combination of environmental and genetic risk factors can lead to a 
depressive episode, and along with clinical symptoms, structural and molecular 
changes have been observed across many different studies. MDD is a multifactorial 
mood disorder with etiologically heterogeneous symptoms that has been proposed to 
have a neuroprogressive nature. Neuroprogression is considered a potentially 
progressive stage-related process of neurodegeneration that includes apoptosis, 
reduced neurogenesis, reduced neuronal plasticity and increased autoimmune 
responses (Moylan et al., 2013; Vaváková et al., 2015). The phenomenon of 
neuroprogression can be recognized on clinical, structural and biochemical levels in 
MDD. On a clinical level it is common for patients to have increasing number and 
length of depressive episodes, a progressive reduction in inter-episode duration, poor 
response to treatment with the time course of the disease and functional and cognitive 
decline (Moylan et al., 2013). This could be partially explained by the sensitization 
theory, suggesting that repeated administration of psychological or organic stressors 
causes progressive time-dependent amplification of neuronal responses leading to 
increased susceptibility to further stimuli (Ursin, 2014).  
Different studies suggest that a history of depression is associated with an increased 
risk of developing cognitive dysfunction and eventually dementia (Caraci et al., 
2010). A study that aimed to investigate whether the risk of developing dementia 
increases with the number of affective episodes in patients with MDD found that the 
rate of dementia increased by 13% with every depressive episode leading to hospital 
admission (Kessing and Andersen, 2004). A meta-analysis published a few years 
later, that included 20 studies aggregating data of 102172 individuals from 8 
countries, showed that persons with a history of depression were more likely to be 
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diagnosed with Alzheimer’s disease later in life. In addition to being a remote risk 
factor for Alzheimer’s disease, depression may also be a prodromal feature of it 
(Ownby et al., 2006). The longest longitudinal study that covered 17 years of follow-
up reported a 70% increased risk of developing dementia in individuals with 
depression (Saczynski et al., 2010), whereas as mentioned above, the last published 
meta-analysis found a twofold increased risk of developing dementia in patients with 
a history of late-life depression (Cherbuin et al., 2015).  
It is now well recognized that decreased cognitive performance is a major contributor 
to the disability associated with the depressive disorder and it needs to be addressed 
with psychopharmacological therapy (Talarowska et al., 2014). A cognitive 
dysfunction in affective disorders suggests that brain structures responsible for 
emotional expressions and cognitive functions are linked to each other. One of the 
brain areas commonly affected in Alzheimer's disease patients and those experiencing 
mild cognitive impairment is the hippocampus (Mueller et al., 2010). Notably, 
neurodegenerative characteristics in this region of the brain is a consistent finding in 
depressed patients, who show decreased hippocampal volume (Videbech and 
Ravnkilde, 2004) along with structural alterations in the amygdala, orbitofrontal 
cortex, anterior cingulate cortex and basal ganglia. The role of the hippocampus 
which is implicated in the pathogenesis of depression and is relevant to this thesis will 
be described in further detail in section 1.1.6.  
There are a variety of neurobiological mechanisms that are common between 
depressive disorders and those of a neurodegenerative conditions such as dementia. 
Alterations at a molecular level, which together with diverse environmental influences 
contribute to the pathophysiology and neuroprogression of MDD, mediate changes in 
the brain chemistry and structure, including decreased adult neurogenesis, which will 
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be discussed in section 1.1.6.2. In addition to impaired neurogenesis, major pathways 
include variations in neurotransmitter systems, hypothalamic-pituitary-adrenal (HPA) 
axis modulation, inflammatory alterations, epigenetic influences, mitochondrial 
dysfunction and OS (Figure 1). In particular, OS is one of the neurobiological 
mechanisms that hugely contributes to neurodegenerative processes (Gandhi and 
Abramov, 2012), and as described in section 1.3.1 it is commonly found to be 
increased in depressed patients. However, what happens at a molecular level in the 
brain of those depressive disorder patients is not clear (Balmus et al., 2016).  
This thesis focuses on furthering the understanding of the role of OS in the 
pathogenesis of depression by modelling it in a relevant human in vitro system, 
investigating also if various compounds with antidepressant action are capable of 






Figure 1. A combination of factors leading to a major depressive episode. A 
combination of psychological and physical stressors together with pre-existing 
vulnerability can cause a major depressive episode. Various dysregulated molecular 
mechanisms, including OS, can lead to the damage of cellular components, induction 
of apoptosis and reduced neurogenesis. These events can precipitate structural brain 
abnormalities, cognitive and functional decline, increased tolerance to treatment and 
vulnerability to future episodes (Moylan et al., 2013).  
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1.1.5   Monoamine deficiency theory of depression 
Despite the evidence of several systems being involved in the pathogenesis of MDD 
as described above in 1.1.4, most currently available pharmacological treatments on 
the market target monoamine neurotransmitters. The monoamine theory of depression 
emerged serendipitously from clinical observations back in 1950s when clear mood-
raising effects were noted in tuberculosis patients upon treatment with a 
tuberculostatic drug - iproniazid. Later it was shown that administration of iproniazid 
to experimental animals produced a rapid increase in brain levels of serotonin and had 
a significant stimulant effect on behaviour. The effects of iproniazid are mainly due to 
inhibition of the enzyme monoamine-oxidase-A (MAO-A) located at the level of the 
mitochondrial membrane, and capable of oxidative deamination of the biogenic 
amines, in particular adrenaline, noradrenaline and serotonin (López-Muñoz and 
Alamo, 2009). These monoamines are major neurotransmitters in the brain, 
responsible for signal transduction between the neurons. They are released from 
synaptic vesicles into the synaptic cleft where they bind to the receptors on the 
dendrites of other neurons (Figure 2). Along with iproniazid another drug, 
imipramine, that was initially used in psychotic patients but demonstrated 
antidepressant effects, was found to reduce the uptake of noradrenaline in the synaptic 
nerve endings. These psychopharmacological findings gave rise to the first biological 
hypotheses on the genesis of mental illnesses, known as the monoaminergic theory of 
depression. It was hypothesized that a primary cause of low mood is a functional 
deficiency of noradrenergic or serotonergic (or both) neurotransmission in certain 
brain areas (Pare and Sandler, 1959). On the bases of this monoaminergic theory over 
the last 60 years, alternative classes and generations of antidepressants were designed 
and introduced to the market, with higher selectivity, better safety profile and greater 
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convenience. However, all of them continue to share an action mechanism that 
revolves around the enhancement of aminergic functioning: inhibitors of 
noradrenaline and serotonin reuptake, antagonists of serotonergic 5-HT2 receptors, 
specific noradrenergic and serotonergic antidepressants and selective inhibitors of 
noradrenaline reuptake. According to the British Association of Psychopharmacology 
guidelines the first line pharmacological treatment choices are selective serotonin 
reuptake inhibitors (SSRIs), due to better tolerability and safety in overdose (Cleare et 
al., 2015). Yet, there are still considerable issues such as the delay in the onset of 
antidepressant response or the percentage, estimated at around 30%, of patients who 
do not respond or partially respond to treatment to be addressed with regards to 
creating modern treatments. As research progressed in the neuropsychopharmacology 
field, a lot of non-monoamine-based actions have been explored for most of the 
antidepressants, such as immunomodulatory (Walker, 2013), neurotrophic (Berton 
and Nestler, 2006) and antioxidative effects (Behr et al., 2012). Based on these 
findings, the future of antidepressant therapy appears to be turning towards 
extraneuronal non-aminergic mechanisms or mechanisms that modulate the 




Figure 2. Serotonin neurotransmission. Serotonin or 5-hydroxytryptamine (5-HT) 
is synthesized from plasma tryptophan via hydroxylation and decarboxylation by the 
enzymes and stored in vesicles where it is ready for release. Once serotonin is 
released to the synaptic cleft it binds to various 5-HT receptors on the postsynaptic 
membrane and these leads to a cascade of events and cellular response. “Excessive” 
serotonin is removed by the reuptake mechanisms which involve active transport via 
plasma membrane serotonin transporter proteins (SERT) to the neuronal terminals 
where it is metabolised by MAO to 5-hydroxyindoleacetic acid. Adapted from Purves 
et al., 2004. 
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1.1.6   Hippocampus 
The hippocampus is a paired structure of the brain located in the medial temporal lobe 
in humans and forms a part of the limbic system responsible for emotion processing, 
together with the amygdala and the olfactory cortex (Phelps, 2004). The hippocampus 
is a heterogeneous structure, with sub regions having different functions and 
developing along different growth trajectories. It is one of the most highly connected 
areas of the brain, and although it has traditionally been considered the “memory 
area”, it has started to emerge as a brain integrator of emotion and cognition. 
Behavioural, anatomical, and gene expression studies support a functional 
segmentation of the hippocampus into three compartments: dorsal, intermediate, and 
ventral. The dorsal or posterior hippocampus performs primarily cognitive functions 
whereas the ventral or anterior relates to stress, emotion, and affect (Fanselow and 
Dong, 2010). In healthy individuals, the anterior portion of the hippocampus, which 
interacts with the amygdala, prefrontal cortex and HPA axis and plays a role in 
anxiety-related behaviour, associative memory, and emotional processing, shows 
volume reduction with increasing age. Conversely, posterior regions (particularly, the 
CA3 region), which play a significant role in spatial learning and contextual memory, 
gradually increase over time (Gogtay et al., 2006). Anatomical connectivity and 
lesion studies point to discrete roles for these sub-regions. Additionally, the 
contribution of differential gene expression in ventral and dorsal hippocampus has 
been studied using microarray screening and in situ hybridization techniques aimed at 
identifying genes in the CA1 region of the adult murine hippocampus. Results in this 
study indicate the existence of CA1 sub-regionalized gene expression with known and 
unknown functions, where some genes exhibit a graded expression pattern across the 
dorsal–ventral axis, and others restricted to a discrete region (Leonardo et al., 2006). 
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Data from the Allen Brain Atlas project, which aims to understand the genetic 
structural and cellular architecture of the mouse brain by generating a genome-scale 
collection of cellular resolution gene expression profiles, shows that dorsal/ventral 
heterogeneity is very common with the top over-represented functional category 
within the regional gene set being cell adhesion. Furthermore, different neuropeptides 
were observed to be restricted to either dorsal or ventral hippocampus providing 
evidence for functional differentiation involving discrete signalling pathways (Lein et 
al., 2007). 
Due to associations of the hippocampus with stress regulation and mood, this brain 
area has been implicated in affective disorders and has become the focus of 
depression research (Egeland et al., 2015). 
 
 
1.1.6.1   Hippocampus in depression 
Enormous amount of research implicates the hippocampus in the pathogenesis of 
MDD, clinically recognized as a highly stress-sensitive illness. Psychosocial stress, in 
turn, is associated with structural changes to the hippocampus, likely due to being 
densely populated with receptors for stress hormones that are released in response to 
stressful experiences and known to be neurotoxic (Snyder et al., 2011). In particular, 
it has been numerously demonstrated in animals that increased levels of 
corticosterone (analogue of cortisol, the major stress hormone in humans) induce 
depressive-like behaviour, hippocampal volume reduction, change in neuronal 
morphology and decreased neurogenesis in the hippocampus, that could be reversed 
by glucocorticoid receptor antagonists or antidepressants (Mayer et al., 2006; Murray 
et al., 2008; Sapolsky, 1985; Tata and Anderson, 2010). Additionally, human 
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conditions of chronic hypercortisolemia such as Cushing’s disease, are associated 
with hippocampal atrophy and cognitive deficits that are reversible following 
normalization of cortisol levels (Starkman et al., 1999, 1992).  
Reduction in hippocampal volume is consistently present in depressed patients with 
illness duration of more than two years and in those with more than one depressive 
episode (McKinnon et al., 2009). It has been reported in a meta-analysis that the total 
hippocampal volume is decreased in depressed patients for 8% on the left side and 
10% on the right side, also showing a direct correlation between increasing episode 
number (Videbech and Ravnkilde, 2004) and length of untreated episodes (Sheline et 
al., 2003). It has been hypothesised that this hippocampal volume loss may explain 
the long lasting mood and memory disturbances which occur in depression (Gould et 
al., 2007; Sahay and Hen, 2007). In line with this notion, the domains of memory 
function that are found to be impaired in depressed patients are those that are most 
dependent on hippocampal function (MacQueen and Frodl, 2011). 
The importance of the hippocampus in depression is also indicated by the finding that 
a larger hippocampal volume predicts a better response to antidepressant treatment 
(MacQueen et al., 2008), and successful antidepressant treatment can reverse the 
reduction in hippocampal volume in depression in humans (Sheline et al., 2003). It 
has also been noted that subjects at risk for MDD have reduced hippocampal volumes 
before the clinical onset of illness (MacQueen and Frodl, 2011) implying that 
molecular alterations might precede clinical signs. There is still no consensus 
regarding the nature of the underlying cellular changes that constitute hippocampal 
volume loss detected in depression (MacQueen and Frodl, 2011).   
Connectivity studies have identified the hippocampus as one of several regions, 
including the dorsomedial and dorsolateral prefrontal cortex, and the anterior 
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cingulate cortex as components of a network that is dysregulated in MDD (Frodl et 
al., 2008). Additional evidence from neuroimaging, neuropathological and lesion 
analysis studies further implicates the hippocampus in the central nervous system 
networks normally regulating aspects of emotional behaviour (Drevets et al., 2008). 
Limbic–cortical–striatal–pallidal–thalamic circuits, including the prefrontal cortex, 
amygdala, hippocampal subiculum, ventromedial striatum, mediodorsal and midline 
thalamic nuclei and ventral pallidum are brain regions with which hippocampus has 
afferent and efferent connections (Miller et al., 2010).  
In addition to the hippocampus being regularly found to be reduced in size in 
depression, implicated in the function of mood and emotional regulation, it is also the 
part of the brain most sensitive to environmental changes, particularly to stressful 
stimuli (Thomas et al., 2007). Both psychological and psychosocial stress have been 
associated with structural changes in the hippocampus (MacQueen and Frodl, 2011), 




1.1.6.2   Adult hippocampal neurogenesis  
Until recently the dogma was that the mammalian adult brain had no capacity to 
produce new neurons. However, the discovery of the formation of new born neurons 
out of neural progenitor cells, called “neurogenesis”, throughout adult life shifted the 
paradigm of brain development. There are two discrete neurogenic niches described 
in the adult mouse brain, the dentate gyrus of the hippocampus and the sub-
ventricular zone (SVZ) of the lateral ventricles (Deng et al., 2010).   
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It takes approximately eight weeks for new born neurons to reach morphological 
maturity, with the number of spines reaching a plateau at this point with considerable 
connectivity to the local circuit (Song et al., 2012). During this period these new born 
neurons are highly plastic and regulated by neural activity and modulatory systems. 
The pioneering studies of Ernst and Frisen have affirmed the existence of adult 
neurogenesis in humans and demonstrated more extensive neuronal turnover than 
many had predicted (Ernst and Frisen, 2015). It has been estimated that 35% of the 
total numbers of hippocampal neurons are subject to turnover, with a median turnover 
rate of 1.75% per year, producing around 700 new born neurons each day, so that 
over the course of a lifetime hippocampal neurons subject to exchange come to make 
up the entire population of dentate gyrus (Spalding et al., 2013). In addition to 
neurogenesis in the hippocampus and SVZ, in humans newly generated cells were 
also found in the striatum, the brain area associated with motor control and various 
cognitive functions, such as reward cognition and motivation (Ernst et al., 2014). The 
process of adult hippocampal neurogenesis (AHN) has been extensively studied in 
animals and distinct developmental stages and markers have been identified 
(Kempermann et al., 2004). Interestingly, these studies have revealed that 
neurogenesis does not occur at a persistent low rate; instead, neurogenesis is a heavily 
regulated and dynamic process that is sensitive to environmental influence through 
positive inducers such as physical exercise, enriched environments, learning, certain 
dietary regimens (e.g. caloric restriction) and nutritional supplementation (e.g. 
polyphenols and poly-unsaturated fatty acids) and also by factors which have negative 
effects such as sleep deprivation and glucocorticoids associated with stress (Figure 3)  
(Aimone et al., 2014; Snyder et al., 2011). AHN represents a novel and powerful form 
of neuroplasticity and has been proposed to add a distinctive functionality to the 
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mammalian hippocampus whereby new neurons provide cognitive flexibility in the 
face of diverse environmental conditions (Clelland et al., 2009;  Kempermann, 2012). 
AHN has been particularly implicated in depression, and considered to be essential 
for treatment and recovery from the illness (Lucassen et al., 2016), appearing to play a 
crucial role in the response to antidepressants. Experimental paradigms with animals 
demonstrate that exposure to acute or chronic stress reduces AHN and leads to the 
development of depressive-like symptoms (Schoenfeld and Gould, 2012), whereas 
enriched environment (Veena et al., 2009), exercise (Okamoto et al., 2015) or 
antidepressants (Duman et al., 2001) reverse these changes. Whether decreasing 
neurogenesis is enough in itself to induce depression is a subject of intense debate, 
mirroring the debate regarding the importance of neurogenesis in the action of 
antidepressants. It seems that the experimental reduction of neurogenesis in the 
absence of stress does not of itself induce depression, but rather that reduced 
neurogenesis contributes to the depression-like symptoms in animals by impairing 
stress modulation (Petrik et al., 2012).  
The existing evidence on the involvement of the hippocampus in the pathogenesis of 
depression, together with the critical role of AHN on its development and recovery, 
make the use of the human hippocampal progenitor cell line capable of neurogenesis 
in this thesis of particular relevance to study molecular mechanisms underlining 







Figure 3. Development of the dentate gyrus granule cells to fully mature 
neurons. New neurons are derived from radial glial cells (type 1 cells) and are 
amplified more rapidly from neural progenitor cell (type 2 cells). During the next few 
weeks cells differentiate into neurons with dendrites and axonal projections (Aimone 







1.2   Oxidative stress and molecular mechanisms relevant to depression 
 
1.2.1   Terminology in redox biology 
In order to be consistent in using different terms of redox biology in this thesis, I 
would like to start with the definitions of the most common terms being reported in 
the literature. 
Oxidants or oxidizing agents are chemical species that remove electrons from other 
species. This term can also refer to chemical species that transfer electronegative 
atoms, usually oxygen, to a substrate.  
Reductants or reducing agents are elements or compounds that lose or "donate" 
electrons to other chemical species in a reduction-oxidation (redox) chemical reaction 
and hence become oxidized. 
Free radicals are oxidants possessing unpaired electrons in their outer orbital and are 
capable of independent but very reactive existence. Most of the biological molecules 
are nonradicals, however when a free radical reacts with a nonradical, a new free 
radical is generated and this process can start a free radical chain reaction.  
Reactive Oxygen Species (ROS) are a type of free radicals of particular importance for 
biological species derived from oxygen. ROS are highly reactive unstable ions that 
aim to react with other molecules to gain stability. Recently in the literature ROS has 
been used as a collective term that includes both oxygen radicals and certain 
nonradicals that are oxidizing agents and/or are easily converted into radicals. The 
preferred practice should be to use the name of the identified species (Forman et al., 
2015), however to maintain consistency, I will use the term ROS in the same manner, 
unless a particular species is known.  
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Antioxidants are species that protect biological targets against damage caused by 
ROS. They are usually substances that are present at low concentrations compared 
with those of an oxidizable substrate and which significantly delay or prevent the 
oxidation of that substrate (Halliwell and Gutteridge, 2015).  
Total antioxidant capacity (TAC) (sometimes referred as total antioxidant 
activity/response) is an integrated parameter which means the cumulative capacity of 
free radical scavenging by the radical scavenging antioxidants contained in the test 
samples. This is often reported in clinical studies, since it is difficult to measure 
individual antioxidants (Niki, 2010).  
Oxidative stress (OS) is an imbalance between oxidants and antioxidants in favour of 




1.2.2   Oxidative stress and cellular responses 
Under normal conditions the levels of oxidants are balanced by an antioxidative 
defence system, but when an imbalance between ROS and antioxidants occurs, OS 
leads to an alteration of biomolecules and the loss of control of the intracellular 
signalling pathways "redox related”; both will be discussed in detail below. OS can be 
mainly caused by two reasons: either due to excessive generation of ROS or 
insufficient production or activity of antioxidants. OS can result in injury to both 
cellular as well extra cellular components of the cell and can lead to cell death. ROS 
are mainly generated as a result of physiological intracellular metabolism in 
mitochondria and peroxisomes, involving a variety of cytosolic enzyme systems, in 
particular NADPH oxidases (NOX) that are widespread in the brain (Turrens, 2003). 
NOX2 is the most widely distributed isoform of this enzyme family in the central 
nervous system. There are seven known NOX isoforms that transport an electron from 
cytosolic NADPH to reduce oxygen to superoxide anion (Table 2) (Ma et al., 2017). 
The NOX and DUOX isoforms are structurally similar, with DUOX enzymes having 
an additional seventh transmembrane helix and possessing peroxidase activity 
(Bedard et al., 2007). The distribution and regulation of the NOX and DUOX 
isoforms throughout the body and brain varies depending upon the isoform. 
Table 2 summarizes the reported distribution of NOX and DUOX isoforms in the 
central nervous system. 
In addition, ROS are also produced in the brain as by-products of MAO activity, in a 
process which is vital to the inactivation of the monoaminergic neurotransmitters 
serotonin, dopamine, noradrenaline and adrenaline, involved in the pathophysiology 
of depression (Andreyev et al., 2005). ROS have different chemical properties and 
some of them are less reactive than others. For example, superoxide anion radical 
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(·O2-) reacts directly with few molecules in the human body and can pass through the 
anion exchange proteins in the plasma membranes, whereas hydroxyl radical (·OH) 
can react with anything and when formed in vivo cannot migrate any significant 
distance within the cell (Halliwell, 2005). Notably, a response to oxidative injury may 
be reversible. Cells in an altered redox state do not necessarily lead to cell death, as 
after a variable period of time they can return to “normal”.  
The consequences of OS largely depend on the tissue or cells being affected and on 
the levels of OS (Figure 4), therefore it is essential to study molecular mechanisms 
that involve OS in cell models relevant to the disorder. This research project 
addresses an issue of lack of studies of MDD pathogenesis in clinically relevant 
human models. Interestingly, some cell types, especially stem cells, respond to OS by 
increased proliferation, although moderate levels of OS often halt cell proliferation 
transiently. Adult and embryonic stem cells are exceptionally rich in antioxidants but 
their levels decrease as cells differentiate, presumably because some ROS are needed 
for stem cell differentiation. Generally, the cell's redox state with a more reducing 
environment is associated with cell proliferation, while a more oxidizing environment 
is associated with differentiation (Lewerenz et al., 2013). Mild and moderate levels of 
OS often cause increased upregulation of antioxidant defences and therefore cells 
adapt to these conditions. An elevated activity of antioxidants may increase resilience 
of the cells and completely or to some extent protect them from damage induced upon 
higher levels of OS imposed subsequently. Greater levels of ROS lead to oxidative 
damage of cellular components (lipids, DNA and proteins) and to mitochondria 
impairment, which promulgates the production of more ROS; this will be discussed in 
detail below (1.2.3 section). OS can also cause cellular senescence when cells survive 
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but can no longer divide, due to increased levels of particular proteins that inhibit the 
cell cycle (Halliwell and Gutteridge, 2015). 
Remarkably, adult neurogenesis, implicated in the pathogenesis of MDD, transiently 
generates OS, as was demonstrated both in vivo and in vitro. In young adult mice that 
were maintained under standard housing conditions and used for initial 
characterization of OS, the highest concentrations of oxidized DNA and lipid markers 
were found within the subgranular zone of the dentate gyrus, where production of 
new born neurons occurs. These observations were followed up in vitro to investigate 
if the constitutive cell division within the dentate gyrus was a source of OS. 
Undifferentiated neural stem cells (NSCs) from the SGZ were isolated and induced to 
terminally differentiate. During differentiation, intermediate precursor cells – which 
bridge undifferentiated neural stem and their postmitotic progeny – exhibited the 
highest levels of proliferation (as measured by thymidine analogue incorporation), 
pro-growth mitogen expression, cellular mitochondria and OS load compared to 
more- or less-differentiated counterparts (Walton et al., 2012). Using molecular 
imaging and a new selective fluorescent indicator for H2O2, it was demonstrated that 
adult hippocampal stem/progenitor cells generate H2O2 through NOX2 (an isoform of 
NADPH oxidase) to regulate intracellular growth signalling pathways, which in turn 
maintains their normal proliferation in vitro and in vivo. (Dickinson et al., 2011). In 
line with this, another study demonstrated that both exogenous and endogenous ROS 
can have a significant impact on neural stem and progenitor cell proliferation, self-
renewal, and neurogenesis. Supplementation of H2O2 to culture media produced a 
modest increase in overall cell proliferation and a large increase in multipotent cells 
capable of producing neurons, astrocytes, and oligodendrocytes. When endogenous 
ROS levels were decreased in SVZ cells derived from NOX2 mutant mice, cells 
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displayed a significantly diminished NSCs self-renewal and multipotency, which was 
reversed by H2O2 addition. (Le Belle et al., 2011). Similar effects of OS on 
neurogenesis were observed in a study where rat primary neural progenitor cells 
(NPCs) exposed to H2O2 showed increase in neurogenesis and oligodendrogenesis 
(Pérez Estrada et al., 2014).  
These data suggest that OS is produced as a result of routine adult neurogenesis and 
ROS are not only transit by-products of a highly energy intensive process, but also 
essential signalling molecules for normal cellular growth and further implementation 
of the cellular program. Therefore, in this thesis I sought to investigate how 




Isoform Product Reported in CNS tissue 
 
NOX1 Superoxide Cerebral cortex (Choi et al., 2015; Savchenko, 2013) 
Hippocampus (Choi et al., 2014; Skurlova et al., 2011) 
Cerebellum (Coyoy et al., 2008) 
Substantia nigra (Cristóvão et al., 2009) 
Striatum (Chéret et al., 2008) 
Hypothalamus (Guggilam et al., 2007) 
Cerebral vessels (Ago et al., 2005; Paravicini et al., 
2004) 
NOX2 Superoxide Cerebral cortex (Bruce-Keller et al., 2010; Cooney et 
al., 2013; Serrano et al., 2003)  
Hippocampus (Dickinson et al., 2011; Hernandes et al., 
2014; Le Belle et al., 2011; Serrano et al., 2003; Zhang 
et al., 2009) 
Cerebellum (Coyoy et al., 2008) 
Striatum (Guemez-Gamboa et al., 2011; McCann et al., 
2008) 
Substantia nigra (Qin et al., 2013; Zawada et al., 2011)  
Hypothalamus (Guggilam et al., 2007; Ye et al., 2006) 
Subfornical organ (Lob et al., 2013) 
Lateral ventricle (Lelli et al., 2013)  
Subventricular zone (Lelli et al., 2013) 
Midbrain (Qin et al., 2013)  
Nucleus tractus solitaries (Wang et al., 2004)  




Cerebral cortex (Cooney et al., 2013; McCann et al., 
2008; Vallet et al., 2005)  
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Table 2. Family of NOX enzymes and their distribution in the central nervous 










Hippocampus (Hernandes et al., 2014)  
Cerebellum (Coyoy et al., 2008)  
Hypothalamus (Guggilam et al., 2007; Infanger et al., 
2010; Ye et al., 2006) 
Subfornical organ (Lob et al., 2013)  
Glioblastoma (Cheng et al., 2001)  
NOX5 Superoxide Glioblastoma (Antony et al., 2013; Cheng et al., 2001)  
DUOX1 Hydrogen 
peroxide 
None reported in CNS 
DUOX2 Hydrogen 
peroxide 




Figure 4. General cellular responses to different levels of OS (Halliwell, 2006). 
  
 57 
1.2.3   Oxidative damage  
The brain represents only ∼2% of the total body weight and accounts for more than 
20% of the total consumption of oxygen. Neurons and astrocytes, the two major types 
of brain cells, are largely responsible for the brain’s massive consumption of O2 and 
glucose (Gandhi and Abramov, 2012). Despite the essentiality of oxygen for neurons, 
some of its products such as oxygen radicals (e.g. superoxide, hydroxyl) and non-
radicals (e.g. hydrogen peroxide) can be neurotoxic. Cells in the brain are especially 
vulnerable to the detrimental effects of OS, due to their high metabolic rate, the 
abundance of highly peroxidizable substrates and the modest antioxidant levels 
present. Excessive levels of ROS disrupt the neural cytoarchitecture and affect the 
function of a variety of biological molecules including lipids, nucleic acids and 
proteins, with inevitable damage inflicted to neurons (Friedman, 2011). Living 
organisms have evolved antioxidant defences to counterbalance OS and maintain 
redox homeostasis. These defence systems comprise nonenzymatic scavengers and 
quenchers, as well as enzymatic antioxidants, and include protection at the levels of 
prevention, interception and repair (Sies, 2013). The major enzymatic antioxidants are 
superoxide dismutases (SODs), catalase, and the family of glutathione peroxidases. In 
addition to these major enzymes, other antioxidants, including heme oxygenase, and 
redox proteins, such as thioredoxins, peroxiredoxins and glutaredoxins, have also 
been found to play crucial roles in the human antioxidant defences. Nonenzymatic 
antioxidants include low-molecular-weight compounds such as uric acid, melatonin, 
lipoic acid, coenzyme Q10, glutathione (GSH), β-carotene, flavonoids, polyphenols 
and vitamins A, C, D, and E. Some of them are not synthesised in humans and must 
be received with diet (Birben et al., 2012). Different antioxidants react with different 
ROS at variable rates, act in various locations and protect different molecular targets 
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(Halliwell, 2006), so it is important to identify antioxidant compounds that exhibit 
their properties in human brain cells in order to determine their potential therapeutics 
for MDD that is accompanied by increased levels of OS. 
 
 
1.2.3.1   Lipid peroxidation  
The oxidation of lipids is of particular importance due to the large amounts of 
polyunsaturated fatty acids (PUFAs) in the cellular membranes and organelles of 
brain cells (Innis, 2008). PUFAs contain two or more double carbon-carbon bonds 
and are easily oxidised in comparison with monounsaturated and saturated lipids. The 
initiation of lipid peroxidation can be caused by addition of ROS to the lipid, or by 
hydrogen atom subtraction from a methylene group (-CH2-) of the lipid by a ROS 
(Chen et al., 2008). This can occur at different points of the carbon chain of the 
molecule. Importantly, a single initiation event lead to the propagation stage of lipid 
peroxidation and has the potential to generate multiple lipid peroxides by a chain 
reaction (Halliwell and Gutteridge, 1990). There are two broad outcomes to lipid 
peroxidation: structural damage to membranes and generation of oxidation-specific 
epitopes (Catalá, 2012). Lipid peroxidation has several altering effects on the 
structure and function of the membrane and ultimately on the cell. It decreases the 
viscosity of the lipid bilayer and increases membrane leakiness and therefore the 
molecules that normally do not cross the membrane other than through specific 
channels can pass. Eventually, membrane proteins are damaged and as a result 
various receptors, enzymes and transport protein are inactivated, ultimately leading to 
loss of membrane integrity. As a result of the continued oxidation and fragmentation 
of fatty acids, a variety of aldehydes and hydrocarbons are produced. Oxidized lipids 
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can have similar effects to hydrogen peroxide on the cells, stimulating or inducing 
proliferation depending on their concentration, and inducing apoptosis or necrosis at 
higher levels (Sevanian and McLeod, 1997). In addition to PUFAs, other molecules 
that contain double bonds such as vitamin A (retinol) or carotenoids can be also 
oxidized and at high levels serve as pro-oxidants.  
 
 
1.2.3.2   End products of lipid peroxidation 
End products of lipid peroxidation, including isoprostanes (IsoPs), malondialdehyde 
(MDA) and 4-hydroxy-2-trans-nonenal (4-HNE), are widely used as biomarkers of 
OS, despite some considerations about their validity. Lipid peroxidation products are 
cytotoxic, can act as antigens and promote immune responses, as they are recognized 
by the immune system as alien epitopes (Leonard and Maes, 2012). In mitochondria, 
the products of lipid peroxidation inhibit oxidative phosphorylation,  compromise the 
permeability of the inner membrane, dissipate the mitochondrial membrane potential 
and reduce the Ca2+ buffering capacity, thus contributing to overall toxicity (Orrenius 
et al., 2007). These compounds also act as signalling molecules; for example, 4-HNE 
and IsoPs can rise cellular antioxidant defences, such as GSH and heme oxygenase 1 
(HO-1) and activate the primary antioxidative defence transcription factor nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) (Zhang et al., 2014).  
IsoPs are prostaglandin-like compounds usually generated in vivo from the free 
radical-initiated peroxidation of PUFAs with at least three double bonds, such as 
linolenic acid, arachidonic acid, eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) (Roberts and Morrow, 2002). F2-IsoPs, the most studied class of IsoPs, 
are potent vasoconstrictors (Milne et al., 2015).  
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MDA largely arises from peroxidation of PUFAs with at least two double bonds and 
can attack proteins and therefore modify its functions and react with DNA bases 
introducing mutagenic lesions (Halliwell and Gutteridge, 2015).  
4-HNE is one of many unsaturated aldehydes formed during peroxidation of omega-6 
PUFAs, and it is especially toxic to neurons, by increasing calcium levels, 
inactivating glutamate transporters and damaging neurofilament proteins. 4-HNE is 
highly reactive and easily binds to biomolecules containing thiol and amino groups 
(Uchida, 2003).  
All these lipid peroxidation end products have been found to be increased in 




1.2.3.3   DNA and protein damage 
Although DNA is a stable structure, it also suffers from the interaction with ROS and 
end-products of lipid peroxidation, by modification of purine or pyrimidine bases, 
single- and double-DNA breaks, damage to the 2-deoxyribose sugar, DNA-protein 
cross-linkage, and indirectly thorough damage to the DNA repair system. Both 
nuclear and mitochondrial DNA may suffer from OS insults and the biological 
significance of the oxidative damage depends on the extent of the damage, location in 
the genome and how fast it can be repaired. Oxidative damage of both nuclear and 
mitochondrial DNA are suggested to contribute to the pathogenesis of 
neurodegenerative disorders and depression (Maes et al., 2009; Tobe, 2013), and 
alterations in mitochondrial function have been proposed to be a potential target for 
depression treatment (Bansal and Kuhad, 2016). Mitochondrial DNA (mtDNA) is 
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mainly damaged due to mitochondrial dysfunction that results from increased OS, 
which further propagates the production of more free radicals and exacerbation of the 
OS cycle. It has been reported that mtDNA undergoes several-fold higher OS damage 
than nuclear DNA due to its proximity to ROS during electron transport and the 
absence of histone protection. In addition, since there are no introns in mtDNA, ROS 
are more likely to damage a gene than in nuclear DNA, although mtDNA is coated 
with proteins in vivo and some lesions can be repaired rapidly. Direct damage to DNA 
can introduce mutagenic lesions, some of which can also be repaired promptly enough 
before cell division. Otherwise, if lesions are not removed before DNA replication, 
mutations increase, eventually leading to programme cell death. Cells may respond to 
unrepaired DNA damage by silencing expression of the affected genomic region 
which may be vital for cell survival rather than by undergoing apoptosis. All these 
changes can affect transcription factor binding and lead to alterations of genetic 
regulation, then causing errors in translation and impairment of protein synthesis 
(Halliwell and Gutteridge, 2015).  
Proteins can undergo direct attack by ROS or indirect deterioration following OS 
including end products of lipid peroxidation, such as MDA or 4-HNE. The 
identification of oxidised proteins as markers of OS in vivo is challenging, as all 
amino acids residues as well as all peptide bonds can be oxidised. Oxidative damage 
might occur to specific amino-acid residues, causing changes in the tertiary structure, 
degradation or fragmentation of the protein. Protein damage can be reversible, such as 
disulphide bond generation or glutathionylation, or irreversible, such as the oxidation 
of amino acid side-chains. In addition, OS can prevent protein synthesis by targeting 
initiation factors. Interestingly, this response might help in decreasing the synthesis of 
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bulk proteins under OS conditions in order not to flood the cell with damaged proteins 
(Halliwell and Gutteridge, 2015).  
 
 
1.2.4   Glutathione (GSH) and system xc− as major regulators of redox 
homeostasis in the brain  
Reduced glutathione (GSH) is a cysteine-containing tripeptide (γ-L-Glutamyl-L-
cysteinyl-glycine) mainly present inside all cell types at millimolar concentrations and 
recognised to play a central role in intracellular endogenous antioxidant defences 
(Rizzo et al., 2010; Snoke and Bloch, 1952). GSH is a multifunctional molecule with 
diverse and still emerging functions that affect critical cellular processes. It serves 
several vital processes such as detoxifying electrophiles, scavenging free radicals, 
maintaining the essential thiol status of proteins, providing a reservoir for cysteine 
and modulating critical cellular processes such as DNA synthesis, microtubular-
related processes, and immune function. In addition, GSH has been shown to 
modulate the activity of neurotransmitter receptors and proteins by post-translational 
modification (protein S-glutathionylation) (Kaplowitz et al., 1985; Lu, 2009; Meister 
and Anderson, 1983). GSH participates in redox reactions by reversible oxidation of 
its active thiol forming glutathione disulphide (GSSG), or by breaking the disulfide 
bridges formed inside and between proteins by the action of oxidants . The major 
provider of cysteine for GSH synthesis is the OS-inducible cystine/glutamate 
exchange system, known as system xc−, consisting of the 4F2 heavy chain (4F2hc) 
and the light chain, xCT/SLC7A11 subunits (Sato et al., 1999). These subunits are 
linked by a disulfide bond, with the regulation of xCT/SLC7A11 being an important 
determinant for the whole system. Importantly, the brain is one among the few organs 
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where system xc− is constitutively expressed in diverse areas, including the nucleus 
accumbens, the striatum, and the hippocampus (Sato et al., 2002). It is highly 
inducible by various stimuli, including OS and inflammation in an Nrf2-dependent or 
-independent manner. System xc−  transports one molecule of cystine, the oxidized 
form of cysteine, into cells in exchange for one molecule of glutamate into the 
extracellular space (Bannai, 1986, 1984; Bannai and Tateishi, 1986) (Figure 5 and 
6). Therefore, system xc− is critical for the maintenance of physiological redox 
conditions inside/outside of the cell and for modulation of extracellular glutamate 
concentrations (Lewerenz et al., 2013; Shih et al., 2006). Glutamate in turn is the 
most important excitatory neurotransmitter in the central nervous system and its 
excessive extracellular accumulation has been implicated in the pathogenesis of 
several neurodegenerative diseases and depression (Mehta et al., 2013; Sanacora et 






Figure 5. System xc−. System xc− is composed of the 4F2 heavy chain (4F2hc) and 
the light chain, xCT, which are linked by a disulfide bond (-S-S-). System xc− imports 





Figure 6. Mechanisms underlying transport of L-cystine via xCT and L-cysteine 
via other neutral amino acids transporters. Oligodendrocytes and astrocytes can 
take up cystine via the cystine/glutamate exchanger xc- system to supply cysteine for 
GSH synthesis. Into neurons most cysteine (80%) goes via the excitatory amino acid 
transporter 3 (EAAT3) with a small fraction supplied via alanine-serine-cysteine 
(ASC) system. GSH is converted to GSSH via redox reactions and is restored to GSH 






1.2.5   Excitatory Amino Acid Transporter  
Excess concentrations of glutamate are excitotoxic due to overactivation of ionotropic 
glutamate receptors and increase in calcium influx leading to neuronal death. Hence, 
glutamate concentration in the synaptic cleft is tightly regulated by the family of 
Excitatory Amino Acid Transporter (EAATs) 1-5, which are commonly observed to 
be down-regulated in many neuropsychiatric diseases (Lau and Tymianski, 2010; 
Sheldon and Robinson, 2007). Extracellular glutamate also acts as a competitive 
inhibitor for cystine uptake via system xc−  completing the loop. It was demonstrated 
that transient overexpression of the neuronal EAATs increased intracellular GSH in 
the presence of high glutamate concentrations and protected hippocampal HT22 cells 
from oxidative glutamate toxicity. These effects were especially pronounced when 
EAAT3 was co-overexpressed with xCT leading to a concomitant decrease in the 
extracellular glutamate and increase in cystine uptake (Lewerenz et al., 2006). 
EAAT3 is a highly abundant, primarily neuronal transporter, with high densities at 
post-synaptic terminals protein that is widely expressed in CNS, with higher 
expression in the cerebral cortex, hippocampus, cerebellum and basal ganglia. 
Impairments in its function have been implicated in a variety of neurodegenerative 
diseases, including Alzheimer’s disease (Bjørn-Yoshimoto and Underhill, 2016). 
EAAT3 plays an important role in glutamatergic termination in areas such as the 
hippocampus and in situations where glutamate reaches abnormally high 
extracellular concentrations, for example under ischemic conditions (Bianchi et al., 
2014). This transporter, however, also contributes to controlling of the the cell redox 
potential due to its ability to transport cysteine (Chen and Swanson, 2003). It was 
demonstrated that EAAT3 knockout mice have a decreased neuronal glutathione 
level (Aoyama et al., 2006) and early onset brain aging, whereas N-acetyl-cysteine 
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(NAC) administration over four weeks significantly elevated glutathione levels in 
the cerebral cortex and hippocampus of mice and attenuated behavioural changes and 
decreased 4-HNE levels (Cao et al., 2012). 
The oxidative glutamate toxicity resulting in cell death through activation of 
signalling pathways, rather than just an increase of ROS was described as a novel 
form of programmed cell death and named oxytosis (Tan, 2001). Interestingly, xCT 
knockout mice did not have a lower hippocampal glutathione content, increased OS or 
brain atrophy or cognitive impairments, however they had significantly lower 
extracellular hippocampal glutamate concentrations compared to wild-type 
littermates. Moreover, intrahippocampal perfusion with system xc− inhibitors lowered 
extracellular glutamate, whereas the system xc− activator NAC elevated extracellular 
glutamate in the rat hippocampus. These findings highlight that system xc− is not the 
only modulator of intracellular GSH and there are alternative mechanisms 
compensating for its deficiency to maintain the intracellular GSH pool in vivo. It also 
indicates that system xc− is important source of extracellular glutamate in the 
hippocampus (De Bundel et al., 2011).  
Taken together, the cooperative action of system xc− and EAATs is necessary to 
ensure optimal protection of neuronal cells from OS by increased cystine uptake, 
GSH biosynthesis and properly controlled extracellular glutamate concentrations, 
processes that are known to be impaired in CNS illnesses with neurodegenerative 
patterns. Thus, I wished to explore if system xc− and EAAT3 might be involved in 
many potential cytoprotective effects of the compounds with antidepressant action 




1.2.6   Cross talk between OS and inflammation in depression 
No single event that happens in the living organism is isolated and changes in redox 
homeostasis are tightly linked to alterations in other various mechanisms linked to 
depression and in particular inflammation (Kim et al., 2016; Rawdin et al., 2013). 
Increased OS markers are often reported along with a neuroinflammatory signature in 
the blood of depressed patients, which is mainly represented by increased pro-
inflammatory cytokines and acute phase proteins (Liu et al., 2016). Our mechanistic 
understanding of molecular pathways through which impaired redox homeostasis 
interacts with immune-inflammatory system in relation to MDD is not 
comprehensive. However, there are some distinct regulatory pathways linking 
inflammation and ROS production that are spread among transcription factors, 
proteins and small molecules, which I will describe below.  
The generation of ROS is tightly regulated by inflammatory signals, such as the 
Negative Response ROS (NRROS) protein, highly expressed in immune organs and 
also detected in the brain. This protein is responsible for the degradation NOX2, one 
of the membrane-bound subunits of the NADPH oxidase complex, through which a 
great number of ROS are produced in response to inflammatory stimuli. The NRROS 
negative regulation of ROS production was shown in interferon-γ (IFN-γ) and 
lipopolysaccharide (LPS) -primed phagocytic cells and in NRROS-knockout mice 
(Noubade et al., 2014). Of relevance, downregulation of NRROS, previously known 
as Lrrc33 protein, led to increased levels of ROS, whereas knockdown of this enzyme 
in dendritic cells greatly increased nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) activation – a major inflammatory transcription factor in 
the absence of any inflammatory stimulation (Liu et al., 2013). Hence, one of the 
mechanisms by which inflammation might lead to increased OS and to further 
 69 
propagation of the vicious cycle in depressed patients could be through down-
regulation of NRROS by chronic inflammation, resulting in an increase in the levels 
of ROS and via a positive feedback loop, a further stimulation of the inflammatory 






Figure 7. Proposed closed loop of inflammation and ROS production. 
Inflammatory stimuli inhibit NRROS protein, in turn inhibiting the degradation of 
NOX2, which is responsible for ROS production. As a result, more ROS are produced 
in response to inflammation. ROS in turn activate NF-κB and further promote 




ROS are necessary for the activation of the multiprotein inflammatory complexes 
known as inflammasomes, which are a major sensor of cellular stress signals. For 
example, the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome, the most extensively studied inflammasome, formed after the 
oligomerization of NLRP3 and subsequent recruitment of pro-caspase-1, increases the 
production of pro-inflammatory cytokine interleukin-1β (IL-1β) and activates NF-κB, 
further promoting inflammatory cascades.  
Importantly, as ROS change the chemical structures of different molecules, they 
generate a variety of modified oxidation-specific epitopes, which are highly 
immunogenic and can cause activation of adaptive immunity, such as 
immunoglobulin G (IgG) or IgM–mediated autoimmune responses. Indeed, 
significantly greater serum levels of IgG and IgM against oxidized low-density 
lipoproteins were reported in patients with major depression compared with controls 
(Maes et al., 2013). Furthermore, a separate study in serum of depressed patients 
detected significant reductions of IgA, which has a role as an immunomodulator 
helping to maintain the proper balance between pro- and anti-inflammatory states 
(Gold et al., 2012). 
As many of the oxidation-specific epitopes have strong pro-inflammatory properties, 
including MDA, 4-HNE, thiobarbituric acid reactive species, 8-iso-prostaglandin-F2a 
and 8-hydroxydeoxyguanosine, they are considered as novel kind of damage-
associated molecular patterns (DAMPs). DAMPs can initiate and perpetuate non-
infectious immune responses as they bind to cellular and soluble pattern recognition 
receptors triggering inflammation. Conversely, some of the molecules that undergo 
oxidative modifications lose anti-inflammatory properties while many more are newly 
formed, with some possessing pro-inflammatory features. For example, PUFAs 
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inhibit prostaglandin E2 synthesis and modulate immune functions by regulating the 
production of a variety of cytokines, including IL-1, IL-6, tumour necrosis factor-α 
(TNF-α) and interferon-α (IFN-α), while upon oxidation these molecules acquire pro-
oxidative and pro-inflammatory characteristics (Zunszain et al., 2012b). 
The cascade of antioxidative and inflammatory events is orchestrated by several 
transcription factors and two key ones that are widely expressed in the central nervous 
system and researched in this thesis are nuclear factor Nrf2 and NF-κB (Buelna-
Chontal and Zazueta, 2013). The full dynamics of the interactions between Nrf2 and 




1.2.6.1   Nrf2 – major antioxidant transcription factor 
Nrf2 is the major antioxidant transcription factor and the master regulator of the 
cellular defence pathway, which is activated in different cell types as a result of OS 
and other stimuli, leading to increased induction of the target antioxidants and 
enzymes that defend against oxidative damage (Mann and Forman, 2015). In addition, 
Nrf2 contributes to diverse cellular functions including differentiation, proliferation, 
inflammation and lipid synthesis. Interestingly, there is an increasing association of 
aberrant expression and function of Nrf2 in neurodegenerative diseases (Bryan et al., 
2013). Under unstressed conditions Nrf2 is anchored in the cytoplasm through 
binding to Kelch like ECH associated protein 1 (Keap1), which degrades it by 
ubiquitination. Upon OS, Nrf2 travels to the nucleus where it forms a heterodimer 
with small Maf protein, binds to a DNA promoter antioxidant responsive element 
(ARE) and initiates transcription of genes that code for proteins that have 
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cytoprotective effects (Figure 8) (Itoh et al., 1999, 1997; Moi et al., 1994). Recent 
research has shown that oxidative and electrophilic stressors do not directly cause 
release of Nrf2 from Keap1, but rather conformational changes in the Keap1-Nrf2 
complex that strengthen Keap1-Nrf2 binding leading to Nrf2 stabilization, its 
endogenous synthesis and increased binding to ARE sequence in the promoter of 
target genes (Baird and Dinkova-Kostova, 2011). In particular, Nrf2 inducers 
inactivate Keap1 via the modification of cysteine residues (Cys), (also known as 
“cysteine code” concept), Nrf2 is stabilized, and de novo synthesized Nrf2 
translocates into the nucleus (Suzuki and Yamamoto, 2015). Thus, Keap1 turns out to 
be a sensor of electrophiles and ROS, and once a signal is detected it is transmitted for 
Nrf2 activation and induction of cytoprotective gene expression. Furthermore, 
degradation of Nrf2 is controlled by phosphorylation of one of its domains, which can 
be regulated by glycogen synthase kinase-3 (GSK-3), providing supplementary 
effects to the Keap1 pathway. It was shown that activation of GSK-3 in Keap1-null 
mouse embryonic fibroblasts (MEFs), or in human lung A549 cells that contain 
mutant Keap1 by inhibition of the phosphoinositide 3-kinase (PI3K)–protein kinase B 
(PKB)/Akt pathway markedly reduced endogenous Nrf2 protein and decreased to 10–
50% of normal the levels of mRNA for prototypic Nrf2-regulated enzymes 
(Chowdhry et al., 2013). 
Nrf2 keeps under control the regulation of DNA damage recognition, repair and 
removal, as well as the modulation of proteasomes that are responsible for the 
degradation of damaged or misfiled proteins (Zhang et al., 2015). Major Nrf2 
downstream proteins are NADPH dehydrogenase (quinone) 1 (NQO1), glutathione S-
transferases (GST), heme oxygenase 1 (HO-1), antioxidant and related proteins, 
thioredoxins, γ-glutamate cysteine ligase (γ-GCS), glutathione peroxidase, glutathione 
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reductase, ubiquitination enzymes and proteasomes, and drug transporters (Niture et 
al., 2010). It also controls the levels of other key regulatory molecules, including 
protective proteins such as BDNF and the anti-inflammatory IL-10. Interestingly, it 
was shown that Nrf2 protects many different cell types by co-ordinately up-regulating 
classic ARE-driven genes, as well as cell type-specific target genes that are required 
for the defence system of each cell type in its unique environment (Lee et al., 2005). 
The broad functions of Nrf2 upon activation by OS have been shown with primary 
cortical neurons, where microarray data revealed that Nrf2 is important for the 
expression of immune and inflammation genes together with growth factors, 
signalling proteins and neuron-specific genes (Lee et al., 2003). Further support for 
the beneficial role of this transcription factor comes from mice studies where its 
deletion resulted in depressive-like behaviour, reduced levels of dopamine and 
serotonin and increased levels of glutamate in the prefrontal cortex (Martín-de-
Saavedra et al., 2013). Interestingly, treatment of these Nrf2 knockout mice with the 
anti-inflammatory drug rofecoxib reversed their depressive-like behaviour, suggesting 
the involvement of Nrf2 in the induction of inflammatory cascades. The follow-up 
study based on the same Nrf2 knockout model of depression that used liquid 
chromatography–mass spectrometry to monitor neurotransmitter and metabolite levels 
found significantly decreased levels of another chief inhibitory neurotransmitter, γ-
Aminobutyric acid (GABA), in various areas of the rat brain (Wojnicz et al., 2016). 
Conversely, inflammation around birth may have long-term detrimental effects on the 
Nrf2 system. As such, prenatal inflammation of rodents by exposure to LPS resulted 
in a dysfunctional Nrf2 response in adulthood, indicated by lower levels of GSH and a 
decrease in the activity of GSH synthase (Zhu et al., 2007). Due to the vast variety of 
these protective effects, Nrf2 has been suggested as a promising target to counteract 
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Figure 8. Activation of transcription factors by ROS. ROS can activate different 
transcription factors directly and/or through kinases. At low levels of OS, Nrf2 is 
activated: it is released from the cytoplasm and translocates into the nucleus where it 
forms a heterodimer with small Maf protein, binds to a DNA promoter Antioxidant 
Responsive Element (ARE) and initiates transcription of antioxidative genes, leading 
to cytoprotective effects. At higher levels of OS, NF-κB is activated: IκB is 
phosphorylated by IKK and as a result NF-κB is released from the cytoplasm and 
translocated into the nucleus. Depending on the cellular context, NF-κB can activate 
inflammatory cascades, pro-oxidant or antioxidant genes (Bakunina et al., 2015; 
Gloire et al., 2006; Itoh et al., 1999, 1997; Son et al., 2011). 
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1.2.6.2   NF-κB – a redox sensitive transcription factor 
NF-κB is a transcription factor that has been widely implicated in the inflammatory 
hypothesis of the pathogenesis of MDD (Miller and Raison, 2016). The heterodimeric 
protein NF-κB is identified as highly redox sensitive and involved in the control of a 
large number of physiological cellular processes, such as immune responses, cellular 
proliferation and migration, differentiation and survival and cell death programs. 
Under normal conditions it is inactive in cellular cytoplasm, where it is bound to the 
inhibitory protein IkB. Upon ROS stimulation (or another stimulus, e.g., cytokines) 
IkB is phosphorylated by IkB-kinase and as a result p50/p65 NF-κB dimers are 
released from the cytoplasm, translocate into the nucleus, bind to its DNA target 
sequence and initiate gene transcription. This NF-κB pathway activation is recognised 
as the canonical or classical pathway. The noncanonical or alternative pathway differs 
from the canonical pathway in that only certain receptor signals can activate it and it 
leads to liberation of the p52/RelB NF-κB complex (Gilmore, 2006) (Figure 9). 
Whereas oxidants enhance NF-κB nuclear translocation and consequently its 
activation, the direct oxidation of NF-κB decreases its DNA binding activity and 
therefore transcription of genes. Although NF-κB is commonly associated with 
triggering pro-inflammatory cascades, it can also target antioxidant genes, as well as 
promote ROS production, which has physiological relevance. Furthermore, ROS can 
modulate NF-κB activity both positively and negatively depending on the context. For 
example, activation of c-Jun N-terminal kinase (JNK) by TNF-α, contributing to 
inflammatory responses requires the generation of ROS, and this process can be 
counteracted by NF-κB through the induction of genes that encode antioxidant 
enzymes such as manganese-superoxide dismutase (MnSOD) and ferritin heavy chain 
(Nakano et al., 2005; Perkins, 2007). 
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Of note here, the vast majority of studies concerning oxidant-induced NF-κB 
activation have used H2O2 as a direct source of ROS. However, studies suggest that 
NF-κB activation by H2O2 is highly cell-type specific and involves quite different 
mechanisms. This is even more true for NF-κB activation by cytokines and OS, where 






Figure 9. Canonical and non-canonical NF-κB signalling pathways. Adapted from 
Zhou et al., 2015. 
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1.2.6.3   Kynurenine pathway affected by OS  
Among other potential mechanisms that are involved in the pathogenesis of MDD  
and are linked to both increased OS and neuroinflammation is the kynurenine 
pathway (Maes et al., 2011). The pathway starts from the amino acid tryptophan 
(TRP), a serotonin precursor, which is metabolized to kynurenine (KYN). This 
transformation is catalysed by indoleamine 2,3-dioxygenase (IDO), an enzyme 
inducible by pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-2 and IL-1β, and 
also directly by ROS (Ocampo et al., 2014). Notably, one of the major products of 
direct tryptophan oxidation identified in vivo is KYN. KYN may be further 
metabolized to either kynurenic acid (KYNA), a potentially neuroprotective 
metabolite, or to excitotoxic free radical generator compounds including 3-
hydroxykynurenine (3-HK) and quinolinic acid (QUINA), whose increased levels, 
together with increased IDO, have been associated with MDD (Gabbay et al., 2010; 
Savitz et al., 2015) (Figure 10). Thus, OS contributes to the perturbation of the 
kynurenine pathway that has been implicated in the pathogenesis of depression and 
neurodegeneration (Lovelace et al., 2016). Additionally, the formation of new 
epitopes contributes to inflammation and to pathogenic inflammatory pathways 
postulated to underlie depression, such as these tryptophan catabolites produced by 
the kynurenine pathway. 
The kynurenine pathway has two main relevant outcomes to these conditions: the 
reduction of available serotonin, putatively linked to increased metabolism of 
tryptophan into KYN by activated IDO, and the increased neurotoxicity due to the 
relative balance of QUINA and KYNA (Maes et al., 2009c; Myint et al., 2007; Savitz, 
2016; Wichers et al., 2005). 
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These pathways also affect hippocampal neurogenesis. Indeed, tryptophan-2,3-
dioxygenase (TDO) knockout mice show increased neurogenesis (Kanai et al., 2009). 
Recently, our lab demonstrated that treatment with the pro-inflammatory cytokine IL-
1β reduces neurogenesis in the human hippocampal progenitor cells that are also 
utilised in this thesis, by a mechanism involving a shift in the balance of the 
kynurenine pathway towards neurotoxic metabolites (Zunszain et al., 2012a). 
Therefore, I further investigated if redox shifts lead to alterations in the kynurenine 
pathway in my OS model.  
OS and inflammation are intimately linked with each other in the pathophysiology of 
depression. Molecular consequences of OS that are hypothesized to take place in the 





Figure 10. Simplified kynurenine pathway of tryptophan metabolism (Zunszain 





Figure 11. Schematic molecular consequences of OS that are hypothesized to 




1.2.7   Redox signalling 
The generation of ROS within physiological levels is necessary to maintain redox 
homeostasis in a living organism. Interestingly, although ROS have been 
conventionally considered as toxic by-products of cellular metabolism, they also act 
as critical secondary messengers and essential elements of fundamental 
neurobiological processes such as cell growth, proliferation and differentiation, 
signalling, migration and adhesion, immune responses, biological synthesis, 
regulation of gene expression and regulated forms of cell death. Additionally, ROS 
are crucial molecules in fighting bacterial agents causing infections (Nathan and 
Cunningham-Bussel, 2013). Therefore, although the antioxidant defence network 
must minimize the levels of most ROS, it still needs to permit enough to remain for 
their essential roles (Halliwell and Gutteridge, 2015). The activation of various 
molecular pathways by OS provides numerous examples of cell and tissue specificity 
and demonstrates the complexity of the mechanism governing its activation. As 
introduced above, ROS cause post-translational protein modifications in a variety of 
ways, and the cysteine residues that are the most susceptible to oxidation. Thiol 
transformations are particularly important because they are reversible and therefore of 
great physiological relevance in cellular signalling.  
ROS also affect the activities of serine/threonine kinases and the best known of these 
are members of the mitogen-activated protein kinase (MAPK) family (Maher and 
Schubert, 2000). The transformations of MAPKs, including extracellular signal-
regulated kinase (ERK), JNK and p38, are most critical to cell fate and were 
researched in this thesis. These MAPKs are modulated upon diverse stimuli including 
OS, whereas antioxidants and inhibitors of ROS producing enzymatic systems, such 
as NOX2 block their activation. Each subgroup of MAPKs is activated through a 
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cascade of sequential phosphorylation events, beginning with the activation of MAPK 
kinase kinases (MKKK or MAP3Ks), followed by downstream activation of dual 
specificity MAPK kinases (MAP2Ks), which in turn stimulate MAPK activity 
through dual phosphorylation on threonine and tyrosine residues (Figure 12) (Son et 
al., 2011).  
ERKs are often activated by growth factors and are primarily involved in cell 
proliferation and differentiation, whereas JNK and p38 MAPK are primarily activated 
in response to pro-inflammatory cytokines and environmental stress and are 
implicated in inflammatory responses, cell cycle arrest, DNA repair and cell death 
(Maher and Schubert, 2000). Interestingly, ERK1/2, p38 and JNK have been indicated 
as potential kinases that promote NF-κB and Nrf2 activation (Buelna-Chontal and 
Zazueta, 2013). All three members of the MAPK family potentially can be activated 
by redox stimulus, however kinase activation may be cell type dependent. Therefore, 
it is important to study how MAPKs activity is modulated upon OS in human brain 
cells in order to reveal potential molecular redox-related mechanisms involved in the 
pathogenesis of depression.  
It was demonstrated that direct exposure of rat cerebral cortex neurons to exogenous 
H2O2, used to mimic OS, has led to activation of MAPK pathways (Wang et al., 
2003), while pre-treatment with NAC of rat pheochromocytoma and human 
neuroblastoma cells abrogated activation of MAPKs and neuronal death (Chen et al., 
2009). The mechanisms by which ROS can activate MAPK pathways and the precise 
molecular targets of ROS in theses cascades are not well defined. Plausible 
mechanisms include oxidative modifications of MAPK signalling proteins and 
inactivation of MAPK phosphatases that dephosphorylate and deactivate MAPKs 
(Son et al., 2011). Depending on the site of modification, products of these 
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transformations can inhibit or stimulate kinase activity in a similar way, as happens 
through phosphorylation. Whether these pathways are activated or inhibited and 
which specific ROS leads to modulation of its activity mostly depend on the cell type 
and the level of OS. Interestingly, not only ROS can activate MAPKs, but 
pathophysiological concentration of 4-HNE, a by-product of lipid peroxidation, could 
also increase the phosphorylation/activity of the major three MAPK pathways 
(Forman et al., 2008). 
Of relevance to depression, post-mortem studies have reported decreased levels of 
ERK pathway molecules (Raf, MEK and ERK) in the hippocampus of depressed 
suicide subjects (Dwivedi et al., 2006; Yuan et al., 2010). An increased expression of 
a negative regulator of MAPK/ERK signalling, MAP kinase phosphatase 1 (MKP1) 
was observed in post-mortem hippocampus of depressed subjects and in chronically 
stressed rodents hippocampus, which was normalized by antidepressant treatment 
(Akbarian and Davis, 2010; Duric et al., 2010). Further studies have demonstrated 
that ERK signalling is reduced by chronic stress and reversed by fluoxetine (First et 
al., 2011), and that blockade of ERK signalling produces depressive and anxiety 
behaviours in animal models of depression (Qi et al., 2009). Conversely, acute 
administration of a MAPK inhibitor that inhibits ERK phosphorylation produced 
depressive-like behaviour and blocked the antidepressant-like effects of desipramine 
and sertraline in a mouse behavioural model for depression (Duman et al., 2007). 
In contrast to these findings, some studies report that inhibition of ERK activation 
upon OS attenuated neuronal death and cellular injury, indicating a pro-death role for 
ERK1/2 (Satoh et al., 2000). The activation of p38 and JNK MAPK that is mainly 
associated with a stress response has been demonstrated in animal models of 
depression (Meller et al., 2003) and depressed individuals (Felger et al., 2011). In 
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particular, administration of LPS to IL-1 receptor deficient mice lead to activation of 
p38 MAPK pathways, which enhanced brain serotonin transporter activity. This effect 
was abrogated by blocking p38 MAPK with an inhibitor (Zhu et al., 2010). Similarly, 
social defeat stress produced depressive-like behaviour in wild-type mice, but not in 
mice having p38α MAPK selectively deleted in serotonin-producing neurons of the 
dorsal raphe nucleus. In addition, the stress-induced activation of p38α MAPK 
translocated the serotonin transporter to the plasma membrane and increased the rate 
of transmitter uptake at serotonergic nerve terminals (Bruchas et al., 2011). 
Thus, changes in redox homeostasis influence cell behaviour via complex 
mechanisms that involve transmission of the signal through activation of MAPKs, 
which may result in altered mood. Therefore, considering the possible role of OS in 
the pathophysiology underlining MDD, redox biology may provide further targets for 
pharmacological intervention. Therefore, relevant models to study molecular 
mechanisms are necessary, as there are a lot of exceptions to theoretical paradigms, 
partially due to the differences in the signal transduction machinery as well as 







Figure 12. MAPK cascades. MAPK signalling pathways mediate intracellular 
signalling initiated by extracellular or intracellular stimuli. MAP3Ks phosphorylate 
MAP2Ks, which in turn phosphorylate MAPKs. Activated MAPKs phosphorylate 
various substrate proteins (e.g., transcription factors), resulting in regulation of 
various cellular activities (e.g., proliferation, differentiation, inflammatory responses, 
and apoptosis). Activation by MAPK signalling cascades is achieved through a series 
of binary interactions among the kinase. Adapted from Son et al., 2011. 
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1.3   Oxidative stress in depression 
 
1.3.1   Oxidative stress in clinical studies of depressed patients 
Over the last decades elevated biomarkers of OS in MDD have been reported across 
many studies providing evidence for its contribution to the pathophysiology of 
depression, and suggesting clinical implications of these findings with regards to 
novel treatment strategies (Smaga et al., 2015). In order to assess the level of OS in 
clinical samples different products of oxidation or levels of antioxidants are widely 
used. These are indirect markers of OS, however due to the very short half-life of 
ROS this is the only possible way to obtain information on the oxidative state of the 
subject. Commonly, end products of lipid peroxidation mentioned in section 1.2.3.2, 
such as F2-IsoPs, 4-HNE and MDA; of DNA oxidation, such as 8-hydroxy-2’-
deoxyguanosine (8-OHdG) mentioned in section 1.2.3.3; and antioxidative enzymes 
SOD, catalase (CAT), GSH, glutathione peroxidase and glutathione reductase, are 
reported in studies examining the rates of OS in depression and response to therapy 
(Lopresti et al., 2014).  
Several meta-analyses showing interest in the oxidative status of depressed patients 
have been conducted recently. One of these included all studies reporting an 
association between depression and OS and antioxidant status markers, and found a 
positive correlation between the illness and the oxidative and antioxidant parameters. 
(Palta et al., 2014). The heterogeneity among included studies was high: sample sizes 
varied from 30 to 3000 subjects, there were 12 different OS measures, with MDA and 
nitric oxide being most frequently reported, and diverse antioxidant status were 
assessed, with SOD and glutathione peroxidase being the most common. Since an 
association between depression and OS was found with this variety of measures and 
diverse samples, this might suggest that it is even a more robust finding. A recent 
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meta-analysis which focused only on two measures of oxidative damage in depressed 
patients, including ten studies measuring 8-OHdG and eight studies evaluating F2-
isoprostanes, revealed that both OS markers are increased in depressed patients when 
compared to control groups, indicating that depression is associated with increased 
oxidative damage to DNA and lipids (Black et al., 2015). Another meta-analysis that 
looked at studies measuring lipid peroxidation only in depressed patients, consisting 
of 17 studies, also demonstrated that lipid peroxidation was greater in MDD than in 
controls and was correlated with depressive symptom severity (Mazereeuw et al., 
2015). 
Findings form the most recent studies that were not yet included in published meta-
analyses are not fully consistent. A cross-sectional and longitudinal study with a 
sample of 3009 participants revealed an association of depressive symptoms with 
increased F2-isoprostanes and decreased carotenoids, known to possess antioxidant 
properties. Although F2-isoprostanes were higher in subjects with depression after 
adjustment for socio-demographic characteristics, there was no difference after 
further adjustment for health and lifestyle factors. Additionally, carotenoids were 
lower in depressed patients independent of all factors, as revealed by regression 
analyses (Black et al., 2016). Later the same research group published results from 
another study conducted with a separately recruited smaller group of MDD patients (n 
= 2251), where a different diagnostic tool had been used for MDD assessment, and 
where oxidative biomarkers had been measured at one time point only. Contrary to 
previous findings, it was reported that OS was not increased in MDD patients, as no 
difference in the levels of F2-isoprostanes and 8-OHdG between depressed patients 
and healthy controls was observed. However, 8-OHdG levels were lower in patients 
receiving antidepressant therapy than in those with no treatment or controls, 
 91 
suggesting antioxidant properties of antidepressants (Black et al., 2016). Finally, 
another recent study that assessed oxidative status in drug naive, first episode, non-
smoker major depression patients found that MDA levels were significantly higher 
and SOD activity significantly lower in depressed patients than healthy controls, with 
similar CAT activity in both groups (Camkurt et al., 2016).  
In addition to human in vivo studies, a number of post-mortem studies detected 
differences in the oxidative status of depressed patients. These include a significant 
increase in oxidative damage to RNA but not DNA observed in 47 samples of 
hippocampal tissue (dentate gyrus, CA1, CA3 regions) from patients with MDD (Che 
et al., 2010) and elevated concentration of SOD in the prefrontal cortex, but not in the 
hippocampus from seven depressed patients (Michel et al., 2007). Although caution 
must be taken as the sample size in this study was small, it might suggest that an 
increase in antioxidant defence biomarkers is due to a compensatory response to OS. 
A later study identified diminished levels of reduced, oxidized, and total glutathione 
in 14 samples of post-mortem prefrontal cortex from depressed patients compared to 
controls (Gawryluk et al., 2011).  
 
 
1.3.2   Association between increased OS, MDD and other factors: severity of 
MDD, gender differences and telomere length 
In addition to the association between depression and OS status, some studies 
addressed also some specific issues, such as correlation of the severity of depression 
with levels of OS, gender-related differences in regards to oxidative status, links to 
gender-associated MDD vulnerability and correlation between depression and 
telomere shortening, known to be mainly caused by OS.  
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Thus, one study demonstrated a direct relationship between the potency of OS and the 
severity of depression (Yanik et al., 2004). However, later research that hypothesised 
that patients with a first episode of depression and patients with recurrent major 
depression would have different levels of oxidative status and immune-inflammatory 
markers on the level of mRNA reported no differences in the expression of SOD2 
gene, coding the enzyme responsible for detoxifying superoxide generated by 
mitochondrial respiration (Talarowska et al., 2015). Another study that aimed to 
determine whether any gender-related difference exists concerning OS revealed that 
women are more susceptible to OS than male. However these gender-based 
differences do not seem to provide a biochemical basis for the epidemiologic 
differences in MDD susceptibility between sexes, which indicates that OS is not an 
independent factor contributing to MDD vulnerability (Wiener et al., 2014). Another 
cross-sectional study that focused on middle-aged females and researched association 
between oxidative status and various health parameters such as menopausal status, 
body composition, cardiovascular characteristics, lifestyle factors (e.g., smoking, 
exercising) and depressive symptoms, found that out of all parameters being 
investigated only depression was positively correlated with high levels of urinary 8-
OHdG (Hirose et al., 2016).  
As mentioned above, there is a high rate of comorbidity between age-related somatic 
illnesses and early mortality in depressed patients (Maurya et al., 2016), which 
suggests the notion that these diseases may share the same biological pathways and 
pathological mechanisms, with OS having a key role  (Maes et al., 2011). As such, 
OS is known to be involved in the pathogenesis of age-related diseases; it is 
recognised to play a key role in cellular senescence and to be a major mechanism for 
telomere damage, itself indicative of aging (Houben et al., 2008). Telomeres are 
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nucleoprotein structures located at the ends of chromosomes with high sensitivity to 
oxidative damage due to their high content of guanines. Their function is to prevent 
chromosomal ends from fusion and degradation, and they are subjected to shortening 
at each cycle of cell division. Senescent cells were found to accumulate oxidative 
damage to nucleobases and contain 30% more oxidative modified guanine in their 
DNA and four times as many free 8-OHdG (Valavanidis and Vlachogianni, 2010). 8-
OHdG is a particular oxidative transformation of one of the DNA bases that is 
commonly measured as a marker of OS and have been found increased in various 
neurodegenerative diseases and depression (Wang et al., 2005; Jorgensen et al., 
2013). A recent study showed that patients with depression had more DNA breaks, 
alkali-labile sites and oxidative DNA damage compared with non-depressed 
individuals, and that those lesions may be accumulated by impairments of the DNA 
repair systems (Czarny et al., 2015). In addition, a recent cross-sectional study 
demonstrated that MDD patients had significantly higher mitochondrial oxidative 
damage than the comparison group (Chang et al., 2015a). 
Several studies demonstrated an exponential correlation between cellular OS levels 
and telomere shortening rates, suggesting the significant contribution of OS—
mediated DNA telomere damage as an important determinant of cellular senescent 
phenotype (Blackburn, 1991; Kawanishi and Oikawa, 2004; von Zglinicki, 2000). An 
initial study examining leucocyte telomere length found a significant reduction in 
their length in depressed patients versus healthy controls, but with no influence due to 
the applied therapy, the duration of illness or the severity of depression (Hartmann et 
al., 2010). However, later studies with much larger samples indicated that accelerated 
aging at the level of leukocyte telomeres was proportional to lifetime exposure to 
MDD and also inversely correlated with OS, both in depressed subjects as well as in 
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controls (Verhoeven et al., 2014; Wolkowitz et al., 2011). A recently conducted meta-
analysis that summarised all research that has been carried out in this field and 
included 21040 participants concluded that depression was associated with shorter 
telomere length (Schutte and Malouff, 2015). Thus, it would be interesting to perform 
further research on the correlation between the potency of OS and MDD severity, as 
well as regarding  gender susceptibility to OS and MDD, in order to advance in 
personalised treatment approach. Of great importance is studying factors that might 
prevent OS–induced telomere shortening in depression. By addressing this issue 
patients might benefit not only in regards to depression treatment but other conditions 
comorbid to MDD.  
 
 
1.3.3   Effects of antidepressant treatments on OS in clinical studies  
The involvement of OS in the pathophysiology of depression is further supported by 
the reduction of OS biomarkers levels in response to antidepressant treatment 
observed in patients (Lee et al., 2013). A recent meta-analysis that included 29 studies 
identified elevated levels of MDA accompanied by decreased levels of the antioxidant 
compounds uric acid and zinc and the antioxidant-enhancing enzyme SOD in MDD 
patients vs controls before treatment, while there was no change in total nitrites, CAT 
and glutathione peroxidase. This study demonstrated that different classes of 
antidepressants, which significantly reduced HAM-D scores, reduced MDA and 
increased uric acid and zinc levels, so that no distinction was observed in the levels of 
these markers when compared with healthy controls (Jiménez-Fernández et al., 2015).  
Another meta-analysis that integrated such parameters as TAC, various enzymatic and 
non-enzymatic antioxidants, some free radicals and oxidative damage products 
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included 273 studies and identified increased levels of OS markers and decreased 
levels of TAC and several antioxidants in depressed patients against healthy controls 
(Liu et al., 2015). Upon pharmacotherapy of these patients, increased serum uric acid, 
albumin and vitamin C levels and decreased serum nitrite, red blood cells and serum 
MDA levels were observed (Liu et al., 2015). A further study published after the 
meta-analyses measured superoxide and hydroxyl radicals and TAC in the plasma of 
healthy controls and in 35 first-episode depressed patients before and after receiving a 
12-week treatment of sertraline using a very sensitive chemiluminescence method. 
The results indicate that patients with MDD had significantly lower TAC values at 
baseline than healthy controls, while there were no significant differences in baseline 
levels of superoxide and hydroxyl radicals between patients with MDD and control 
subjects. At the end of the 12-week antidepressant treatment, TAC values were 
significantly higher and the levels of superoxide radical and hydroxyl radical were 
significantly lower than baseline values (Chang, et al., 2015). Interestingly, not only 
pharmacological interventions for depression may result in reduction of OS. It was 
reported that in 49 MDD subjects with increased level of lipid peroxidation and a 
decrease in total thiol content before treatment, these parameters were reversed by 
seven individual weekly sessions of cognitive behavioural therapy (Kaufmann et al., 
2015).  
However, results are not consistent, as some studies failed to find alterations in 
oxidative status of MDD patients by antidepressants (Maes et al., 2009b; Sarandol et 
al., 2007). Discrepancies in findings could be explained mostly by inconsistency in 
OS biomarkers and antioxidative parameters being used across studies or by 
treatment-resistant groups being examined. Consistent with this idea, in a recent study 
when the MDD group was subdivided into those who showed clinical response to 
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antidepressant therapy and those who did not, only the non-response group showed 
lower TAC, while the response group showed no significant difference to controls at 
baseline. After eight weeks of antidepressant treatment, TAC in both the response and 
non-response groups was similar, and there was no significant difference among the 
groups (Baek et al., 2016). 
Despite the dominant hypothesis that antidepressants restore noradrenergic and 
serotoninergic neurotransmitter systems, a new concept of antidepressant action has 
been suggested, based on the growing evidence demonstrating the antioxidant effects 
of these medications (Zafir et al., 2009). Nevertheless, the molecular mechanisms 
underlying the antioxidative properties of antidepressants are not yet understood. In 
this thesis the in vitro effects of antidepressants preventing oxidative damage in a 
relevant cell model are examined. 
 
 
1.3.4   Findings of molecular mechanisms of OS in MDD, coming from animal 
models of depression  
This thesis addresses the lack of relevant in vitro studies on OS and MDD and aims at 
furthering the understanding of potential molecular mechanisms linked to redox 
alterations in depression. Most of the insights into molecular mechanisms of OS 
involvement in the pathogenesis of MDD and antioxidative mechanisms of 
antidepressants come from animal models of depression and therefore it is worth 
briefly describing them. Overall, these pre-clinical models report lipid and protein 
peroxidation, DNA damage and a general down-regulation of antioxidant defence in 
different regions of brain tissues, plasma and serum. Conversely, a reduction of the 
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oxidative status along with attenuation of depressive-like behaviour is reported upon 
use of antidepressants (Smaga et al., 2015).  
Studies that sought to investigate the molecular mechanisms of these changes in 
rodents suggested that increased OS in chronic isolation models of depression might 
occur due to alterations in the primary antioxidant transcription factor Nrf2–Keap1 
signalling pathway (Djordjevic et al., 2015; Martín-de-Saavedra et al., 2013; Martín-
Hernández et al., 2016) or NADPH oxidase 2 activation in microglia (Schiavone et 
al., 2009). For example, inhibition by apocynin of the family of NADPH oxidase 
enzymes (which generates superoxide) prevented the depressive-like behavioural and 
histopathological oxidative alterations induced by social isolation in rats (Colaianna et 
al., 2013). Fluoxetine demonstrated to recover the activity levels of the antioxidative 
SOD, CAT and GSH in the rat brain after restraint stress and partially reversed the 
increased generation of ROS in peripheral blood cells obtained from restraint-stressed 
mice (Novío et al., 2011; Zafir et al., 2009). In addition, fluoxetine reversed the 
decreased expression of Nrf2 and its downstream genes in the cortex and 
hippocampus in a mouse model of depression induced by glucocorticoids to mimic 
the effects of chronic stress and induce an anxiety/depression-like phenotype in mice. 
(Mendez-David et al., 2015). The long-term administration of venlafaxine, that has 
been also studied in this thesis, protected against stress-induced oxidative lipid and 
DNA damage in male mice (Abdel-Wahab and Salama, 2011). Additionally, a single 
dose of the novel promising fast-acting antidepressant compound ketamine, which 
was also under investigation in my thesis, induced long-term antidepressant effects 
and reversed the protein oxidative damage and lipid peroxidation produced in adult 
rats following maternal deprivation (Réus et al., 2015). However, pro-oxidative 
effects of ketamine have also been reported, including increased hydroxyl radical 
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production and lipid peroxidation, and reduced activity of SOD and CAT in the 
rodent brain (da Silva et al., 2010; de Oliveira et al., 2009; Zuo et al., 2007). More 
research is warranted. 
 
 
1.3.5   Antioxidant compounds with antidepressant properties 
Since antidepressants have been demonstrated to restore altered redox homeostasis in 
MDD patients and animal models of depression, studies have examined whether 
antioxidant compounds might exhibit antidepressant properties (Xu et al., 2014). The 
literature on neuroprotective and antidepressant properties of various exogenous 
antioxidants ranging from rare herbs (Bahramsoltani et al., 2015) to pharmacological 
agents that have been widely used in medicine for a long time like NAC is enormous. 
It is not yet well-defined what molecular mechanisms of antioxidants lead to 
antidepressant effects, but it is determined that in a biological context, antioxidant 
compounds protect against oxidative damage by these main mechanisms: preventing 
ROS formation by sequestering transition metal ions into complexes, scavenging or 
quenching free radicals and other reactive species, breaking chain reactions initiated 
by free radicals and inducing antioxidants and repair systems (Scapagnini et al., 
2012). Therefore, my work sought to investigate potential antioxidative mechanisms 
of various antidepressant compounds, also using NAC as one of the conventional 
antioxidants with antidepressant properties as a positive control. 
NAC, a thiol compound that can act as a direct ROS scavenger or provide cysteine for 
glutathione production, has been used to treat psychiatric and neurological disorders 
over the past decade. Although conclusions are mixed, NAC efficacy has been 
demonstrated in the treatment of Alzheimer’s disease, autism, schizophrenia, bipolar 
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disorder and addictions (Deepmala et al., 2015). A recent meta-analysis that included 
574 participants found that MDD subjects receiving NAC improved depressive 
symptoms as assessed by Montgomery-Asberg Depression Rating Scale and HAM-D 
when compared to placebo, had better depressive symptoms scores on the Clinical 
Global Impressions-Severity of Illness scale at follow-up and showed better global 
functionality than subjects on placebo (Fernandes et al., 2016). Animal studies that 
determined antidepressant properties of NAC attributed its effect to direct antioxidant 
characteristics (Ferreira et al., 2008; Smaga et al., 2012), capability to inhibit 
inflammation (Beloosesky et al., 2012; Möller et al., 2013), potentiation of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors and as a 
result indirect modulation of noradrenaline and serotonin pathways (Costa-Campos et 
al., 2013; Linck et al., 2012) and direct modulation of cortico-striatal monoamines 
(Möller et al., 2013). The evidence of NAC efficacy in MDD patients is however 
limited. A double-blind, randomized, placebo-controlled trial conducted over 12 
weeks revealed positive effects of NAC added to conventional antidepressants, 
observed only 4 weeks after discontinuation of the treatment, and in the group with 
more severe depression or those bipolar patients who were in the depressive phase 
(Berk et al., 2008).  
Other extensively studied antioxidant compounds with antidepressant potential are 
flavonoids (Gong et al., 2014; Guan and Liu, 2016; Herrera-Ruiz et al., 2011), 
ascorbic acid (Binfaré et al., 2009; Khajehnasiri et al., 2016; Moretti et al., 2012), α-
tocopherol (Lobato et al., 2010; Sepehrmanesh et al., 2016), coenzyme Q10 (Aboul-
Fotouh, 2013), different polyphenols, such as curcumin (Seo et al., 2015) and 
resveratrol (Ge et al., 2013). For example curcumin, a polyphenolic substance, 
reduces OS through activation of heterodimers of Nrf2, leading to induction of the 
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antioxidant defensive genes and inhibition of MAO-A and MAO-B. In addition, 
curcumin modulates the levels of noradrenaline, dopamine and serotonin in the brain 
and decreases inflammation. (Kaufmann et al., 2016; Scapagnini et al., 2012). These 
findings provide a convincing rational for studying molecular mechanisms of 
antioxidant compounds and investigating their effects beyond the re-establishing of 
redox balance.      
 
 
1.3.6   Omega-3 fatty acids as potential antidepressants with antioxidative 
properties 
It is well recognised that omega-3 PUFAs are essential for nervous system activity, 
cognitive development, memory-related learning, neuroplasticity of nerve 
membranes, synaptogenesis and synaptic transmission (Mazza et al., 2007). The 
omega-3 PUFAs are derived from fish and some plants and they cannot be 
endogenously synthesized in humans. Although there are numerous PUFAs, the 
omega-3 fatty acids EPA (eicosapentaenoic acid, 20:5ω3) and DHA 
(docosahexaenoic acid, 22:6ω3) have been found to be particularly important in brain 
function, along with their precursor molecule ALA (α-linolenic acid, 18:3ω3) (Beltz 
et al., 2007). EPA and DHA are incorporated into neuronal phospholipids, and the 
fatty acid composition determines the biophysical properties of neuronal membranes 
and influences neurotransmission (Mazza et al., 2007). PUFAs have been shown to 
inhibit various aspects of inflammation, known to contribute to shifts in redox state, in 
both animals and humans (Calder, 2015; Dyall, 2015; Rapaport et al., 2016). In 
humans, positive correlations have been found between higher levels of EPA and 
DHA in red blood cells and larger total brain volume and hippocampal volume, which 
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is consistently reported to be decreased in MDD (Pottala et al., 2014). A recent review 
that analysed 24 studies on the effect of PUFA intake on brain function and structure 
indicated that EPA and DHA intake may be associated with increased functional 
activation of the prefrontal cortex in children, and greater grey matter volume and 
white matter integrity during aging. However, the study found limited evidence to 
support that omega-3 PUFA supplementation is beneficial in MDD (Bos et al., 2016). 
Although clinical trials give conflicting results on antidepressant properties of 
PUFAs, a recent meta-analysis demonstrated that PUFA preparations with EPA 
accounting for greater than 60% of their composition were effective against 
depression, while those with less were ineffective (Sublette and Ellis, 2011). Another 
meta-analysis comprised of 14 studies demonstrated lower levels of EPA, DHA and 
total omega-3 PUFAs in depressed patients suggesting that fish oils contribute to the 
pathophysiology of depression (Lin et al., 2010). Later it was identified that chronic 
or severe MDD cognitive decline is associated with lower EPA concentrations and 
higher AA/EPA ratios in erythrocyte membranes (Chiu et al., 2012). Interestingly, 
significant improvement in cognitive performance, after dietary PUFAs intake, 
particularly DHA treatment, was observed in children with low literacy ability and 
malnourishment, as well as in older adults with age-related and/or mild cognitive 
decline (Stonehouse, 2014). The most recent evidence indicates that MDD responds 
to EPA or EPA + DHA treatments, differentially or synergistically, with the most 
effective effects observed with higher doses of EPA combined with lower doses of 
DHA (Song et al., 2016). The combination of EPA with SSRIs had been shown to 
ameliorate MDD better than antidepressant monotherapy, suggesting that there are 
synergetic effects between fish oils and antidepressant treatment (Gertsik et al., 2012). 
Additionally, recent clinical study demonstrated that patient’s high baseline levels of 
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EPA and DHA predict favourable depression outcomes in patients receiving omega-3 
supplements together with conventional antidepressant (Carney et al., 2016). A very 
recent study, where an inverse association between the omega-3 index and depressive 
symptoms was observed among participants with elevated OS biomarkers, linked 
together the notion that PUFAs possess both antioxidative and antidepressant 
properties (Bigornia et al., 2016). These data suggest that the OS status may identify 
those who might benefit from fish oils consumption to improve depressive symptoms.  
Additionally, in vitro and in vivo research suggest that omega-3 PUFAs and EPA in 
particular exert antidepressant-like effects by modulating monoamine 
neurotransmission, inflammatory responses and neurogenesis (Song et al., 2016). 
Deteriorated serotoninergic, noradrenalinergic, dopaminergic neurotransmission and 
hypercortisolemia, that are often found in depressed patients have been related to 
omega-­‐3 PUFA deficiency in rats, suggesting that supplementation with omega-­‐3 
PUFAs may restore the monoamine neurotransmission and normalize HPA function 
in MDD (Kodas et al., 2004; Zimmer et al., 2002). This is supported by the 
observation that an omega-3 PUFA enriched diet promotes hippocampal plasticity 
and BDNF levels in mice (Venna et al., 2009). Additionally, DHA reverses the anti-
neurogenic effect of LPS–activated microglia in mouse neural progenitor cells 
(Antonietta Ajmone-Cat et al., 2012) and increases neurite outgrowth of immature 
neurons in embryonic hippocampal cells (Cao et al., 2009). DHA-deficient embryonic 
rat brains show decreased neurogenesis (Coti Bertrand et al., 2006), while transgenic 
mice with high levels of endogenous DHA demonstrate increased levels of 
neurogenesis (He et al., 2009). Also, DHA partially alleviates age-related reductions 
in levels of neurogenesis in rats (Dyall et al., 2010). Although PUFAs are known to 
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be linked to neurogenesis, the mechanism behind its role has yet to be elucidated 
(Crupi et al., 2013). 
Given the antidepressant and antioxidative properties of EPA and DHA, in this thesis 
I sought to investigate the capability of these PUFAs to prevent the exogenously 
induced OS in my in vitro model and some possible underlying mechanisms. 
 
 
1.4   Human hippocampal progenitor cells as a research tool to study the 
role of OS in depression and effects of antidepressant compounds 
Previous work aimed at understanding the role of OS in the pathogenesis of human 
depression has been limited to examinations of peripheral samples or post-mortem 
brain tissues. In contrast to the plenty of data available from animal studies, no in 
vitro studies have looked at the role of OS or the antioxidant properties of 
antidepressants in human brain cells. Moreover, despite a plethora of evidence 
available from clinical trials and animal models suggesting that treatment with 
antidepressants and antioxidants can reduce OS and ameliorate depressive-like 
behaviours, a poor correlation between in vitro and in vivo antioxidant properties of 
these compounds has been observed. Therefore, both approaches, while useful, do not 
allow a species-specific and cell-specific understanding of the pathological pathways, 
that would allow a better translation to clinical practice. The human hippocampal 
progenitor cell line HPC0A07/03C used in this thesis provides a relevant 
experimental platform to study the role of OS, including underlying molecular 
mechanisms. These cells exhibit the same characteristics as adult hippocampal 
progenitor cells: they express specific progenitor markers, such as GFAP, nestin and 
SOX2, they proliferate indefinitely, and they have the potential to develop into the 
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main cell types of the human central nervous system: neurons, astrocytes and 
oligodendrocytes, recapitulating human neurogenesis. This cell line has been 
successfully validated as a model of "depression in a dish". It has been used to study 
other domains of the pathogenesis of the disorder, including the role of stress and 
inflammation, and the ability of monoaminergic antidepressants and PUFAs to 
modify these domains (Anacker et al., 2013a, 2013b, 2011; Horowitz et al., 2015; 
Zunszain et al., 2012a). Here I present the first in vitro study that models OS in these 
cells, examining its role in neurogenesis, investigating molecular changes and the 
ability of antidepressant compounds to prevent the detrimental oxidative damage.  
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1.5   Aims and hypothesis of the study 
This thesis aims to evaluate the cellular and molecular effects of OS on human 
hippocampal progenitor cells, as well as the ability of antidepressant compounds to 
prevent detrimental changes caused by oxidative damage. Specifically, this thesis 
aims to address the following: 
 
Aim 1. To establish a controlled and robust model of OS in the human hippocampal 
progenitor cells; 
 
Aim 2. To study how neurogenesis is affected in the cells upon the chosen OS 
treatment, by looking at proliferation and differentiation markers and identifying 
potential signalling pathways underlining changes observed; 
 
Aim 3. To test the hypothesis that the chosen OS treatment causes activation of the 
pleiotropic transcription factors NF-κB and Nrf2, and to evaluate whether this leads to 
downstream inflammation and up-regulation of antioxidative stress genes. 
 
Aim 4. To compare the effects of antidepressants and fish oils versus antioxidants on 




2   Materials and Methods 
 
2.1   Study design  
 
This thesis examines the damaging effects of OS, known to contribute to the 
pathogenesis of depression, on human hippocampal progenitor cells and the ability of 
different compounds with antidepressant action (including a selective serotonin 
reuptake inhibitor, a serotonin–noradrenaline reuptake inhibitor, an N-methyl-D-
aspartate (NMDA) receptor antagonist and two polyunsaturated fatty acids) to prevent 
the detrimental changes inflicted by the OS insult. Additionally, the effects of OS on 
neurogenesis, that is considered to be impaired in depressed patients, were researched 
in this project. In order to investigate the cellular and molecular changes caused by 
exogenously-induced OS, a human embryonic hippocampal progenitor cell model 
(HPC0A07/03C, ReNeuron, UK) that is capable of neurogenesis and is of particular 
relevance to depression has been utilised. OS was induced by treating the cells with a 
range of concentrations of 70% aqueous solution of tert-butyl hydroperoxide (t-BHP, 
Sigma), which is a membrane permeable oxidant that can be easily metabolized and 
cause a variety of changes in biological and biochemical systems. t-BHP is an organic 
hydroperoxide that has been previously used successfully as a compound to generate 
OS damage in various in vitro models, including rat primary neuronal cultures 
(Shimmyo et al., 2008) and human astrocytes (Steinbrenner et al., 2006), and it was 
chosen due to its higher stability than H2O2, another commonly used peroxide to 
induce OS in vitro (Liu et al., 2014). HPC0A07/03C cells were expanded in culture 
and subsequently used for a variety of assays described in this thesis upon induction 
of redox shifts in the system. The underlying changes in cell viability, lipid 
peroxidation, immunoprotein secretion, transcription factor activation, proliferation, 
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differentiation and gene expression caused by OS were studied with a range of 
cellular and molecular biology techniques. Cell viability was determined using the 
MTS assay (Promega) in live cells. To assess the level of lipid peroxidation I used the 
TBARS assay (R&D), measuring the amount of MDA and other thiobarbituric acid 
substances in the supernatant. Immunocytochemistry was conducted to detect changes 
in proliferation and differentiation caused by t-BHP using specific antibodies for 
proliferation markers and for immature and mature neurons. Changes in the levels of 
apoptotic marker Cleaved Caspase-3 (CC3) and NF-κB p65 subunit nuclear 
translocation, indicative of its activation, were also assessed with 
immunocytochemistry using relevant antibodies. All images were analysed using an 
automated platform for cell imaging the CellInsight* NXT High Content Screening 
Platform (ThermoScientific). Nrf2 nuclear translocation was measured using a 
commercially available ELISA kit (Active Motif) using nuclear protein lysates. 
Kynurenine metabolites were measured in the cell culture supernatant by high 
performance liquid chromatography and mass spectrometry. Cytokines expression 
was detected using commercially available kits using ELISA and Luminex 
technology. Levels of gene expression were determined from whole cell RNA by 
quantitative real-time PCR. For analysis of protein expression whole cell protein 
lysates were obtained and subjected to electrochemiluminescence assay (Meso Scale 








Figure 13. Overview of experimental techniques employed in this PhD thesis. All 
techniques will be described in detail below. 
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2.2   Human hippocampal progenitor cells and culture  
All experiments were performed using the human embryonic hippocampal progenitor 
cell line HPC0A07/03C (provided by ReNeuron Ltd., Surrey, UK). This is a 
multipotent progenitor cell line that was conditionally immortalized. Multipotent stem 
cells have the same basic features of all stem cells, they are unspecialized cells that 
have the ability to self-renew for long periods of time and to differentiate into 
specialized cells with specific functions. In contrast to totipotent or pluripotent stem 
cells, multipotent stem cells are limited in their ability to differentiate, meaning that 
multipotent hippocampal progenitor cells can give rise to neural cells and glia, but not 
to other cell types. HPC0A07/03C cells therefore have the potential to proliferate 
indefinitely before they differentiate into a target cell (neuron, astrocyte or 
oligodendrocyte), depending on which cell culture condition is applied (Figure 14). 
HPC0A07/03C cells were generated by ReNeuron Ltd. as described previously  
(Pollock et al., 2006). Briefly, primary cells were isolated from the hippocampal 
region of a 12-week-old female foetus and transfected with the c-myc-ERTM gene. 
The c-myc-ERTM technology was developed by Littlewood and colleagues and is 
based on a fusion protein comprising the growth promoting gene c-myc and the 
genetically modified murine oestrogen receptor (ER) G525R (Danielian et al., 1993; 
Littlewood et al., 1995). The mutant oestrogen receptor is exclusively responsive to 
the synthetic steroid 4-hydroxytamoxifen (4-OHT) and will activate the c-myc gene 
only in the presence of 4-OHT (Danielian et al., 1993). HPC0A07/03C cells 
containing the c-myc-ERTM thus proliferate indefinitely in the presence of 4-OHT, the 
basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), whereas 
proliferation is ceased whenever 4-OHT, bFGF and EGF are removed from the cell 
culture media (Littlewood et al., 1995; Pollock et al., 2006). 
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Cells were cultured as described by Johansson et al. (2008) with minor modifications. 
Working stock cultures of 2 x 106 cells/ vial, passaged 11 times after they were 
generated (p11), were kept in 10% DMSO solution in liquid nitrogen at -120°C. Upon 
removal from the liquid nitrogen tank, cells were quickly thawed in a water bath at 
37°C under constant agitation, transferred to a microbiological safety cabinet and 
resuspended in 10 ml of fresh Reduced Modified Media (RMM) consisting of 
Dulbecco’s Modified Eagle’s Media/F12 (DMEM:F12, Invitrogen, Paisley, UK) 
supplemented with 0.03% human albumin (Baxter Healthcare, Compton, UK), 100 
µg/ml human apo-transferrin, 16.2 µg/ml human putrescine DiHCl, 5 µg/ml human 
rec. insulin, 60 ng/ml progesterone, 2 mM L-glutamine and 40 ng/ml sodium selenite. 
To maintain proliferation, 10 ng/ml human bFGF, 20 ng/ml human EGF and 100 nM 
4-OHT were added (Table 3). To induce differentiation, cells were cultured in RMM 
without bFGF, EGF or 4-OHT (later will be referred as RMM---) (Table 4). Cells 
were centrifuged at 900 rpm for 5min, media supernatant was aspirated, and cells 
were resuspended in fresh media to remove any residual DMSO. Cells were counted 
using a standard Neubauer hemocytometer and 1.2 x 106 cells were plated on laminin 
pre-coated 75cm2 tissue culture flasks (Nunclon) in 12 ml RMM. During normal 
expansion in a humidified cell culture incubator at 37°C and 5% CO2, HPC0A07/03C 
cells proliferate with a doubling time of 72 hours (Johansson et al., 2008). Cells were 
thus passaged every 72 hours at approximately 80% confluence. For passaging, cell 
culture media was aspirated and cells were incubated in 3 ml pre-warmed Accutase 
(Sigma) for 5 min at 37°C to detach cells from the flask. The bottom of the flask was 
then washed with 6 ml pre-warmed RMM (with a 1:2 ratio Accutase:RMM) and the 
cell suspension was collected in 15 ml centrifuge tubes (Corning). Cells were 
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centrifuged at 900rpm for 5min, supernatant was aspirated, cells were resuspended in 






Figure 14. Schematic of ReNeuron’s HPC0A07/03C cells with c-myc-
ERTM technology. Human embryonic hippocampal progenitor cells stably expressing 
the c-myc-ER transgene proliferate in the presence of the growth factor EGF and 
bFGF, and the synthetic compound 4-OHT which activates the c-myc-ER transgene. 
Upon removal of EGF, bFGF and 4-OHT, HPC0A07/03C cells cease to proliferate 











Table 3. Components added to DMEM for proliferation media. (DiHCl, 
dihydrochloride; rec, recombinant; FGF, fibroblast growth factor; EGF, epidermal 






Table 4. Components added to DMEM for differentiation media. (DiHCl, 










2.3   Experimental design 
 
2.3.1   Identification of the working doses of t-BHP 
The first aim of this thesis was to establish a robust model of OS in human 
hippocampal progenitor cells using tert-butyl hydroperoxide (t-BHP). Therefore, it 
was necessary to identify the optimal doses of t-BHP and the duration of the treatment 
that inflicted a significant oxidative damage to the cells. At the same time the purpose 
of this experiment was to confirm that there was a sufficient amount of viable cells 
left after being exposed to different concentrations of t-BHP in order to follow up the 
cells fate. 
The optimal dose and duration of treatment of t-BHP required to provoke a robust OS 
insult was first determined by examining multiple doses and treatment periods. Cells 
were plated in 96 well plates (Nunclon) at a density of 1.5 x 104 cells per well (Table 
6) in 100µL of RMM in the presence of growth factors and allowed to firmly attach 
overnight. Subsequently, cells were initially treated with t-BHP at a dose of 1µM, 
2.5µM, 5µM, 7.5µM, 10µM, 25µM, 50µM, 75µM, 100µM, and 1mM for 24 hours 
before performing a cell viability assay (Figure 15a). Each t-BHP concentration 
represents a separate condition in all experiments described. Following the results of 
this experiment the range of t-BHP concentrations was changed and narrowed down 
to 1µM, 10µM, 25µM, 50µM, 100µM, 200µM, 500µM, and 1mM. Due to dramatic 
difference in cell viability between close concentrations, 10µM and 25µM of t-BHP, 
treatment time was reduced to 1 hour, after which fresh media was added, and cells 
were cultured for the following 23 hours. After 24 hours in total cell viability assay 
was performed (Figure 15b). 
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2.3.2   Assays with antidepressant compounds 
To assess the capability of antidepressants (previously reported to possess 
antioxidative effects in vivo) and omega-3 fatty acids (known to have antidepressant 
properties) to prevent oxidative damage inflicted by t-BHP in human neural 
progenitor cells the assay described below was conducted. Antioxidants were also 
used in this assay as a positive control. Table 5 briefly outlines compounds under 
investigation and pharmacological class of the drugs.  
Cells were plated in 96 well plates (Nunclon) at a density of 1.5 x 104 cells per well 
(Table 6) in 100µL of RMM with growth factors and allowed to firmly attach 
overnight. Cells were then pre-treated with each of the compounds in two different 
concentrations for 1 hour or 24 hours. After that cells were co-treated with the 
compounds under investigation and 100µM or 500µM of t-BHP for 1 hour followed 
by 23 hours culturing in fresh media. Subsequently, cell viability assay was 
performed (Figure 15c). This paradigm was used for all experiments, unless 
otherwise stated. 
Treatment doses for antidepressants and omega-3 fatty acids were informed by 
previous in vitro research in our lab with this particular cell line (Anacker et al., 2011; 
Horowitz et al., 2015), as well as therapeutic levels where known (Schulz et al., 2012) 
before performing viability assays in our cells. All treatments had the same vehicle 
(including 0.01% DMSO and 0.1% ethanol) to exclude the possibility of any 






Figure 15. Experimental design. Cells were plated in 96 well plates and allowed to 
firmly attach overnight. The next day a) cells were treated with t-BHP for 24 hours 
and followed by the cell viability, b) cells were treated with t-BHP for 1 hour and 
then cells were cultured in fresh media for 23 hours followed by the cell viability 
assay, c) cells were pre-treated with each of the compounds for 1 or 24 hours. After 
that cells have been co-treated with the compounds under investigation and t-BHP for 
1 hour followed by 23 hours culturing in fresh media. Subsequently, cell viability 
assay was performed. 
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Compound Pharmacological class 
Sertraline hydrochloride Selective serotonin reuptake inhibitor (SSRI) 
Venlafaxine hydrochloride Serotonin-norepinephrine reuptake inhibitor (SNRI) 
Ketamine hydrochloride N-methyl-D-aspartate (NMDA) receptor antagonist 
Eicosapentaenoic acid 
(EPA) 
Omega-3 fatty acid 
Docosahexaenoic acid 
(DHA) 
Omega-3 fatty acid 
N-Acetyl-L-cysteine 
(NAC) 
N-acetyl derivative of naturally occurring amino acid 
L-cysteine – a precursor of the biological antioxidant 
glutathione 
Glutathione reduced ethyl  
ester 
Membrane/lipid permeable derivative of biological 
antioxidant glutathione 
 
Table 5. Comounds under investigation in this thesis. 
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2.3.3   Proliferation assay 
To assess whether the oxidative insults caused by t-BHP lead to changes in neuronal 
proliferation, progenitor cells were plated on 96-well plates (Nunclon) at a density of 
1.2 × 104 cells per well in 100µl RMM media (Table 6). Cells were cultured in the 
presence of EGF, bFGF and 4-OHT for 24 hours prior, followed by 72 hours 
experimental condition (1µM, 10µM, 25µM, 50µM, 100µM of t-BHP) also in the 
presence of growth factors (Figure 16a). At the end of the total incubation time (72 
hours), cells were fixed with 4% paraformaldehyde (PFA) for 20 minutes at room 
temperature. Cells were washed three times in PBS and stored at 4°C in PBS 
containing 0.2% sodium azide in preparation for immunocytochemistry. 
 
 
2.3.4   Differentiation assay 
As described above for proliferation, to assess whether the oxidative insults caused by 
t-BHP leads to change in neuronal differentiation, progenitor cells were plated on 96 
well plates (Nunclon) at a density of 1.2 × 104 cells per well in 100µl RMM media 
(Table 6). Cells were cultured in the presence of EGF, bFGF and 4-OHT for 24 hours 
prior, followed by 72 hours incubation experimental condition (1µM, 10µM, 25µM, 
50µM, 100µM of t-BHP). After this initial proliferation phase, cells were washed 
twice for 15 min in RMM (---) media, and then cultured in RMM (---) media with the 
same concentrations of t-BHP for subsequent 7 days. At the end of the total 
incubation time (10 days) cells were fixed with 4% PFA for 20 min at room-
temperature (Figure 16b). Cells were washed three times in PBS and stored at 4°C in 
PBS containing 0.2% sodium azide before further processing by 
immunocytochemistry. This experimental paradigm was also utilised in 6-well plates 
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so that protein could be extracted to investigate the signalling pathways underlying 




Figure 16. Experimental design for the cell viability assay. Cells were plated in 96 
or 6-well plates and allowed to firmly attach overnight. The next day a) cells were 
treated with t-BHP for 72 hours in proliferation media and fixed after the incubation 
time; b) cells were treated with t-BHP for 72 hours in proliferation media, then 
washed with warm DMEM and treated with t-BHP for the next 7 days. After 10 days 
in total cells from a 96-well plate were fixed in preparation for immunostaining and 
from a 6-well plate whole cell lysate was obtained. 
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Experiment Plate Number of cells used 
MTS assay 96-well plate 15 000 
Immunocytochemistry 96-well plate 15 000 
12 000 for 3+7 assay 
ELISA, Luminex 96-well plate 15 000 
HPLC-MS 96-well plate 15 000 
Electrochemiluminescence 6-well plate 350 000 
TBARS assay 6-well plate 350 000 
qPCR 6-well plate 350 000 
TransAM 75cm2  flask 3 000 000 
 
 
Table 6. Plates and number of cells used in the experiment according to the 
protocol requirements of the assay. 
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2.4   Cell viability assessment by MTS assay 
Cells were plated in 96 well plates (Nunclon) at a density of 1.5 × 104 cells per well in 
100µL of RMM and allowed to firmly attach overnight (Table 6). Depending on the 
experiment being conducted cells were then either treated directly with t-BHP or pre-
treated with each of the compounds under investigation followed by t-BHP co-
treatment (Figure 15). Subsequently cell viability assay was performed. Four 
technical replicates per condition were prepared and at least three independent 
experiments were conducted on three independent cultures. 
To determine cell viability on the culture plate the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega) was used. This is a colorimetric method 
that allows to estimate the amount of viable cells in the condition. The kit contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazine ethosulfate; PES) for enhancing chemical stability. PES allows it to be 
combined with MTS to form a stable solution. The MTS tetrazolium compound is 
bioreduced by cells into a coloured formazan product that is soluble in tissue culture 
medium. This conversion is presumably accomplished by NADPH or NADH 
produced by dehydrogenase enzymes in metabolically active cells.  
The procedure was conducted according to the manufacturer’s instructions. Briefly, 
assays were performed by adding 40µL of the CellTiter 96® AQueous One Solution 
Reagent per well per 200µL of media directly to culture wells. Cell were incubated 
for 3 hours in the presence of the assay reagent and then the absorbance was recorded 
at 490 nm with a using a DTX 880 Multimode Detector (Beckman-Coulter). The 
quantity of formazan product as measured by absorbance at 490 nm is directly 
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2.5   Lipid peroxidation assessment by TBARS assay 
Thiobarbituric acid-reactive substances (TBARS) assay is the most commonly used 
method for measuring lipid peroxidation, including MDA and other thiobarbituric 
acid-reactive substances, and was also employed in this research project. Cells were 
plated in 6-well plates (Nunclon) at a density of 3.5 × 105 cells per well in 2ml of 
RMM and allowed to firmly attach overnight (Table 6). Based on previous 
experiments where the working doses of t-BHP were identified, cells were treated 
with 50µM 100µM, 200µM 500µM and 1mM for 1 hour. Then the supernatant was 
collected and immediately stored at -80°C for the later lipid peroxidation assay 
performance. Four independent experiments were conducted on four independent 
cultures, and each sample was tested in duplicate. 
In order to identify the level of lipid peroxidation in the cells exposed to a range of 
concentrations of t-BHP the Thiobarbituric Acid Reactive Substances (TBARS) 
Parameter Assay Kit (TBARS, R&D) was used. The oxidative degradation of lipids 
by ROS results in the formation of highly reactive and unstable lipid peroxides. 
Decomposition of lipid peroxides in turn results in the formation of TBARS, 
including MDA. In the presence of heat and acid, MDA reacts with 2-thiobarbituric 
acid (TBA) and produces a coloured end product that is measured with a 96 plate 
reader at 532 nm (Figure 17). The intensity of the colour corresponds to the level of 
lipid peroxidation in the sample.  
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The procedure was performed according to the manufacturer’s instructions. Briefly, in 
order to clarify the samples from precipitating interfering proteins and other 
substances, prior to the assay performance 300µL of the sample was treated with 
300µL of TBARS Acid Reagent in a microcentrifuge tube. Then samples were mixed, 
incubated for 15 minutes at room temperature and centrifuged at 14,000 x g for 4 
minutes. Supernatants were retained and used in the assay. Afterwards, 150µL of 
standards and samples were added to each well followed by addition of 75µL of TBA 
Reagent. The optical density of each well was pre-read using a using a DTX 880 
Multimode Detector (Beckman-Coulter) set to 532 nm. The microplate was incubated 
for 2-3 hours at 45-50°C and then the optical density of each well was read with the 
same wavelength. Pre-reading was subtracted from the final reading and data were 
analysed using a four parameter logistic algorithm to derive concentrations of samples 






Figure 17. Assay Principle for the TBARS Parameter Kit. Step1: Acid-treated 
samples and standards and the TBA reagent are added to a 96-well microplate. Step 
2: During 3 hours incubation in the presence of heat (45-50 °C) MDA in the sample 
reacts with the TBA reagent and produces a coloured end product Step 3: The 
microplate is read at 532nm and the intensity of the colour corresponds to the level of 
lipid peroxidation in the sample. Picture source: https://www.rndsystems.com 
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2.6   Immunocytochemistry 
PFA-fixed cells were first incubated in 50µl of blocking solution comprising 
5% normal donkey serum (D9663, Sigma) in PBS containing 0.3% Triton X-100 
(T8787, Sigma) for 60 minutes at room temperature. Primary antibodies to measure 
proliferation, differentiation, apoptosis, transcription factor nuclear translocation 
(Table 7) were diluted in appropriate concentrations of blocking solution buffer and 
30µl/well were added and left at 4°C overnight. In the negative control for unspecific 
binding condition 30µl/well of blocking without primary antibody was added. The 
next morning, cells were washed, incubated in blocking solution for 30 minutes and 
then incubated with appropriate fluorescently tagged secondary antibodies (Alexa 
Fluor 488 donkey anti-rabbit, A-21208, 1:1000; Alexa Fluor 555 donkey anti-mouse, 
A-315070, 1:1000; both from Life Technologies) at 30µl/well for 2 hours at room 
temperature. After 3 washes, cells were counter-stained with 0.02mg/ml DAPI at 
50µl/well for 5 minutes and washed on 3 more occasions. At least three independent 
experiments were conducted on three independent cultures, and each condition 









1:500 Ki67 is a nuclear protein present during all 
active phases of the cell cycle (G1, S, G2 




9664, Cell Signalling) 





1:1000 Doublecortin is a microtubule-associated 
protein expressed by neuronal precursor 




1:500 Microtubule-associated protein 2 is 
involved in microtubule assemble. This is a 
neuron-specific cytoskeletal protein that is 
enriched in dendrites 
NF-κB p65 
(Mouse/ 
sc-8008, Santa Cruz) 
1:100 NF-κB is a transcription factor involved in 
regulation of immune-responses and 




Table 7. List of primary antibodies 
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2.6.1   Automated quantification of immunofluorescence  
An automated approach was employed to quantify cell number, markers of 
proliferation, differentiation, apoptosis and nuclear translocation of a transcription 
factor (Table 7) using the CellInsight* NXT High Content Screening (HCS) Platform 
(ThermoScientific). First, images were acquired by autofocus on nuclear staining 
(Channel 1, DAPI positive, fluorescence in the wavelength 386) in order to determine 
the field of interest. Next, exposures were adjusted in channels 2 (as revealed by 
fluorescence at 488nm wavelength) and 3 (as revealed by fluorescence at 555nm 
wavelength) in order to obtain the optimum exposure times for all wells and 
conditions across the 96-well plate. Subsequently, images at x10 magnification were 
acquired for further analysis (Figure 18). 15 fields of view per each well were used to 
quantify images. 
For identification of the markers in the nucleus (Ki67, NF-κB p65) only labelling 
confined within the nuclear perimeter as stipulated by DAPI staining was quantified 
(Figure 19a and 20). For quantification of the markers expressed in the cell body and 
dendrites (CC3, Dcx and MAP2) the software relies upon nuclear staining to aid 
construction of a concentric circle around the immediate vicinity of the nucleus. The 
creation of such a circle creates a map or region of interest. Staining confined within 
the region between the outer circle (edge of cell body) and inner circle (outside of the 
nucleus) was deemed positive (Figure 19b and 20).     
Based on values from the negative staining controls and good examples of positive 
staining, distinct and robust thresholds were set for average intensity of target regions 
of interest (e.g. nuclear or cell body) to delineate positive populations in both channel 
two and three. Any cell with an average intensity bigger than the threshold set was 
deemed positive. Crucially, the same settings were applied to each well upon 
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scanning of the plate, significantly reducing counting bias. Moreover, these same 
settings were applied to all corresponding plates within an experiment, ensuring 





Figure 18. An automated approach to quantifying the number of cells and 
markers of interest using the Cell Insight Platform (ThermoScientific). Images 
are acquired by autofocus on nuclear staining Channel 1 (wavelength 386nm) and 
then exposures are adjusted in channels 2 (wavelength 488nm) and 3 (wavelength 





Figure 19. Example of an automated identification of the area of interest. a) For 
identification of the markers in the nucleus, circle around the nucleus is formed and 
labelling confined within the circle is quantified. b) For quantification of the markers 
expressed in the cell body and dendrites, circle around the nucleus and around the 
immediate vicinity of the nucleus is formed. Staining within the area between the 
outer circle (edge of cell body) and inner circle (outside of the nucleus) is quantified. 
circle around and outside of the 
nucleus (both manually adjustable 
by the user) 
staining that is deemed positive 
between the nucleus and the circle
and outside of the nucleus









Figure 20. Algorithm of an automated identification of the area of interest. First, 
the software identifies the primary object - the nucleus of the cell, stained with DAPI. 
Then according to the user’s assigned region of interest – either within the nucleus, or 
outside of the nucleus, the software quantifies positive staining. 
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2.6.2   Representative images 
Figure 21 displays representative images of immunolabelling of the human 
hippocampal progenitor cells (HPC0A07/03C) as captured with the Cell Insight 
Imaging Platform (ThermoScientific): a) neuroblasts (Dcx-positive) and immature 
neurons (MAP2-positive); b) proliferating cells (Ki67-positive); c) nuclear 






Figure 21. Representative images of neurogenic markers acquired using the Cell 
Insight Imaging Platform (ThermoScientific): a) immature neurons detected by 
Dcx (green) and MAP2 (red) b) staining proliferating cells as labelled Ki67 (purple) 
c) apoptotic cell death revealed by the CC3 (red) and d) nuclear translocation of NF-
κB p65 subunit (yellow). 15 fields of view per each well were used to quantify 
images.  
a)                DAPI                            Dcx MAP2                       Composite
c)                DAPI                        Nf-kB p65                     Composite
d)                DAPI                        CC3                               Composite
b)                DAPI                        Ki67                              Composite
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2.7   Secreted protein quantification using ELISA method 
Cells were plated in 96 well plates (Nunclon) at a density of 1.5×104 cells per well in 
100µL of RMM and allowed to firmly attach overnight (Table 6). Then cells were 
treated with 1µM, 10µM, 25µM, 50µM, 100µM, 200µM 500µM and 1mM of t-BHP 
(200µL per well) for 1 hour and supernatant was collected. Cells were then washed 
and fresh media was added for another 23 hours and supernatant was collected again. 
Upon supernatant collection samples were immediately transferred to storage in 
aliquots to avoid future multiple freeze/thaw cycles at -80°C for later measurement. 
At least three independent experiments were conducted on three independent cultures 
with four technical replicates per condition, and each sample was tested in duplicate. 
IL-6 secreted into the supernatant (both after 1 hour and after subsequent 23 hours) by 
the cells treated with t-BHP was quantified using the human IL-6 Quantikine enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems, Abingdon, UK). The 
procedure was performed according to the manufacturer’s instructions. Briefly, cell 
supernatant and standard dilutions were incubated in wells pre-coated with IL-6 
antibody for two hours. IL-6 conjugate, a polyclonal antibody specific for human IL-6 
conjugated to horseradish peroxides, was then added and incubated for two hours. 
Finally, a substrate solution of TMB was incubated for thirty minutes causing a colour 
change, before being terminated with a stop solution of sulphuric acid. Absorbance 
was read at 450 nm using a DTX 880 Multimode Detector (Beckman-Coulter). Data 
were analysed using a four parameter logistic algorithm to derive concentrations of 
samples from known standards using SoftMax Pro (Molecular Devices, Sunnyvale, 




2.8   Multiplex protein quantification using Luminex platform 
Experiments were conducted and samples were stored as outlined in section 2.7. Cells 
supernatants were run on the Human Cytokine Magnetic 25-Plex Panel (Invitrogen) 
according to the manufacturer’s instructions. Briefly, samples were incubated with 
25µL of a suspension of antibody beads containing 25 antibodies to different 
chemokines and cytokines for two hours, along with standard curves, generated by 
serial dilution (containing all 25 immunoproteins assayed). Antibodies form primary 
complexes in proportion to the amount of soluble immunoprotein specific to that 
antibody. Each antibody is covalently bound to magnetic microspheres which are 
dyed with red and infrared fluorospheres (known as a bead region), which allows for 
differentiation of one bead (and therefore the bound antibody) from another using 
infrared lasers. Samples were then incubated with a biotinylated detector antibody 
(100µL per well) for one hour. The final incubation step consists of 100µL of 
Streptavidin-RPE solution in each well. The samples were then read on a Luminex 
200 platform which using the principle of flow cytometry to read individual beads on 
two characteristics: their bead region (determined by infrared lasers) and their 
fluorescent intensity (proportional to the amount of original immunoprotein (Figure 
22). Data was analysed with a four-parameter logistic algorithm to derive 





Figure 22. Cytokine Human Magnetic 25-Plex Panel protocol. Samples and 
standards were incubated in turn with antibody-bound beads to 25 immunoproteins, 
followed by incubation with a biotinylated detector antibody and finally with a 
streptavidin-RPE solution that produces a fluorescent signal in proportion to the 
amount of original immunoprotein. This signal is then read, along with an infrared 
marker distinguishing immunoprotein antibodies from each other, by the Luminex 
xMAP system working on the principle of flow cytometry. Picture source: 
https://tools.thermofisher.com 
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2.9   Nrf2 transactivation assay 
 
2.9.1   Nuclear protein extraction 
Nuclear extracts were obtained using a Nuclear Extraction kit (Active Motif, 
Rixensart, Belgium) according to the manufacturer’s instructions. All manipulations 
were performed on ice. First, cells were washed once in 5ml ice cold PBS. Cells were 
then scraped in 5ml ice-cold PBS, transferred to 15ml centrifuge tubes and 
centrifuged at 3000 rpm for 10 min in a pre-cooled centrifuge at 4°C. The supernatant 
was carefully discarded and each cell pellet was gently resuspended in 400µl 
hypotonic buffer. Samples were transferred to 1.5ml microcentrifuge tubes and 
incubated for 15 min on ice. 20µl of detergent was added and samples were vortexed 
for 10 seconds at the highest setting. The suspensions were then centrifuged at 14,000 
x g for 2 min at 4°C and the supernatant (cytoplasmic fraction) was removed. Cell 
pellets (nuclear pellets) were resuspended in 50µl of complete lysis buffer containing 
protease inhibitors (Active Motif) and vortexed for 30 seconds at the highest setting. 
The samples were incubated for 30 min at 4°C on a rocking platform at 400 rpm. 
Afterwards, the lysates were vortexed for 1 min at the highest setting and centrifuged 
for 10 min at 14,000 x g in a pre-cooled microcentrifuge at 4°C. The supernatants 
(nuclear fraction) were transferred to a fresh microcentrifuge tube and stored at -80°C 
until further analysis.  
 
 
2.9.2   Protein quantification 
Protein concentrations were quantified using a bicinchoninic acid (BCA) colorimetric 
assay system (Novagen). Protein samples were diluted 1:10 in protein lysis buffer and 
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incubated with the kit reaction mixture in a ratio of 1:8 (sample: reaction mixture) for 
30 min at 37°C. Absorbance was measured with a microplate reader (DTX 880 
Multimode Detector, Beckman Coulter, Brea, USA) at 562nm and the protein 
concentration of each sample in duplicate was determined by comparison with a 
bovine serum albumin (BSA) standard curve (0µg/ml, 1.25µg/ml, 5µg/ml, 10µg/ml, 




2.9.3   TransAM Nrf2 assay  
Nuclear extracts were obtained after treatment of the cells with 25µM 50µM and 
100µM of t-BHP for 1 hour in 75cm2 flasks (Table 6). Samples were thawed on ice 
and diluted to a final concentration of 5µg per condition directly before the assay 
performance. Nrf2 binding to the ARE consensus binding site (5’-
GTCACAGTGACTCAG-CAGAATCTG -3’) was analysed using the TransAM Nrf2 
assay (Active Motif). The active form of Nrf2 contained in nuclear extract (obtained 
as described in 2.9.1) specifically binds to this oligonucleotide. The primary antibody 
used to detect Nrf2 recognises an epitope on Nrf2 protein upon DNA binding. 
Addition of an HRP-conjugated secondary antibody provides a colorimetric readout 
quantified by spectrophotometry. 40µL of complete binding buffer was added to each 
well and 5µg of nuclear protein extracts or provided positive control extracts diluted 
in complete lysis buffer or plain complete lysis buffer for blank wells were added to 
the wells accordingly. Nuclear protein extracts were incubated with the Nrf2 
oligonucleotide in binding buffer for 1 hour at room temperature on a rocking 
platform set for 100 rpm. Plates were washed three times with wash buffer and 
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sequentially incubated with 100µL of Nrf2 antibody (1:1000) for 1 hour at room 
temperature without agitation. Plates were washed again three times with wash buffer 
and 100µL of HRP-conjugated antibody (1:1000) was added and incubated for 1 hour 
at room temperature without agitation. Plates were washed now four times with wash 
buffer and 100µL of warmed to room temperature developing solution was added. 
After protected from light 15 minutes incubation at room temperature 100µL of stop 
solution was added. Then the absorbance was read with a spectrophotometer (DTX 
880 Multimode Detector, Beckman Coulter, Brea, USA) at 450 nm with a reference 
wavelength 655nm (Figure 23). Specificity of the assay was confirmed using wild-






Figure 23. Flow chart of Nrf2 transactivation assay using the Nrf2 TransAM kit 
from Active Motif. Nuclear protein extracts were incubated with the Nrf2 response 
element oligonucleotide on the assay plate and sequentially incubated with Nrf2-
antibody and with HRP-conjugated antibody for 1 hour at room temperature. 
Absorbance was measured to quantify the amount of Nrf2 bound to the Nrf2 sequence 
on the plate. Picture source: www.activemotif.com   
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2.10   Electrochemiluminescence assay using Meso Scale Discovery 
platform 
 
2.10.1   Whole cell lysate extraction 
Experiments were conducted in 6-well plates as outlined in section 2.3.4 (Figure 16b, 
Table 6). Whole cell lysates were obtained according to the manufacture’s 
recommendations and all manipulations were performed on ice. Briefly, cells were 
washed once with ice cold PBS, then 1ml of PBS was added in the wells and cells 
were scraped from the surface of the dish and transferred into 15ml conical tubes. 
Cells were centrifuged at 500 x g for 3 minutes at 4°C, the supernatant was removed 
and the pallet was resuspended in 500µL of complete lysis buffer, containing protease 
and phosphatase inhibitors (Table 8). Cell lysate was immediately transferred to 
storage at -80°C for later measurement. Directly before the assay performance protein 
concentrations were quantified using a bicinchoninic acid (BCA) colorimetric assay 






Tris Lysis Buffer (1X Incomplete) 
 
150mM NaCl 






Complete Lysis Buffer 
10ml 1X Tris Lysis Buffer 
100µL Phosphotase Inhibitor I 
100µL Phosphotase Inhibitor II 
100µL Protease Inhibitor Solution 
 
 
Table 8. Complete Lysis Buffer. 
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2.10.2   Meso Scale Discovery assay 
To compare the levels of phosphorylated MAP kinases across treatment conditions 
and vehicle the MAP Kinase Pshospooprotein Assay Whole Cell Lysate Kit (MSD® 
MULTI-SPOT Assay System) was used. This is a multiplex sandwich immunoaassay, 
where an array of capture antibodies against different targets – phospho-p38, 
phospho-ERK1/2, phospho-JNK is patterned on distinct spots in the same well 
(Figure 24). Analytes in the samples bind to these capture antibodies and detection 
antibodies against the targets that are added over the course of incubation periods and 
are conjugated with an electrochemiluminiscence compound - MSD SULFO-TAG 
label, bind to the sample analyte. Upon addition of the MSD read buffer appropriate 
chemical environment for the electrochemiluminiscence is provided. Then the plate is 
loaded into an MSD SECTOR® Imager for analysis. Electrochemiluminescent labels 
generate light when voltage is applied to the plate electrodes and the instrument 
measures intensity of the emitted light to provide a quantitative measure of phospho-
p38, phospho-ERK1/2, phospho-JNK present in the sample (Figure 25).  
Cell lysate samples were thawed on ice and diluted to a final concentration of 20µg 
per well. The assay procedure was performed according to the manufacturer’s 
instructions. Briefly, 150µl of blocking solution was added into each well and the 
plate was incubated for 1 hour with vigorous shaking at 1000 rpm at room 
temperature. The plate was washed three times with tris wash buffer, then 25µL of 
samples was added and the plate was incubated for three hours with vigorous shaking 
at 1000 rpm at room temperature. The plate was washed again three times with tris 
wash buffer and 25µL of detection antibody solution was added and the plate was 
incubated for 1 hour with vigorous shaking at 1000 rpm at room temperature. The 
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plate was washed again three times with tris wash buffer, then 150µL of 1xread buffer 




Figure 24. Spot diagram showing placement of analyte capture antibody. The 
numbering convention for the different spots is maintained in the software 




Figure 25. Principle of electrochemiluminesce in an immunoassay. 
Electrochemiluminescent labels generate light when stimulated by electricity in the 
appropriate chemical environment. This reaction is incorporated into immunoassays 
to provide the light signal used to measure biomedical molecules. 
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2.11   Gene expression analysis 
 
2.11.1   RNA isolation 
Experiments were conducted in 6-well plates as outlined in section 2.3.2, (Figure 
15c, Table 6). For analysis of gene expression changes, RNA was isolated using 
RNeasy micro kit Qiagen, Crawley, UK) according to the manufacturer’s instructions. 
HPC0A07/03C cells were gown in a monolayer in 6-well plates flasks (Nunclon) until 
~80% confluence and the cells were lysed in 350µl lysis buffer RLT (Qiagen) with 
addition of 3.5µl of ß-mercaptoathanol and physically removed from the plates. One 
volume (350µl) of 70% molecular biology grade ethanol (Sigma) was added to the 
lysate and the solution was mixed well by pipetting. Each sample (700µl) was 
transferred to an RNeasy spin column. The spin column was placed into a 2ml 
collection tube and centrifuged for 1min at 10,000 rpm. The flow through was 
discarded and 700µl of wash buffer RW1 was added to the RNeasy spin column. The 
spin column was centrifuged for 1 min at 10,000 rpm and 500µl buffer RPE was 
added and centrifuged once for 1 min at 10,000 rpm. Another 500µl of buffer RPE 
was added and spin columns were centrifuged for 2min at 10,000 rpm. The spin 
columns were placed into a clean 2 ml collection tube and centrifuged for 1min at 
13,000 rpm to eliminate any possible carryover of buffer RPE, or any residual flow-
through remains on the outside of the spin column which may impair RNA quality. 
To elute the RNA from the spin column, spin columns were then placed into 1.5ml 
collection tubes and 30µl of RNase-free water was added. Columns were centrifuged 
for 1min at 10,000 rpm and the RNA-containing eluate was stored at - 80°C until 
further processing. 
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The concentration and purity of extracted nucleic acids was measured using the 
NanoDrop™ 1000 spectrophotometer (Thermo Scientific) directly before performing 
reverse transcription. The 260/280 and 260/230 absorbance ratios were used to assess 
the purity of RNA. A 260/280 ratio ≈2.0 and a 260/230 ratio in range of 1.8-2.2 




2.11.2   Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Complimentary DNA (cDNA) was synthesised using SuperScript® III Reverse 
Transcriptase (18080-044, Life Technologies). 1 µg of RNA was combined with 250 
ng of random hexamers (N8080127, Life Technologies) and 1mM dNTP mix (R0191, 
Thermo Scientific) made up to 13µl with nuclease-free H2O (Sigma-Aldrich). The 
mix was incubated for 5 minutes at 65°C on a heated block to denature RNA 
secondary structure. It was then promptly placed on ice and incubated for 1 minute. 
The mix was then made up to 20µl with the following reagents: 1x First Strand Buffer 
(Invitrogen), 5mM dithiothreitol (18080-044, Life Technologies), 40 units 
RNaseOUT™ (10777, Life Technologies), 200 units SuperScript® III Reverse 
Transcriptase (Invitrogen) and 3µl of nuclease-free H2O (Sigma-Aldrich). Samples 
were incubated at 25ºC for 5 minutes, 50ºC for 1 hour (optimal temperature of 
Superscript® III), 55ºC for 30 minutes (to remove any secondary structures) and 
finally 70 ºC for 15 minutes to terminate the reaction. For qPCR applications, samples 




2.11.3   Quantitative Real-Time PCR (qPCR) 
Quantitative Real-Time PCR (qPCR) was performed using commercially available 
TaqMan® assays (Thermo Fisher Scientific). Each assay includes target primers and a 
sequence specific probe optimized for the best functional performance of the assay, 
therefore it is a sensitive and specific method for gene expression analysis. The 
company does not divulge primer sequences. 10uL of qPCR reaction mix per one 
assay consisted of the reagents and cDNA template presented in the Table 9. 
 
qPCR was run on Chromo4™ Real-Time PCR detector (Bio-Rad) using the following 
parameters: 
Initial denaturation: 50ºC for 2 minutes 
Denaturation: 95ºC for 10 minutes 
Annealing: 95ºC for 15 seconds 
Extension: 60ºC for 1 minute 
Annealing and Extension cycles were repeated 40 times. Fluorescence was recorded 








20xTaqMan® Gene Expression Assay 0.5µL 
TaqMan® Gene Expression Master Mix 5µL 
cDNA template sample 4µL 
RNase-free water  0.5µL 
 
Table 9. qPCR reaction mix 
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First, to choose the reference genes appropriate for my specific experimental 
conditions five housekeeping genes previously used with HPC0A07/03C cell line in 
our laboratory (beta-actin (ACTB), RPL13A, GAPDH, RPLP2 and YWHAZ) were 
tested with control and each experimental condition in three independent experiments. 
ACTB and RPL13A were chosen as the reference genes for subsequent experiments 
due to the smallest variability in its expression across all conditions and replicates 
(cycle threshold variability was within 0.5). 
Each target gene (NQO1, SLC1A1, HMOX1, SLC7A11, GCLM, Keap1) and two 
reference genes (ACTB and RPL13A) assays were validated by creating a standard 
curve, consisting of five serial dilutions. Each sample was assayed in triplicate and 
each target was normalized to the geometric mean of the two reference genes. The 
Pfaffl Method (Pfaffl, 2001) was used to determine relative target gene expression. 
Data are expressed as fold change from the vehicle treated control condition. 
 
 
2.12   Kynurenine pathway quantification 
 
2.12.1   Sample preparation 
Experiments were conducted as outlined in 2.7 (Table 6). Both supernatants after 1 
hour and after subsequent 23 hours were measured. Perchloric acid 0.5M (HClO4), 
was used to extract analytes from cell culture medium. 1ml of cell supernatant from 
each experimental condition was centrifuged (2000 × rpm, 5 min) to pellet and 
remove dead cells. 100 µL of each supernatant sample was collected and combined 
with an equal volume of ice cold solvent (1M HClO4) fortified with internal standard 
(final concentration 1µM); then samples were centrifuged (15000 × g, 10 min) and the 
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supernatants were collected and stored at -80 °C until high performance liquid 
chromatography (HPLC) analysis. The supernatants were directly injected into the 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) device. 
 
 
2.12.2   Liquid chromatography 
The analysis was performed using an Agilent HP 1200 liquid chromatograph 
(Agilent, Milan) consisting of a binary pump, an autosampler and a thermostated 
column compartment. Chromatographic separations were carried out using a 
Discovery HS-F5 column (150 x 4.6 mm, 5 µm) using 0.1% formic acid in water 
(solvent A) and acetonitrile (solvent B) as mobile phase. The HPLC analyses were 
carried out using a linear elution profile of 15 minutes from 5% to 90% of acetonitrile 
(ACN). The column was washed with 90 % of acetonitrile for 3.5 min followed by the 
equilibration of the column for 5 min with 5 % acetonitrile. The flow rate was 0.5 
ml/min. The injection volume was 40µL. An Agilent 6410 triple quadrupole-mass 
spectrometer with an electrospray ion source operated in positive mode was used for 
detection. Flow injection analysis was used to optimise the fragmentor and source 
parameters. The optimized source parameters for MS analysis were: drying gas 
temperature 350 °C and gas flow 12 L/min, nebulizer gas flow pressure 35 psi and 
capillary voltage 4500 V. 
 
 
2.13   Statistical analysis  
 
For cell viability assays, at least 3 independent experiments performed on different 
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experimental days (biological replicates, indicated as ‘n’) with 4 technical replicates 
(four different wells on the same plate in the same experiment) were conducted for 
each set of experiments. For lipid peroxidation assay 4 independent experiments 
conducted on different experimental days were performed and TBARS assay was 
conducted in duplicates for each sample. For proliferation and differentiation 
immunocytochemistry assays at least 3 independent experiments performed on 
different experimental days with 6 technical replicates were conducted for each set of 
experiments. For measurement of cytokine levels in the supernatant by ELISA or 
Luminex multiplex immunoassay at least 3 independent experiments performed on 
different experimental days with 4 technical replicates were conducted for each set of 
experiments and the assay was performed in duplicates. For Nrf2 transactivation 
assay at least 4 independent experiments performed on different experimental days 
were conducted and the assay was performed in duplicates. For 
electrochemiluminescence assay at least 3 independent experiments performed on 
different experimental days were conducted and the assay was performed in 
duplicates. For gene expression analysis, at least 5 independent experiments 
performed on different experimental days were conducted. One RT-PCR was 
conducted per sample per experiment, and quantitative Real-Time PCR was 
conducted in triplicates for each sample. 
Data in each individual experiment was normalized to the average value of the vehicle 
condition. The percentage change from the vehicle condition is presented as the mean 
value ± SEM. All statistical analyses were performed with GraphPad Prism 6.0g 
(Graph Pad Inc., La Jolla, CA, USA) on independent biological replicates (indicated 
as ‘n’). One-Way ANOVA with Newman-Keuls post hoc test was used for multiple 
comparisons between treatment groups and controls. Student’s t-test was used to 
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2.14   Drugs and reagents  
All drugs and reagents were purchased from Sigma–Aldrich (St Louis, MO, USA), 
unless otherwise stated. Growth factors EGF and bFGF were purchased from 
Peprotech (London, UK). FR180204 ERK1/2 inhibitor was purchased from 
Selleckchem (USA) and dissolved in DMSO. Sertraline hydrochloride, venlafaxine 
hydrochloride, EPA (>98% pure, extracted and purified from fish), DHA (>98% pure, 
extracted and purified from algal vegetable oil), were dissolved in 100% ethanol 
(EtOH). Ketamine hydrochloride, N-acetyl-L-cysteine and glutathione reduced ethyl 
ester were dissolved in RMM. 
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3   Results  
 
3.1   Oxidative stress induced by t-BHP causes cell damage in human 
progenitor hippocampal cells 
 
3.1.1   t-BHP causes cell damage and cell death in a dose-dependent manner, 
with intensity of effects dependant on time of exposure   
In order to establish the experimental set up of induced OS in the human progenitor 
hippocampal cell line, I first sought to identify the doses of t-BHP that cause 
significant cell damage. As described in current literature, toxic doses of t-BHP vary 
with both the density of cells and the cell types studied (Chen and Chen, 2011; 
Steinbrenner et al., 2006). Therefore, initially cells were treated in 96-well plates with 
a range of concentrations of t-BHP from 1µM to 1mM for 24 hours and then cell 
viability was assessed using the MTS assay. No significant change in cell viability 
was observed at 1µM, 2.5µM, 5µM, 7.5µM and 10µM concentrations of t-BHP. A 
significant reduction in cell viability to 65%, p<0.05 occurred at 25µM of t-BHP, and 
this reduction increased reaching 30%, p<0.0001 at 50µM of t-BHP. At 75µM, 
100µM and 1mM doses of t-BHP the reduction in cell viability reached only 5% and 
less (p<0.0001) suggesting that almost all cells died because of the massive oxidative 
damage inflicted by the peroxide (Figure 26). 
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Figure 26. Dose-dependent decrease in cell viability after 24 hours of t-BHP 
treatment. A significant decrease in cell viability was observed at 25µM to 65% and 
at 50µM to 30%, while at 75µM, 100µM and 1000µM of t-BHP almost all cells died. 
Data are shown as mean ± SEM, *p<0.05, ****p<0.0001, compared with vehicle 





























Given such drastic decreases in cell viability, and hoping for more controlled 
reductions, I changed the experimental design, modifying the time of exposure. In this 
new paradigm I treated cells with the same range of concentrations of t-BHP for 1 
hour, then cells were cultured in fresh media for the following 23 hours, keeping the 
same total culture time before the MTS assay was performed (so 24 hours in total). 
Evaluating which experimental set up is more physiologically relevant is not 
straightforward; in my first one I was identifying cell damage straight after the OS 
insult, in the second one I determined if cells survived after a certain period 
subsequent to the inflicted OS insult. This last acute 1 hour treatment with t-BHP 
caused a significant delayed decrease in cell viability in a dose-dependent manner 
when compared with vehicle: at 100µM to 71%, at 200µM to 42%, at 500µM to 28% 






Figure 27. Dose-dependent decrease of cell viability after 1 hour of t-BHP 
treatment followed by 23 hours of culturing in fresh media. A significant decrease 
in cell viability was observed starting at 100µM of t-BHP: at 100µM to 71%, at 
200µM to 42%, at 500µM to 28% (p<0.0001) and at 1mM to 14%. Data are shown as 
mean ± SEM, ***p<0.001, ****p<0.0001, compared with vehicle treatment. Four 

































Given these reductions in cell viability after treatment with t-BHP for 1 hour  
followed by 23 hours with no treatment (fresh media), two doses of t-BHP, 100µM 
and 500µM, were selected to be used in those subsequent experiments designed to  
identify compounds that can prevent damage. Since there was no significant decrease 
in viability when cells were treated using this paradigm with 1µM, 10µM, 25µM or 
50µM of t-BHP, these concentrations were used in subsequent experiments to study 
cell signalling pathways as I hypothesized that mild redox shifts in the system towards 
more a oxidised environment would cause upregulation of cellular antioxidative 
defences and influence the cell fate. 
 
 
3.1.2   t-BHP induces lipid peroxidation in a dose-dependent manner 
In order to check whether t-BHP causes lipid peroxidation in the human hippocampal 
progenitor cells I measured thiobarbituric acid reactive substances, performing the 
TBARS assay. Cells were treated in 6-well plates with 50µM, 100µM, 200µM, 
500µM and 1000µM of t-BHP for 1 hour, then the supernatant was removed and 
stored at -80°C until analysis. Results are presented as percentage change of 
concentration of TBARS from the vehicle. A significant increase in the level of 
TBARS was observed in cells treated with 500µM (+56%, p<0.001) and 1000µM of 
t-BHP (+96%, p<0.0001). Although at 50µM, 100µM and 200µM of t-BHP statistical 




Figure 28. Dose-dependent increase in lipid peroxidation after 1 hour t-BHP 
treatment. A significant increase in lipid peroxidation measured through 
thiobarbituric acid reactive substances was observed at 500µM and at 1000µM. Data 
are shown as mean ± SEM, ***p<0.001, ****p<0.0001, compared with vehicle 



































3.1.3   t-BHP treatment does not cause differences in expression of Cleaved 
Caspase-3 
To investigate if the damage induced by t-BHP on the human hippocampal progenitor 
cells involved apoptotic mechanisms, cells were treated in 96-well plates with 10µM, 
25µM, 50µM, and 100µM of t-BHP for 1 hour. Cells were then washed and fresh 
media was added for another 23 hours. After 24 hours in total, cells were fixed with 
4% PFA in preparation for immunocytochemistry. To assess apoptosis, cells were 
immunolabelled with Cleaved Caspase-3 (CC3), a commonly used apoptotic marker, 
and staining was analysed using the automated approach CellInsight* NXT HCS 
Platform. While treatment with t-BHP caused a significant reduction in the number of 
cells at all concentrations evaluated (Figure 29a), there were no significant 
differences in the expression levels of CC3 (Figure 29b). Results are expressed as 





Figure 29. Treatment of cells with t-BHP for 1 hour followed by 23 hours of 
culturing in fresh media did not cause differences in the expression levels of 
Cleaved Caspase-3. a) The total number of cells was significantly lower upon 
treatment with t-BHP at doses of 10µM and higher. b) No significant differences in 
the level of expression of CC3 were observed across conditions when compared to 
vehicle. Data are shown as mean ± SEM, *p<0.05, ****p<0.0001, compared with 
vehicle treatment. Three independent experiments were conducted on three 




































































3.2   Effects of t-BHP on neurogenesis 
My second aim was to explore how neurogenesis is affected in the human 
hippocampal progenitor cells upon induction of redox shifts by t-BHP treatment and 
to identify potential signalling pathways involved. Increased OS biomarkers in 
depressed patients have been reported across many different studies (Black et al., 
2015; Liu et al., 2015) and there is also evidence of impaired neurogenesis in MDD 
coming mainly from animal models (Lucassen et al., 2016). However, it is not clear 
how alterations in redox homeostasis might influence neurogenesis, in particular in 
the human hippocampal progenitor cells. Current literature suggests that adult 
neurogenesis transiently generates OS (Walton et al., 2012) and neural stem cells 
(NSC) are extremely sensitive to redox regulation and maintain a high ROS status for 
implementation of the normal cellular functioning (Le Belle et al., 2011). Thus, I 
sought to induce redox shifts in the human hippocampal progenitor cells by t-BHP 
treatment and assess the levels of proliferation and differentiation in the neural 
progenitors by labelling them with relevant markers.  
 
 
3.2.1   Effects of t-BHP treatment on proliferation  
In order to investigate the effects of t-BHP on proliferation, I first treated proliferating 
human hippocampal progenitor cells for 72 hours with t-BHP at concentrations of 
1µM, 10µM, 25µM, 50µM and 100µM. After this incubation time cells were fixed 
with 4% PFA in preparation for immunocytochemistry. Cells were immunolabelled 
with Ki67, a marker of cellular proliferation, and images were obtained and analysed 
using the CellInsight* approach. Treatment with t-BHP showed no distinct effects on 
cell proliferation at 1µM and 10µM, causing a decrease in proliferation at 25µM 
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(72%, p<0.01) and at 50µM (37%, p<0.0001) (Figure 30a). Data is presented as the 
percentage of Ki67-positive cells in treated cultures compared to those in control 





Figure 30. Treatment of human hippocampal progenitor cells with t-BHP for 72 
hours of proliferation caused decrease in Ki67-positive cells. a) A significant 
decrease in Ki67-positive cells was observed at 25µM (72%) and at 50µM (37%). b) 
A significant decrease in the total number of cells was observed at 10µM (77%), at 
25µM (35%), at 50µM (8%) and at 100µM (5%). Data are shown as mean ± SEM, 
**p<0.01, ****p<0.0001, compared with vehicle treatment. Three independent 





























































3.2.2   Effects of t-BHP treatment on differentiation 
To examine the effects of t-BHP on neuronal differentiation and neuronal maturation, 
I treated the human hippocampal progenitor cells in 96-well plates with 1µM, 10µM, 
25µM, 50µM, 100µM of t-BHP for 72 hours during proliferation (in the presence of 
growth factors) and for subsequent 7 days during differentiation (in the absence of 
growth factors) as described in 2.3.4. Thus, cells were treated continuously during 
both the proliferation and the differentiation phase for 10 days in total. After fixation 
of the cells upon completion of the incubation time, immunocytochemistry was 
conducted to visualize young Dcx-positive neuroblasts and mature MAP2-positive 
neurons and also analysed using the CellInsight* NXT HCS Platform. Treatment with 
t-BHP led to a significant increase in the amount of Dcx-positive neuroblasts when 
treated with 1µM (+38%, p<0.01) and 10µM (+30%, p<0.05). No effect was observed 
at 25µM of t-BHP (Figure 31a). The percentage of MAP2-positive neurons rose 
when treated with 1µM (+34%, p<0.05) and 10µM (+33%, p<0.05), whereas at 25µM 
of t-BHP no significant difference was observed (Figure 31b). Treatment with t-BHP 
during these 10 days caused a significant decrease in the total number of cells when 
exposed to a dose of 25µM (50%, p<0.0001), with higher decreases observed at 50µM 
and 100µM of t-BHP, where almost all cells died (Figure 31c). Data is presented as 
percentage change from the vehicle, calculated as the number of Dcx-positive and 
MAP2-positive cells in each condition over the number of cells (stained with DAPI) 
in the corresponding wells (Figure 31a, b). For the number of cells data is presented 




Figure 31. Treatment of human hippocampal progenitor cells with t-BHP during 
proliferation and differentiation caused increase in neurogenesis and decrease in 
the number of cells. a) A significant increase in the amount of Dcx-positive cells was 
observed at 1µM (+38%) and at 10µM (+30%); b) A significant increase in the 
amount of MAP2-positive cells was observed at 1µM (+34%) and at 10µM (+33%); 
c) A significant decrease in the number of cells was observed at 25µM to 50%, and 
almost all cells died at 50µM and at 100µM. Data are shown as mean ± SEM, 
*p<0.05 **p<0.01, ****p<0.0001, compared with vehicle treatment. Six independent 
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3.3   Modulating effect of t-BHP treatment on MAP kinases 
 
I wished to investigate whether the effects of t-BHP on progenitor cell differentiation 
are mediated through MAP kinase signalling pathways. Therefore, I first sought to 
explore whether treatment of the cells with t-BHP would lead to an increase in 
phosphorylation, indicative of activation of p38, ERK1/2 and JNK kinases. My 
intention was to then block activation (if any observed) with relevant inhibitors and 
examine whether it would abrogate the pro-neurogenic effects induced by t-BHP 
treatment. To compare the levels of these phosphorylated MAP kinases across 
treatment conditions and vehicle I treated cells in 6-well plates in order to obtain 
enough protein (Table 6) with the same concentrations of t-BHP and in exactly the 
same manner as in 3.2.2 (Figure 16b). Upon 10 days of total incubation time, whole 
cell lysates were obtained as described in methods 2.10.1. and stored at -80°C until 
the assay performance. All cell lysates were thawed at once directly before the assay 
and protein concentration was calculated with the BSA method to then normalise 
across conditions for the electrochemiluminiscence immunoassay assay, using the 
MAP Kinase Phosphoprotein Assay Whole Cell Lysate Kit (MSD® MULTI-SPOT 
Assay System). Treatment with t-BHP did not lead to a significant increase in 
phospho-p38, phospho-ERK1/2 or phospho-JNK kinases in the human progenitor 




Figure 32. t-BHP treatment during proliferation and differentiation did not 
cause changes in the levels of phosphorylated MAP kinases. Treatment with 1µM, 
10µM and 25µM of t-BHP did not lead to significant changes in the levels of 
expression of phospho-p38, phospho-ERK1/2 and phospho-JNK kinases in the human 
hippocampal progenitor cells. Data are shown as mean ± SEM. Three independent 



























































To examine whether the effect of t-BHP on MAP kinase activation could be time-
dependant, I repeated the experiment treating cells with t-BHP for 24 hours only, 
using the two lowest concentrations of the peroxide this time, due to the high cost of 
the assay. Upon 24 hours of total incubation the same procedures were repeated as 
described above. Again no significant increase in expression of the kinases under 
investigation was observed, only showing a similar trend in the level of the phospho-





Figure 33. t-BHP treatment for 24 hours during proliferation did not cause 
changes in the levels of phosphorylated MAP kinases. Treatment with 1µM and 
10µM of t-BHP did not lead to significant changes in the levels of expression of 
phospho-p38, phospho-ERK1/2 and phospho-JNK kinases in the human hippocampal 
progenitor cells. Data are shown as mean ± SEM. Three independent experiments 



















































3.3.1   Inhibition of ERK1/2 abrogated the increase in MAP2-positive cells 
induced by t-BHP  
Although the increase in phospho-ERK1/2 did not reach statistical significance, based 
on the signal obtained and due to the expenses of the assay I decided to proceed and 
block the phospho-ERK1/2 with the FR180204 inhibitor and investigate whether it 
would prevent the t-BHP-induced changes in neurogenesis. Thus, there was a slight 
modification to the experimental design described in 2.3.4. Cells were first pre-treated 
in 96-well plates with 10nM or 100nM of FR180204 for 24 hours and then co-treated 
with either 1µM or 10µM of t-BHP for the following 48 hours during proliferation. 
After 72 hours of proliferation cells were washed and differentiated with the same 
conditions as in proliferation, so co-treated with 10nM or 100nM of FR180204 with 
either 1µM or 10µM of t-BHP. To test if FR180204 inhibitor had an effect on it is 
own, cells were also treated with FR180204 only. Treatment with 1µM and 10µM of 
t-BHP increased the amount of MAP2-positive cells (+21%, p<0.01, and +27%, 
p<0.0001, respectively) and the amount of Dcx-positive cells (+32%, p<0.001 and 
+33%, p<0.01, respectively) when treated with 1µM and 10µM of t-BHP. Treatment 
with the inhibitor alone showed no effect.  
I then evaluated the effect of pre-treatment with the inhibitor. Cells were treated with 
10nM and 100nM of FR180204 inhibitor for 24 hours, followed by co-treatment with 
1µM or 10µM of t-BHP during 48 hours of proliferation and 7 days of differentiation 
(Figure 34). This pre-treatment with the inhibitor did not lead to significant changes 
in the amount of Dcx-positive cells when compared to the cells treated with t-BHP 
only (Figure 35). When cells were pre-treated with 10nM of FR180204, a trend 
towards a decrease in the amount of MAP2 positive cells was observed, reaching 
significance with the higher concentration of the inhibitor. Pre-treatment with 100nM 
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of FR180204 and co-treatment with 10µM of t-BHP caused a complete reduction in 
the amount of MAP2 positive cells (p<0.01), when compared to the condition where 
cells were treated with 10µM of t-BHP only. Also, a clear trend towards a decrease in 
the amount of MAP2 positive cells was observed when cells were pre-treated with 
100nM of the FR180204 and co-treated with 1µM of t-BHP, however a significant 






Figure 34. Experimental design of the assay with FR180204 – ERK1/2 inhibitor. 
Human hippocampal progenitor cells were seeded in 96-well plates and incubated 
overnight. Cells were then either pre-treated with media or FR180204 inhibitor for 24 
hours and subsequently co-treated with media, t-BHP or t-BHP plus FR180204 
inhibitor for the next 48 hours. After 72 hours of proliferation cells were washed with 
warm DMEM and the same treatment conditions in media without growth factors 
were applied for the next 7 days. After 10 days of total incubation time cells were 
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Figure 35. t-BHP-induced increase of neuroblasts and the effect of FR180204 
inhibitor. A significant increase in the amount of Dcx-positive cells was observed at 
a) 1µM (+32%) and at b) 10µM (+33%). a, b) FR180204 inhibitor did not affect t-
BHP–induced increase in the amount of Dcx-positive cells. Data are shown as mean ± 
SEM, **p<0.01. Three independent experiments were conducted on three 
























































































Figure 36. Abrogation of t-BHP-induced increase of neuronal maturation by 
blocking ERK1/2 with FR180204 inhibitor. a) A significant increase in the amount 
of MAP2-positive cells was observed at 1µM (+21%). b) A significant increase in the 
amount of MAP2-positive cells was observed at 10µM (+27%). 100nM of FR180204 
in the presence of 10µM of t-BHP completely prevented an increase in MAP2-
positive cells caused by t-BHP and was significantly different from the condition 
treated with 10µM of t-BHP. Data are shown as mean ± SEM, **p<0.01, 

























































































3.4   Oxidative stress induced by t-BHP causes activation of pleiotropic 
transcription factors NF-κB and Nrf2 
The inducible regulation of gene expression through pleiotropic transcription factors 
is a central element of the normal cell physiology and is key to the ability of 
multicellular organisms to adapt to various environmental stresses. NF-κB and Nrf2 
are two redox-sensitive transcription factors critical for a myriad of interrelating 
events determining the cell fate (Figure 8) (Bakunina et al., 2015). In particular, Nrf2 
is a major antioxidant transcription factor and its activation leads to up-regulation of 
its antioxidative downstream genes. NF-κB is a master regulator of immune responses 
and it also broadly influences gene expression that impact cell survival, differentiation 
and proliferation (Hayden and Ghosh, 2008). The activation time of these 
transcription factors depends on the biological context and I decided to investigate 
whether NF-κB is activated already after 1 hour of oxidative stimulus and whether it 
stays activated within 24 hours in the presence of oxidative stimulus. Based on NF-κB 
activation after 1 hour and 24 hours, my plan was to choose the time-points for future 
experiments to measure cytokine expression, hypothesizing that the more pronounced 
NF-κB expression the higher the production of cytokines would be. I tested Nrf2 
redox-activation after 1 hour only because I wanted to evaluate whether the effects I 
had observed for the compounds under investigation in the cell viability assay were 
associated with alterations in gene expression downstream of Nrf2. 
 
 
3.4.1   t-BHP induces Nrf2 nuclear translocation 
To examine if Nrf2 transcription factor is activated in the human progenitor 
hippocampal cells I performed the transactivation assay the TransAM Nrf2 assay 
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(Active Motif). As described in methods (section 2.9.3), cells were treated in 75cm2 
flasks with 25µM, 50µM and 100µM of t-BHP for 1 hour and then nuclear extracts 
were obtained and stored at -80°C until further analysis. After normalisation of the 
protein concentration across samples the transactivation assay was performed. A 
significant increase in the level of nuclear Nrf2 was observed in cells treated with 
50µM and 100µM of t-BHP (+46%, p<0.01 and +113% p<0.0001 respectively) when 






Figure 37. Dose-dependent increase of the amount of Nrf2 in nuclear protein 
extracts after 1 hour of t-BHP treatment. A significant increase in the amount of 
Nrf2 was observed at 50µM (+46%) and at 100µM (+113%). Data are shown as mean 
± SEM, ** p<0.01, ****p<0.0001, compared with vehicle treatment. Four 
































3.4.2   t-BHP induces NF-κB p65 subunit nuclear translocation 
In order to investigate if treatment of the human hippocampal progenitor cells with t-
BHP leads to activation of the NF-κB transcription factor, I followed the nuclear 
translocation of its p65 subunit by immunostaining. Upon activation the p65 subunit 
is released form the cytoplasm, translocates to the nucleus and binds to its nuclear 
localization sequence, initiating transcription of several downstream genes. In this 
experiment cells were treated for 1 hour with t-BHP at concentrations of 25µM, 50µM 
and 100µM of t-BHP and then cells were fixed with PFA in preparation for 
immunocytochemistry. To investigate whether redox NF-κB activation occurs at 
lower concentrations of t-BHP and stays for a longer period of time, in a separate 
experiment cells were treated with 1µM and 10µM of t-BHP for 24 hours. 
Considering that higher concentrations of t-BHP are toxic when applied for 24 hours 
(Figure 26), they were not tested in this experiment. 
The images were obtained and analysed using the CellInsight* automated approach 
Treatment of the cells with t-BHP for 1 hour caused significant increase in the NF-κB 
p65 subunit positive cells within the nucleus at 50µM and 100µM reaching 16% and 
17% and being significantly different when compared to vehicle (p<0.0001) (Figure 
38a). Treatment of the cells with t-BHP for 24 hours caused a much smaller, but 
significant increase in the NF-κB p65 subunit positive cells within the nucleus at 
10µM to 4% (p<0.05) with no effect at 1µM when compared to vehicle (Figure 38b). 
Data is presented as percentage of NF-κB p65 positive cells, considered as those with 
staining detected in the nucleus only, over the total number of cells (stained with 





Figure 38. t-BHP treatment of the human hippocampal progenitor cells caused 
increase in the nuclear translocation of the NF-κB p65 subunit. a) A significant 
increase in the NF-κB p65 subunit nuclear translocation after 1 hour of t-BHP 
treatment was observed at 50µM (16%) and 100µM (17%) when compared to vehicle. 
b) A significant increase in the NF-κB p65 subunit nuclear translocation after 24 
hours of t-BHP treatment was observed at 10µM (4%). Data are shown as mean ± 
SEM, *p<0.05, ****p<0.0001, compared with vehicle treatment. Three independent 
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3.5   Oxidative stress induced by t-BHP in the human progenitor 
hippocampal cells: in pursuit for inflammation  
Many studies demonstrate increased biomarkers of OS and inflammation in depressed 
patients, however the underlying molecular mechanisms of the complex interplay of 
these systems remain to be unclear. Some of the proposed potential ways by which 
increased OS might trigger inflammatory cascades and vice versa are described in the 
introduction of this thesis, section 1.2.6. One of those mechanisms is a redox-induced 
activation of NF-κB transcription factor, mostly associated with the immune response 
and propagation of pro-inflammatory cascades, despite the diversity of biological 
roles it fulfils. Previously it was reported that the human hippocampal progenitor cells 
I use in this thesis are immunocompetent, that is, they respond to, and produce, 
inflammatory molecules (Horowitz et al., 2015). Immunocompetent cells respond to 
inflammatory stimulation by activation of intracellular signalling mechanisms, 
leading to the transcription of a number of cytokines and their secretion from the cell. 
In particular, stimulation with IL-1β leads to the secretion of a number of pro-
inflammatory cytokines including IL-6 (Horowitz et al., 2015), that is routinely found 
increased in the blood of depressed patients along with other cytokines, and have been 
implicated in the pathogenesis of depression (Howren et al., 2009; Dowlati et al., 
2010; Jansen et al., 2015). This inflammatory stimulation in response to IL-1β was 
accompanied by activation of NF-κB, which I found to be significantly increased in 
cells treated with 50µM and 100µM of t-BHP. Thus, I sought to investigate whether 
the peroxide lead to increased levels of cytokines, indicative of an activated immune 
response. 
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3.5.1   t-BHP treatment does not lead to increased secretion of cytokines 
In order to measure the levels of cytokines produced by the cells upon OS insult I 
used two different methods: I performed an ELISA assay to detect IL-6 using the 
human IL-6 Quantikine ELISA kit (R&D Systems) and I conducted a multiplex 
protein quantification with Luminex platform using the Human Cytokine Magnetic 
25-Plex Panel (Invitrogen). Cells were treated in 96-well plates with a range of 
concentrations of t-BHP from 1µM to 1mM for 1 hour. The supernatant was collected 
and stored at -80°C for further analysis, cells were washed and fresh media was added 
for another 23 hours and the supernatant was collected again and stored at -80°C 
before the assay performance. Both supernatants collected after one hour and after 
subsequent 23 hours were analysed. The concentration of all of the cytokines across 
all samples was either below the detection range or outside of the standard curve and 
therefore not qualified for analysis. A representative example of the standard curve 
and pg/ml concentrations of IL-6 in the samples treated with t-BHP derived from the 





Figure 39. Standard curve based on the results from the provided standards in 
IL-6 Quantikine ELISA kit (R&D Systems) generated using SoftMax Pro 
(Molecular Devices).  
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vehicle 1µM 10µM 25µM 50µM 100µM 200µM 500µM 1000µM 
1st repeat 0.033 0.01 0.005 below 
range 
0.028 0.014 0.001 below 
range 
0.032 




3rd repeat 0.024 0.805 0.124 0.056 below 
range 





Table 10. Concentrations of IL-6 in pg/ml in the supernatants collected from the 
human hippocampal progenitor cells treated with a range of concentrations of t-
BHP after 1 hour. Data from three independent experiments conducted on three 
independent cell cultures presented as the mean of a duplicate of the sample in pg/ml 
of IL-6. Data analysed with a four parameter logistic algorithm to derive 




3.5.2   t-BHP treatment did not affect the kynurenine pathway  
Increased OS is associated with alterations in the kynurenine pathway that has been 
implicated in the pathogenesis of depression (Tan et al., 2012; Lovelace et al., 2016). 
I therefore wished to investigate whether t-BHP would lead to perturbations in the 
kynurenine pathway in the human hippocampal progenitor cells. Cells were treated in 
96-well plates with 200µM, 500µM and 1000µM of t-BHP for 1 hour. The 
supernatant was collected and stored at -80°C, cells were washed and fresh media was 
added for another 23 hours and the supernatant was collected again and stored at -
80°C. Both supernatants collected after one hour and after subsequent 23 hours were 
sent for HPLC analysis. Kynurenine (KYN), quinolinic acid (QUINA), tryptophan 
(TRP), anthranilic acid (ANA), 3-hydroxyanthranilic acid (3-HANA), kynurenic 
acid (KYNA) and 3-hydroxykynurenine (3-HK) were measured in the samples. 
QUINA, 3-HANA, KYNA and 3-HK were not detected. KYN, TRP and ANA were 
detected in all samples, however no significant differences across conditions were 





Figure 40. Metabolites of the kynurenine pathway detected in the supernatants 
of the human hippocampal progenitor cells treated with t-BHP. a, b) The 
concentration of kynurenine detected in the samples after 1 hour (a) and subsequent 
23 hours (b) of t-BHP treatment; c, d) The concentration of tryptophan detected in the 
samples after 1 hour (c) and subsequent 23 hours (d) of t-BHP treatment; e, f) The 
concentration of anthranilic acid detected in the samples after 1 hour (e) and 
subsequent 23 hours (f) of t-BHP treatment. Three independent experiments were 












































































































































































3.6   Testing various compounds with antidepressant action for the ability 
to prevent oxidative damage induced by t-BHP 
In order to test whether various compounds with antidepressant action are capable of 
preventing the oxidative cell injury inflicted by t-BHP in the human hippocampal 
progenitor cells I used several paradigms including pre-treatment and co-treatment 
with these drugs before exposure to the peroxide. Two pre-treatment durations were 
implemented, of either 1 hour or 24 hours, while co-treatment of the compounds 
under investigation with t-BHP was always 1 hour. Based on the results of the 
previous experiments (section 3.1.1), two doses of t-BHP, 100µM and 500µM, were 
chosen in order to explore if the ability of antidepressant compounds to prevent 
oxidative cell damage depends on the severity of oxidative insult being applied. 
Following an oxidative injury in all experiments, cells were washed and cultured for 
the following 23 hours in fresh media. Subsequently cell viability assay was 
performed. In all experiments I included the following controls: vehicle conditions for 
the whole duration; exposure to culture media during the pre-treatment periods and 
treatment with either 100µM or 500µM of t-BHP only for 1 hour followed by 23 
hours in fresh media. 
 
 
3.6.1   Testing conventional antioxidants for the ability to prevent oxidative 
damage induced by t-BHP 
I first sought to test the conventional antioxidants N-acetyl-cysteine (NAC) and GSH 
in order to validate the assay. First I tested the effect of NAC at 1mM and 10mM and 
100mM on preventing the oxidative cell damage caused by t-BHP. This was the first 
time when NAC was used with HPC0A07/03C cell line in the OS conditions and 
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therefore, for screening purposes, I decided to use a range of NAC concentrations. I 
wanted to: 1) determine what would be the effective concentration of NAC to prevent 
OS damage in the cells and 2) if 1mM and 10mM of NAC were not effective, to 
ensure that the experimental protocol worked, since it was the first experiment to 
detect if prevention of the OS damage in the cells inflicted by t-BHP by antioxidants 
is possible. In this experiment treatment of the cells with 100µM and 500µM of t-
BHP for 1 hour followed by 23 hours of culturing the cells in fresh media caused 
reductions in cell viability to 52%, p<0.0001 and 37%, p<0.0001 respectively. Pre-
treatment of the cells with 1mM or 10mM of NAC for 1 hour followed by co-
treatment of the cells with 1mM or 10mM of NAC plus either 100µM or 500µM of t-
BHP for 1 hour did not have significant preventing effect on cell viability when 
compared to the cells treated with 100µM and 500µM of t-BHP only. In the same 
experimental design, but with 100mM of NAC cell viability reached 85%, p<0.0001 
when co-treated with 100µM of t-BHP and 76%, p<0.0001 when co-treated with 
500µM of t-BHP, being significantly different from the conditions where cells were 
treated with 100µM and 500µM of t-BHP only (Figure 41). The concentration of 
100mM of NAC was not used in further experiments due to being physiologically 
irrelevant. In my following experiments, NAC was substituted by its cell permeable 
precursor GSH-monoethylester, where preventive effects on OS damage were 





Figure 41. 1 hour pre-treatment and 1 hour co-treatment with 100mM of NAC 
plus t-BHP of the human hippocampal progenitor cells prevented reduction in 
cell viability caused by t-BHP. A significant reduction in cell viability was observed 
a) at 100µM of t-BHP (52%) and b) at 500µM of t-BHP (37%). a) Pre-treatment and 
co-treatment of the cells with 100mM of NAC plus 100µM of t-BHP abridged 
reduction in cell viability reaching 85%; b) 100mM of NAC plus 500µM of t-BHP 
abridged reduction in cell viability reaching 76%. Data are shown as mean ± SEM, 


























































Then I tested the effect of GSH at 1mM and 10mM on preventing the oxidative cell 
damage caused by t-BHP, implementing 24 hours of pre-treatment duration. In this 
experiment treatment of the cells with 100µM and 500µM of t-BHP for 1 hour 
followed by 23 hours of culturing cells in fresh media caused reduction in cell 
viability to 75%, p<0.001 and 46%, p<0.0001 respectively. Pre-treatment of the cells 
with 1mM or 10mM of GSH for 24 hours followed by co-treatment of the cells with 
1mM or 10mM of GSH plus 100µM of t-BHP for 1 hour caused minor reduction in 
cell viability reaching 98%, p<0.05 and 91%, p<0.01 respectively, which presented a 
significant difference when compared to the cells treated with 100µM of t-BHP only. 
In the same experiment the same doses of GSH, but co-treated with 500µM of t-BHP 
caused reduction in cell viability to 76%, p<0.0001 at 1mM of GSH and 73%, 
p<0.0001 at 10mM of GSH, which was significantly different when compared to the 
cells treated with 500µM of t-BHP only (Figure 42). 
There are various commercially available fluorometric kits for detecting  
intracellular GSH, however HPLC is a preferable method. GSH ethyl ester is a 
membrane/lipid permeable derivative of GSH which is effectively transported into the 
cells. For example, it was shown that preloading murine mesencephalic cultures for 
24 h with 1-10mM GSH ethyl ester produced a dose-dependent increase in 
intracellular levels of GSH, reaching an increase of 191% when treated with 10mM of 
GSH ethyl ester compared with basal levels. (Zeevalk et al., 2007). My primary 
interest was to identify whether pre-treatment and co-treatment of the human 
hippocampal progenitor cells with GSH ethyl ester protected cells from t-BHP 
damage and thus I focused on the cell viability assay. However, it would be 
instructive to identify intracellular basal GSH levels and GSH levels upon treatment 





Figure 42. 24 hours pre-treatment and 1 hour co-treatment with GSH plus t-
BHP followed by 23 hours of incubation in fresh media of the human 
hippocampal progenitor. A significant reduction in cell viability was observed a) at 
100µM (75%) and b) at 500µM (46%). a) Pre-treatment and co-treatment of the cells 
with 1mM or 10mM of plus 100µM of t-BHP abridged reduction in cell viability 
reaching 98% and 91% respectively. b) Pre-treatment and co-treatment of the cells 
with 1mM or 10mM of GSH plus 500µM of t-BHP abridged reduction in cell 
viability reaching 76% and 73% respectively. Data are shown as mean ± SEM, 
*p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. Four independent experiments were 























































3.6.2   1 hour pre-treatment and 1 hour co-treatment with antidepressants plus 
t-BHP did not prevent the reduction in cell viability caused by oxidative 
insult 
The commonly used SSRI antidepressant sertraline and the SNRI venlafaxine at 
concentrations 100nM and 1µM were tested in exactly the same experimental 
paradigm as described in the previous section. I chose these treatment doses based on 
previous in vitro research in our lab with this particular cell line (Anacker et al., 2011; 
Horowitz et al., 2015). No significant preventing effect of these drugs on cell viability 
when compared to the cells treated with 100µM and 500µM of t-BHP was observed 
(Figure 43a, b, c, d). I then tested the NMDA receptor antagonist ketamine, more 
recently being used as antidepressant, at two clinically relevant concentrations, 1µM 
and 10µM, similar to those detected in the plasma of depressed patients treated with 
ketamine (Zarate et al., 2012). No significant preventing effect of ketamine on cell 
viability when compared to the cells treated with 100µM and 500µM of t-BHP was 
observed (Figure 43e, f). Data is presented as the percentage of viable cells in treated 





Figure 43. 1 hour pre-treatment and 1 hour co-treatment with antidepressant 
compounds plus t-BHP of the human hippocampal progenitor cells did not 
prevent reduction in cell viability caused by t-BHP. A significant reduction in cell 
viability was observed: a) at 100µM to 72%, b) at 500µM to 59%, c) at 100µM to 















































































































































a,b) sertraline, c,d) venlafaxine and e,f) ketamine on prevention of reduction of cell 
viability inflicted by t-BHP when compared to the cells treated with 100µM or 
500µM of t-BHP only was observed. Data are shown as mean ± SEM, ***p<0.001, 
****p<0.0001. At least four independent experiments were conducted on at least four 
independent cultures (n = 4-6). 
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3.6.3   24 hours pre-treatment and 1 hour co-treatment with EPA plus t-BHP, 
but not antidepressants or DHA, prevented the reduction in cell viability 
caused by oxidative insult of the human hippocampal progenitor cells. 
I hypothesized that a pre-treatment duration of 1 hour may be not sufficient for 
sertraline, venlafaxine and ketamine to develop the antioxidative effect and therefore I 
tested these drugs at the same concentrations, but changing the pre-treatment duration 
from 1 hour to 24 hours. I also tested the omega-3 fatty acids and tested of EPA and 
DHA  at 1µM and 10µM in this experimental paradigm for their ability to prevent the 
oxidative cell damage. These treatment doses were also chosen based on previous in 
vitro research in our lab with this particular cell line (Horowitz et al., 2015). 
Pre-treatment of the cells with 1µM, but not 10µM of EPA for 24 hours followed by 
co-treatment with 1µM of EPA plus 100µM of t-BHP for 1 hour and subsequent 
incubation in fresh media for 23 hours completely prevented the reduction in cell 
viability caused by 100µM of t-BHP (100%, p<0.01).  This was significantly different 
from the cells treated with 100µM of t-BHP, where cell viability decreased to 77%, 
p<0.001 (Figure 44a). When cells were treated with 500µM of t-BHP, EPA was not 
able to prevent the reduction in cell viability to 46% caused by the peroxide, neither 
when used at 1µM nor at 10µM (Figure 44b).  DHA, ketamine, sertraline and 
venlafaxine were also tested in exactly the same experimental paradigm at the doses 
previously evaluated, but they showed no significant preventing effect on cell 
viability when compared to the cells treated with 100µM and 500µM of t-BHP only 




















































































































































Figure 44. 24 hours pre-treatment and 1 hour co-treatment with antidepressant 
compounds plus t-BHP followed by 23 hours of incubation in fresh media of the 
human hippocampal progenitor cells. a) Pre-treatment and co-treatment of the cells 
with 1µM of EPA prevented  decrease in cell viability (100%) caused by 100µM of t-
BHP. A significant reduction in cell viability was observed, when cells were treated 
with t-BHP: a) at 100µM to 77%, b) at 500µM to 46%, c) at 100µM to 77%, d) at 
500µM to 42%, e) at 100µM to 78%, f) at 500µM 56%,  g) at 100µM 78%, h) at 
500µM to 42%, i) at 100µM to 77%, j) at 500µM 42%. Data are shown as mean ± 
SEM, **p<0.01 ***p<0.001, ****p<0.0001. At least three independent experiments 


































































































3.7   Modulation of gene expression by t-BHP and EPA and GSH in the 
presence of oxidative insult in the human hippocampal progenitor 
cells 
In the previous section 3.7.2 I described that pre-treatment of the human hippocampal 
progenitor cells with 1µM of EPA prior to the 1 hour co-treatment with 100µM of     
t-BHP prevented the reduction in cell viability caused by the oxidative insult (Figure 
44a). In order to further investigate potential molecular mechanisms that might 
underlie the antioxidative action of EPA, I sought to determine if EPA has any effect 
on antioxidative genes, so comparing it to the effects of t-BHP on its own in the same 
experimental set up. GSH, that had shown a significant preventive effect on the 
reduction in cell viability caused by t-BHP (Figure 42) was also included in the 
experiments in order to investigate its modulating effect on gene expression. 
Furthermore, I wanted to determine if there were any differential effects for EPA or 
GSH on gene expression. To obtain enough mRNA for gene expression analysis 
(Table 6) cells were grown in 6-well plates and the same experimental design as that 
used in the cell viability assays with a 24 hour pre-treatment period with the 
compounds under investigation was employed (Figure 15c). mRNA extraction was 
followed by RT-PCR and then qPCR was performed using commercially available 
TaqMan® assays for HMOX1, NQO1, GCLM, Keap1, SLC7A11 and SLC1A1 genes. 
I hypothesised that EPA in the presence of an oxidative stimuli might lead to an 
increased activation of Nrf2, a major antioxidant transcription factor, through 
inhibiting the expression of Keap1 and therefore, through regulation of synthesis of 
this protein. Keap1 is bound to Nrf2 in the cytoplasm and by that limits the nuclear 
translocation and activation of the transcription factor (Figure 8) (Itoh et al., 1999, 
1997; Moi et al., 1994). I also wanted to determine if EPA pre-trearment leads to 
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upregulation of the antioxidative stress genes HMOX1, NQO1, GCLM and in 
particular SLC7A11 in OS conditions. SLC7A11 is the gene coding for the light chain 
xCT/SLC7A11 subunit of the system xc−, the major provider of intracellular cysteine 
for GSH synthesis in exchange for one molecule of glutamate into the extracellular 
space (Figure 6). Since excessive extracellular glutamate is excitotoxic and has been 
implicated in the pathogenesis of depression (Mehta et al., 2013; Sanacora et al., 
2012), I hypothesised that EPA pre-treatment of the cells in OS conditions might also 
lead to an enhanced glutamate clearance from the extracellular space through 
upregulation of the SLC1A1 gene, coding for the glutamate transporter EAAT3.  
 
 
3.7.1   Modulation of antioxidative stress genes by t-BHP and EPA and GSH in 
the presence of oxidative insult in the human hippocampal progenitor 
cells 
Treatment of the human hippocampal progenitor cells with 100µM of t-BHP only 
caused a downregulation of Keap1 of -20% (p<0.05); pre-treatment of the cells with 
1µM of EPA and co-treatment with 100µM of t-BHP also caused a slightly higher 
downregulation of Keap1 gene (-35%, p<0.01). Similarly, GSH caused a 
downregulation of Keap1 gene of -47% (p<0.001) (Figure 45a).  
Treatment of the cells with 100µM of t-BHP caused an upregulation of HMOX1 gene 
of +64% (p<0.05), while pre-treatment of the cells with 1µM of EPA followed by co-
treatment with 100µM of t-BHP caused a slightly higher upregulation of this gene of 
+92% (p<0.01). When cells were pre-treated with 1mM of GSH and co-treated with 
100µM of t-BHP in the same experimental set up, no significant difference in 
HMOX1 gene expression were observed when compared to vehicle (Figure 45b). No 
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significant difference in expression of NQO1 or GCLM genes across conditions was 
observed when compared to vehicle (Figure 45c, d). 
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Figure 45. Modulation of antioxidative gene expression by t-BHP and EPA and 
GSH in the presence of t-BHP in the human hippocampal progenitor cells. Cells 
were pre-treated with the compound under investigation for 24 hours, then co-
incubated with t-BHP and the compound under investigation for 1 hour followed by 
incubation in fresh media for 23 hours. a) A significant downregulation of Keap1 was 
observed at 100µM of t-BHP (-20%), at 1µM of EPA plus at 100µM of t-BHP (-35)% 
and at 1mM of GSH plus at 100µM of t-BHP (-47%). b) A significant upregulation of 
HMOX1 was observed at 100µM of t-BHP (+64%), at 1µM of EPA plus at 100µM of 
t-BHP (+92%). c, d) No significant difference was observed in expression of NQO1 























































































mean ± SEM, *p<0.05, **p<0.01 ***p<0.001. At least five independent experiments 
were conducted on at least five independent cultures (n=5-11). 
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3.7.2   Modulation of system xc−  and glutamate transport by t-BHP and EPA and 
GSH in the presence of oxidative insult via gene expression regulation in 
the human hippocampal progenitor cells  
Treatment of the human hippocampal progenitor cells with 100µM of t-BHP caused a 
downregulation of SLC7A11 of -25% (p<0.05). Pre-treatment of the cells with 1µM of 
EPA followed by co-treatment with 100µM of t-BHP prevented the downregulation 
of SLC7A11 caused by the oxidative injury and was significantly different from the 
condition where cells were treated with the peroxide only, showing now an 
upregulation of +38% (p<0.01). GSH did not have similar effects to EPA on the 
expression of SLC7A11, and this condition was not different from the cells treated 
with 100µM of t-BHP only, but was significantly different from vehicle, showing a    
-42% (p<0.001) decrease (Figure 46a). It is possible that in this case the pre-
treatment of cells with GSH ethyl ester had limited effects because significant 
increases in intracellular GSH levels were not achieved. Interestingly, it was 
demonstrated in murine mesencephalic cultures that the half-life for clearance of 
loaded 5mM of GSH ethyl ester for 24 hours which was then switched to fresh media 
was ∼10 hours and ∼14 hours in normal and GSH-depleted cultures respectively 
(Zeevalk et al., 2007). This issue can be addressed in the human hippocampal 
progenitor cells in further research by performing assays to detect the intracellular 
GSH levels. 
Treatment of the cells with 100µM of t-BHP or pre-treatment with 1µM of EPA 
followed by co-treatment with EPA and the peroxide did not cause significant 
changes in the levels of expression of SLC1A1. Pre-treatment of the cells with 1mM 
of GSH and co-treatment with 100µM of t-BHP led to a downregulation of SLC1A1 
gene of -35% (p<0.01) when compared to vehicle (Figure 46b).  
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Figure 46. Modulation of SLC7A11 and SLC1A1 genes by t-BHP and EPA and 
GSH in the presence of oxidative in the human hippocampal progenitor cells. 
Cells were pre-treated with the compound under investigation for 24 hours, then co-
incubated with t-BHP and the compound under investigation for 1 hour followed by 
incubation in fresh media for 23 hours. a) A significant downregulation of SLC7A11 
was observed at 100µM of t-BHP (-25%). 1µM of EPA plus 100µM of t-BHP 
upregulated SLC7A11 (-38%) compared to 100µM of t-BHP only. 1mM of GSH plus 
100µM of t-BHP downregulated SLC7A11 (-48%) compared to vehicle. b) 1mM of 
GSH plus 100µM of t-BHP downregulated SLC1A1 (-35%) compared to vehicle. 
Data are shown as mean ± SEM, *p<0.05, **p<0.01 ***p<0.001. At least five 














































4   Discussion 
 
4.1   Summary of findings 
In this thesis I have set up an experimental in vitro model of OS in human 
hippocampal cells, using the progenitor cell line HPC0A07/03C capable of 
neurogenesis. I have studied potential molecular mechanisms thought to be involved 
in the pathogenesis of MDD, as well as tested the ability of various compounds with 
antidepressant action to prevent detrimental changes caused by oxidative damage. I 
have demonstrated that t-BHP–induced OS caused significant reductions in cell 
viability and an increase in lipid peroxidation, indicative of oxidative damage, in a 
dose-dependent manner, with no difference in the levels of CC3, an apoptotic marker. 
The omega-3 fatty acid EPA and the conventional antioxidants NAC and GSH 
prevented the inflicted oxidative damage caused by t-BHP, by modulating the 
expression of a series of genes involved in the OS response. Neither DHA nor 
sertraline, venlafaxine or ketamine showed similar cytoprotective effects against OS 
in my model. Additionally, I investigated the impact of alterations in redox 
homeostasis on cellular neurogenesis and found that treatment of the cells with low 
doses of t-BHP during proliferation and differentiation lead to major changes in 
neurogenesis – an increase in neuroblasts and mature neurons. I also identified 
potential redox-regulated signal transduction pathways involved in these processes by 
studying the changes in the activity of the family of MAPKs. Blocking ERK1/2 
activation abrogated the peroxide–induced differentiation of the progenitor cells into 
mature neurons. Treatment with t-BHP activated the redox-sensitive transcription 
factor Nrf2, which plays a major role in antioxidant defence. Similarly, t-BHP also 
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activated NF-κB, a known regulator of immune responses, but with no signs of 
inflammation in the human hippocampal progenitor cells.  
The findings in this thesis extend our current understanding of redox-related 
molecular mechanisms considered to underlie the pathophysiology of MDD and 
provide confirmation for the omega-3 fatty acid EPA, known to possess 
antidepressant properties, to have antioxidant characteristics, identified on cellular 




4.1.1   Aim 1  
The first aim of this thesis was to establish a controlled and robust model of OS in the 
human hippocampal progenitor cells using t-BHP. I first identified the doses of t-BHP 
that cause significant cell damage by assessing cell viability using the MTS assay. 
Viability was assessed after 24 hours, both upon a continuous exposure of cells to the 
peroxide or upon an acute peroxide treatment of 1 hour followed by a change to fresh 
media. This last paradigm was chosen for my subsequent experiments as I wished to 
determine if cells survived after a certain period subsequent to the inflicted OS insult. 
To study preventive effects I selected treatments with t-BHP at 100µM and 500µM, 
which caused viability reductions to 71% and 28% respectively, and I decided to 
focus on concentrations below 100µM, that did not affect viability, to research cell 
signalling pathways, as slight redox shifts in the system towards an oxidised 
environment are expected to upregulate cellular defences and influence the cell fate. 
The oxidative damage was confirmed by an increase in levels of lipid peroxidation. 
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There were no significant differences in the apoptotic marker CC3, suggesting that 
cell death occurs through caspase-3 independent mechanisms. 
 
 
4.1.2   Aim 2 
The second aim of my thesis was to investigate how neurogenesis is affected in the 
human hippocampal progenitor cell line upon redox shifts and to identify potential 
underlying signalling pathways. Treatment with t-BHP caused a decrease in 
proliferation at doses of 25µM and 50µM, and an increase in the amount of Dcx-
positive neuroblasts and MAP2-positive neurons at doses of 1µM and 10µM. 
Blocking ERK1/2 activation with the selective inhibitor FR180204 abrogated the 
redox-induced increase in mature neurons. 
 
 
4.1.3   Aim 3 
Aim 3 of this thesis was to gain mechanistic insights related to the pathogenesis of 
depression by investigating the interaction of redox and inflammatory systems. The 
transcription factors NF-κB and Nrf2 were activated by t-BHP treatment. Contrary to 
my hypothesis no cytokine secretion, which would be indicative of immune response 
in the cells, was detected in the supernatant. Treatment with t-BHP modulated 
antioxidative genes, causing an upregulation of HMOX1, coding for the enzyme heme 
oxygenase 1 that catalyzes the degradation of protein-unbound heme. The peroxide 
also caused a downregulation of SLC7A11, coding for the xCT subunit of system xc−  
regulating glutamate release in exchange for cystine, and of Keap1, coding for the 
protein that anchors Nrf2 to cytoplasm and thus keeps it inactivated. No changes were 
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observed in the expression of NQO1, coding for the enzyme that catalyzes the 
reduction of highly reactive quinones, GCLM, coding for a subunit of the rate-limiting 
enzyme in the synthesis of GSH, or SLC1A1, coding for the excitatory amino-acid 
transporter 3 (EAAT3), which plays an essential role in transporting glutamate across 
plasma membranes in neurons.  
 
 
4.1.4   Aim 4 
Finally, aim 4 of this thesis was to compare the effects of compounds with 
antidepressant action versus traditional antioxidants on the prevention of oxidative 
damage inflicted to the cells. Pre-treatment with NAC for a period of 1 hour or with 
GSH and EPA for 24 hours prevented the oxidative cell injury inflicted by t-BHP. 
Neither sertraline, venlafaxine, ketamine nor DHA showed any significant effect on 
prevention of oxidative damage in my in vitro model. EPA in the presence of t-BHP 
downregulated the expression of Keap1 and upregulated HMOX1 and SLC7A11, all 
genes involved in the OS response, potentially enhancing GSH production and 
restoring the t-BHP disturbed redox equilibrium. GSH in the presence of the oxidative 




4.2   Damaging effects of induced OS on the human hippocampal 
progenitor cells 
 
4.2.1   Establishing the model 
In order to establish a controlled and robust model of OS in the human hippocampal 
progenitor cells I had first to identify an appropriate OS-inducing compound, choose a 
reliable method for assessing the inflicted damage and then determine the 
concentration of the chemical to use and the duration of the treatment.   
Although one might argue that the use of hydrogen peroxide is more physiologically 
relevant, t-BHP was chosen as the compound to induce OS in vitro model due to its 
higher stability. Hydrogen peroxide is unstable. A detailed study that assessed factors 
affecting the decomposition of this peroxide has shown that an increase in the 
concentration of copper ions, the presence of solids and changes in pH and 
temperature contribute to its loss in solution. In particular, a temperature-depending 
decrease in concentration was demonstrated when the temperature increased from 
20°C to 50°C over a period of 3 hours, reaching 80% loss at 50°C (Yazici and Deveci, 
2010). Given that the cells are cultured in incubators at 37°C to resemble 
physiological conditions, and considering that all the reagents used need to be pre-
warmed in a water bath at 37°C, it seemed sensible to avoid H2O2 and use t-BHP 
instead, which was demonstrated to start undergoing thermolysis at 69,5° (Liu et al., 
2012) – a temperature that is never reached in cell culture. t-BHP is a membrane 
permeable oxidant that has been previously used successfully to generate OS damage 
in various in vitro models. It is easily metabolized and can cause a variety of changes 
in biological and biochemical systems, such as generation of ROS, peroxidation of 
lipids, permeabilization of cell membranes, impairment of ATP synthesis, DNA 
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damage via radical and non-radical mechanisms and numerous effects on the 
antioxidant defence system (Chen and Chen, 2011).  
There is a variety of commercially available assays that can be used to measure 
oxidative damage of cell constituents in vitro. The most well-established and 
frequently used indicators of oxidative damage are: a) 8-OHdG and 8-OHG that are 
generated upon DNA and RNA oxidation; b) protein carbonyl groups, that are 
produced by carbonylation of proteins; and c) 4-HNE and MDA that are formed upon 
lipid peroxidation. In particular, these biomarkers can be quantified using ELISA kits, 
HPLC or immunostaining using relevant antibodies. Often, multiple assays are 
required to assess oxidative damage of different cell structures. However, my primary 
interest was to identify whether and to what extent t-BHP treatment caused a decrease 
in cell viability of the human hippocampal progenitor cells. To confirm that t-BHP 
initiated oxidative damage I have chosen to measure the level of lipid peroxidation in 
the samples using TBARS assay (described in the next section), hypothesizing that 
lipids would be affected by the peroxide the most due being abundant in the cell 
membranes and thus being exposed to the treatment to a greater extent. It would be 
instructive to detect levels of protein and nucleic acids oxidative damage in my cell 
model in future research, to then further identify which particular molecules are 
mostly protected by particular antioxidative compounds.   
In order to determine the toxic concentrations of t-BHP, I chose MTS, a colorimetric 
method that allows to estimate the amount of viable cells. This method has been 
widely used in in vitro studies to assess cytotoxicity of various compounds. Solid 
evidence that the MTS assay is a reliable test system of high accuracy and 
reproducibility comes from a comprehensive study that tested the cytotoxicity of 
numerous chemicals in two human epithelial cell lines to determine the sensitivity and 
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specificity of the assay. This study revealed that the influence of different operators, 
differences in cell number or tests on different occasions on the accuracy of the 
results is negligible (Malich et al., 1997).  
In vitro studies have shown a huge variation in both the concentration of substances 
used to generate OS and the duration of treatment. Cells of different origin have been 
treated for periods ranging from 15 minutes to 24 hours, and at peroxide 
concentrations between nanomolar and millimolar (Bae et al., 2010; Harvey et al., 
2012; Saffari and Sadrzadeh, 2004; Sée and Loeffler, 2001; Sun et al., 2010). This is 
not surprising, since the effects of induced OS on cells very much depend on the type 
of cells, the peroxide and the experimental conditions, and therefore the concentration 
and duration of treatments always needs to be selected singularly. Thus, in this thesis 
cells were treated with a range of t-BHP concentrations initially for 24 hours. No 
reduction in cell viability was observed at concentrations ranging from 1µM to 10µM, 
whereas a decrease in cell viability to 65% occurred at 25µM of t-BHP. This 
reduction increased to 30% at 50µM, reaching only 5% at 75µM and higher doses of 
t-BHP. Given such a pronounced decrease in cell viability between 25µM and 50µM 
and considering the immense cell death due to the massive oxidative damage inflicted 
by the peroxide already at 75µM of t-BHP I changed the experimental design, 
modifying the time of peroxide treatment to 1 hour. I hypothesized that the longer the 
duration of t-BHP exposure the lower is the toxic dose, suggesting the occurrence of a 
cumulative cytotoxic effect. Therefore, I decided to decrease the time of exposure and 
additionally to determine if cells survived after a certain period subsequent to the 
inflicted OS insult. Thus, a variation in the experimental set-up was applied, treating 
cells acutely for 1 hour followed by 23 hours of culturing in fresh media and keeping 
the same total culture time before the MTS assay was performed (so 24 hours in 
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total). The difference in the paradigms was that in my first one I was identifying cell 
damage straight after the OS insult, in the second one I determined if cells survived 
after an oxidative challenge, when the stimulus is no longer applied. This last acute 1 
hour treatment with t-BHP followed by 23 hours of culturing in fresh media caused a 
significant delayed decrease in cell viability in a dose-dependent manner to 71% at 
100µM, 42% at 200µM, 28% at 500µM and 14% at 1mM. Exposure times greater 
than 24 hours are considered to be logistically difficult in an early screening 
paradigm, while exposures of less than 24 hours may not allow enough time for 
toxicity to occur, a situation that could produce a large number of false negative 
results (McKim, 2010). After removal of the peroxide upon a 1 hour treatment, the 
toxic effect can expand due to chain oxidation reactions initiated by t-BHP, or by 
damaged cells spreading injury to the surrounding “intact” cells by releasing metals 
(Halliwell and Gutteridge, 2015). Treatment of the cells for 1 hour was chosen for all 
subsequent experiments due to a pronounced concentration response curve observed 
in the cell viability experiments. Endpoints obtained after 1 hour of peroxide exposure 
provided a platform for assessment of the cytoprotective effects of the compounds 
under investigation, choosing two doses of t-BHP to estimate if the potential 
antioxidative effect depends on the OS level. 
A significant reduction in the total number of cells was observed by direct counting of 
DAPI-positive cells at doses of t-BHP starting at 10µM, suggesting that there is some 
toxicity effect at lower levels of OS insult. Fixing the cells with PFA in preparation 
for immunocytochemistry allows to obtain only a snapshot of a certain time point. 
Furthermore, PFA cells fixing is a harsh procedure where cells are also subjected to a 
number of washes which contributes to the existing OS insult, and damaged cells are 
likely to be rinsed away, while in a cell viability assay they would contribute to the 
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signal. Thus, it would not be apparent from these data whether the toxic effects were 
due to a direct OS insult or a cumulative effect of OS, or due to PFA and the fixing 
procedure. While immunocytochemistry estimates the total number of cells, the MTS 
assay measures their metabolic capacity and the data represent an average of the 
signal from the total cell population. In this viability assay cells are allowed to 
metabolise the tetrazolium compound added to the culture media into the 
colorimetrically detectable formazan product. Damaged and apoptotic cells still 
remain metabolically active and produce formazan. Therefore, I chose the MTS assay 
and selected the cytotoxicity doses of t-BHP obtained with this method for further 
experiments rather than assessing the most resilient cells that survived after both the 
OS and PFA challenges, as having cells damaged to different extent by OS, which 
also contribute to physiological or pathological processes, is more representative of an 
in vivo situation.  
As a result, a paradigm of 1 hour treatment with 100µM and 500µM of t-BHP 
followed by 23 hours of culturing in fresh media has been chosen to induce OS and to 
test compounds for their ability to prevent oxidative damage. I also wanted to 
examine how redox shifts in my in vitro model might affect cell signalling pathways. 
Considering that high levels of OS cause severe damage, with failure to activate 
protective mechanisms and halted cell cycles, concentrations of t-BHP below 100µM, 
where no reduction in cell viability was observed, were used in experiments 
investigating redox signal transduction pathways, where a moderate and mildly 
oxidised environment is expected to lead to activation of transcription factors, 




4.2.2   Lipid peroxidation 
In my experiments a significant increase in the level of lipid peroxidation, measured 
with the TBARS assay, was observed in cells treated with 500µM and 1000µM of t-
BHP after 1 hour, although a clear trend was already observed at 50µM, 100µM and 
200µM of t-BHP. t-BHP is a strong free radical source and has been particularly 
utilized to induce lipid peroxidation both in vivo (Resende et al., 2008) and in vitro 
(Ayala et al., 2014; Guo et al., 2016; Pavlica and Gebhardt, 2010) in studies 
modelling OS. 
End products of lipid peroxidation are ubiquitously generated in biological systems 
and their effects are particularly important in post-mitotic cells that gradually 
accumulate oxidative damage over time, such as neurons. In particular, lipid 
peroxidation product accumulation in human tissues is a major cause of cellular 
dysfunction playing a major role in neurodegenerative disorders. OS induces 
peroxidation of the cellular membrane lipids and circulating lipoprotein molecules 
generating highly reactive aldehydes, that are much more stable than ROS and are 
capable of spreading from their site of origin and act at more distant sites. Thus, these 
carbonyl compounds can be more destructive than ROS and may have far-reaching 
damaging effects on target sites within or outside membranes, as they can react with 
nucleophilic groups in macromolecules like proteins and DNA (Negre-Salvayre et al., 
2010). One of these products is MDA, a membrane-permeable end-product generated 
by decomposition of arachidonic acid and larger PUFAs, exhibiting various biological 
functions, such as regulating gene expression or modifying DNA bases.  
In order to confirm any oxidative damage in the human hippocampal cells and to 
identify whether t-BHP treatment of the cells leads to an increase in lipid peroxidation 
I used the TBARS assay, which is commonly reported as a measure of MDA across 
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studies (Guo et al., 2016; Pavlica and Gebhardt, 2010). Although it is believed that 
TBARS assay measures MDA in the sample, in fact in complex biological systems, 
many compounds (including simple and complex carbohydrates, protein oxidation 
products, and nucleic acid oxidation products) react with thiobarbituric acid and 
produce coloured adducts (Forman et al., 2015). Moreover, more free radicals are 
generated during the assay procedure which leads to oxidation of more molecules and 
lipids and hence more MDA. Additionally, there are other several compounds other 
than MDA (such as streptomycin, sialic acid and biliverdin) that react in the TBA 
assay and absorb at the same wavelength when analysed with a plate reader. These 
problems can be overcome by using HPLC, where (TBA)2-MDA adducts can be 
separated from other chromogens. By use of this method, picomole quantities of 
MDA can be readily and specifically detected in different biological materials 
(Khoschsorur et al., 2000). However, this technique also has limitations, often is not 
available and is more complex. Irrespective of whether the assay detects only MDA 
or not, in my experiments a clear dose response curve was observed. MDA is the 
major component reacting with thiobarbituric acid. MDA has been widely used as a 
biomarker for lipid peroxidation in clinical studies and is contently found to be 
increased in depressed patients. In a recent meta-analysis that demonstrated greater 
lipid peroxidation in MDD than in controls 12 out of 17 studies included used MDA 
as a biomarker (Mazereeuw et al., 2015). Hence, increased levels of MDA observed 
in depressed patients are resembled in my in vitro OS model for studying molecular 
mechanisms of the MDD pathogenesis. 
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4.2.3   Cleaved Caspase-3—independent cell death 
In this thesis I examined whether t-BHP–induced death of the human hippocampal 
progenitor cells is characterised by changes in expression of the marker cleaved 
caspase-3 (CC3), a hallmark of apoptosis. In my experiments, the oxidative insults did 
not cause an increase in CC3 expression, suggesting that cell death occurred through 
caspase-independent mechanisms.  
Neuronal cell death is regulated by multiple interconnected signalling pathways. The 
most distinct forms of cell death are apoptosis and necrosis. Conventionally, apoptosis 
was considered to be a genetically programmed physiological cell death, regulated by 
enzymatic cascades during development, homeostasis, infection and pathogenesis, 
where an organized degradation of the cell occurs within an intact plasma membrane. 
CC3 is a critical executioner of this type of cell death and is also a feature of many 
chronic neurodegenerative diseases (D’Amelio et al., 2012). Necrosis was mostly 
considered to be a cell death that occurs in response to physicochemical insults and is 
associated with cell swelling, gross membrane damage and leakage of cell 
constituents into the extracellular space (Berghe et al., 2014).  
Both caspase–independent mechanisms of cell death and those involving activation of 
caspase cascades are reported depending on the cellular context (Ryter et al., 2007). 
In particular, it has been suggested that apoptotic or necrotic cell death can occur 
depending on the time of exposure and/or the concentration of the oxidative insult 
(Englert and Shacter, 2002). For example, exposure of PC12 cells to 500µM of H2O2 
resulted in the necrotic death of 90% of the cells 2 hours after the oxidative injury, 
followed by increased cell death exhibiting features of apoptosis, though with absent 
caspase-3 activity, after 12–24 hours (Cole and Perez‐Polo, 2002). It seems that the 
appearance of apoptotic markers and CC3 in particular is transient and may only be 
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detectable within a limited window of time. In my experiments the human 
hippocampal progenitor cells were treated with t-BHP for 1 hour with subsequent 23 
hours of a recovery period and then cells were fixed with PFA. Hence, only a 
snapshot of a certain time point became available for further analysis, which perhaps 
was not representative for depicting CC3 expression. Indeed, apoptotic cell death can 
be switched to necrosis during OS by inactivation of caspases due to oxidation of 
their active site thiol group by oxidants or S-nitrosylation. Since caspases contain an 
active site cysteine which is prone to oxidation, the activity of caspases is optimal 
under reducing environments. Thus, any deviation from such reducing conditions 
within an injured cell could be detrimental to caspases and render them inactive 
(Chandra et al., 2000). In line with this argument, it was demonstrated in vitro 
that H2O2 suppresses both the activation and activity of caspases, possibly through 
modulation of the redox status of the cell and the oxidation of cysteine residues in 
caspases (Hampton and Orrenius, 1997). Another mechanism that could switch 
apoptosis to necrosis is a decrease in cellular levels of ATP due to a failure of 
mitochondrial energy production caused by oxidants, leading to energy requirements 
for apoptosis not being met (Chandra et al., 2000). Generally, after any incubation 
period in OS conditions, which is variable across studies, in vitro apoptotic cells 
ultimately shut down metabolism, lose membrane integrity and release their 
cytoplasmic contents into the culture medium, eventually undergoing secondary 
necrosis. It is plausible that this scenario occurred in the human hippocampal 
progenitors subjected to peroxide treatment, as oxidatively damaged cells reached a 
state of secondary necrosis which was captured by immunocytochemistry.  
It is also important to note that the mechanism of OS-induced cell death largely 
depends on a particular type of ROS. For example, in rat neuronal cultures it was 
 220 
demonstrated that specific ROS could act as initiators or executioners of neuronal 
death and lead to different molecular cell death mechanisms. In this study superoxide 
anion or singlet oxygen induced caspase activation, including CC3, nuclear 
condensation, phosphatidylserine translocation, and a decrease in intracellular 
calcium levels, indicative of apoptosis in cultured cerebellar granule neurons. 
Hydrogen peroxide, however, led to a necrosis-like cell death that did not induce 
caspase activation, phosphatidylserine translocation, or changes in calcium levels 
(Valencia and Morán, 2004). In a different study, treatment of cerebellar granule 
neurons with 100µM of H2O2  for 15 minutes induced an active caspase-independent 
but calpain-dependent process of neuronal death distinct from apoptosis (Sée and 
Loeffler, 2001).  
To my knowledge no studies on levels of CC3 expression in MDD patients have been 
carried out to date. Considering clinical, structural and molecular commonalities 
between MDD and neurodegenerative disorders, it is possible to extrapolate 
observations on both increased apoptosis and necrosis from studies on 
neurodegenerative disorders (Louneva et al., 2008) and speculate that a similar 
increase may exist in depressed individuals. Necrosis has been mostly associated with 
pathological conditions such as neurodegeneration and ischaemia–reperfusion-
induced injury, both accompanied by OS (Berghe et al., 2014). Interestingly, although 
a sizeable fraction of cells dying in vivo in neurodegenerative processes exhibit 
morphological features of necrosis, the molecular mechanisms of pathological cell 
loss partially overlap with the biochemical cascades that mediate apoptosis 
(Vandenabeele et al., 2010). These observations suggest the occurrence of a distinct 
kind of regulated cell death that resembles features of both apoptosis and necrosis, 
which is known as necroptosis or “programmed necrosis” (Ashkenazi and Salvesen, 
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2014). It is important to mention the role of Ca2+, a ubiquitous second messenger that 
supports brain physiology maintaining neural integrity and is involved in the control 
of a broad variety of cellular events including cell death. Although cellular Ca2+ 
overload has been conventionally associated with necrosis, several studies have 
shown that increases of Ca2+ occur both at early and late stages of the apoptotic 
pathway (Kruman et al., 1998; Tombal et al., 1999). Currently, a common view is that 
while severe Ca2+ dysregulation can promote cell death through necrosis, more 
controlled intracellular Ca2+ increases induced by milder insults promote cell death 
through apoptosis (Pinton et al., 2008). The notion that Ca2+ homeostasis plays an 
essential role in apoptosis came from the observation that proteins of the Bcl-2 
family, which regulate apoptosis, are localized in mitochondria and the endoplasmic 
reticulum, organelles deeply involved in Ca2+ handling (Pinton and Rizzuto, 2006). In 
particular, it was verified that Ca2+ is involved in regulating mitochondrial 
morphology and release of pro-apoptotic proteins. In HeLa cells upon treatment with 
ceramide (a pro-apoptotic bioactive lipid), Ca2+ release from the endoplasmic 
reticulum and loading into mitochondria was observed. As a consequence, organelle 
swelling and fragmentation were detected that were paralleled with the release of 
cytochrome c, a major apoptosis effector. Notably, these changes were prevented by 
experimental conditions that lowered Ca2+  in the endoplasmic reticulum as well as by 
antiapoptotic Bcl-2 expression that has been previously demonstrated to reduce Ca2+ 
release from the endoplasmic reticulum (Lam et al., 1994; Pinton et al., 2001). Indeed, 
mitochondria are endowed with multiple Ca2+ transport mechanisms by which they 
take up and release Ca2+ across their inner membrane and thus, regulate local and 
global Ca2+ and Ca2+ -sensitive cellular mechanisms. During cellular Ca2+ overload, 
mitochondria take up Ca2+, which, in turn, induces opening of permeability transition 
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pores, disruption of mitochondrial membrane potential, excessive generation of ROS 
and cell death. In apoptosis signalling, collapse of mitochondrial membrane and 
cytochrome c release from mitochondria occur followed by activation of caspases, 
DNA fragmentation, and cell death (Chinopoulos and Adam-­‐Vizi, 2006; Smaili et al., 
2000).  
Cells undergoing necroptosis rupture and leak their contents into the intercellular 
space, but unlike in necrosis, permeabilisation of the cell membrane is tightly 
regulated. Mechanisms and components of the necroptotic pathway are still being 
uncovered. In recent years it was described that multiple signal transducers and 
metabolic processes that can initiate or mediate cellular demolition by necroptosis are 
ROS generated by mitochondria, suggesting the involvement of redox regulation in 
this type of cell death. Indeed, excessive generation of ROS has been associated with 
apoptosis and yet it also occurs during regulated necrosis (Galluzzi et al., 2012). 
Furthermore, an oxidant-induced cell death known as oxytosis, with morphological 
characteristics of necrosis but which appears to be regulated by its own signalling 
pathways that are independent from classical apoptotic pathways (Tan, 2001) was 
described before “programmed necrosis” was first introduced (Chan et al., 2003).  
Thus, it is probable that oxytosis is a particular kind of necroptotic cell death, which 
may occur in neurodegeneration and could also occur in depression. 
Together, observations suggest that OS-induced cell death presents a continuum of 
molecular processes entailing tightly genetically regulated events and mechanistic 
responses dictated by the redox cellular environment. OS, perturbed energy 
metabolism, and alterations of disease-related proteins result in Ca2+ dependent 
synaptic dysfunction, impaired plasticity, and neuronal demise. Further research on 
the exact molecular mechanisms of OS-induced cell death and its potential prevention 
 223 
may provide a new strategy for the development of cytoprotective agents for 
neurodegenerative disorders and MDD in particular. 
 
 
4.3   Insights into changes in neurogenesis upon redox shifts and 
underlying mechanisms 
 
In this thesis I investigated how neurogenesis is affected in human hippocampal 
progenitor cells upon induction of redox shifts by t-BHP. I then identified potential 
signalling pathways through which the effects of the oxidant are mediated.  
Changes in adult neurogenesis in individuals with neurodegenerative diseases, and 
depressed patients in particular, is one of the most intriguing matters of current 
research because it offers tremendous potential for the development of novel 
therapeutics. The discovery of the existence of adult human neurogenesis and its 
involvement in the pathogenesis of MDD is a breakthrough which has not yet been 
pharmacologically addressed, mainly because its functions and most underlying 
molecular mechanisms are still not fully elucidated. Both alterations in AHN and 
increased OS have been implicated in depression, however how shifts in redox 
homeostasis influence human hippocampal progenitors fate remains unclear. The 
intracellular redox state appears to be a central molecular regulator of the balance 
between self-renewal and differentiation of neural stem cells and relatively small 
changes in intracellular redox homeostasis are associated with profound differences in 
the cell fate (Prozorovski et al., 2015). A key study detected high ROS levels 
throughout the rat brain during embryonic and early postnatal development. 
Remarkably, at postnatal stages, cells with the highest ROS were found in the 
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glomerular layer of the olfactory bulb and in the dentate gyrus of the hippocampus, 
both areas of known adult neurogenesis, and high ROS cells remained in these 
structures in the adult rats (Tsatmali et al., 2005). Opposite to a conventional view 
that excessive ROS can be detrimental to neurons, and that stem cells generally 
maintain low levels of ROS as a protection against oxidative toxicity, these 
observations suggest that the generation of ROS may accompany adult neurogenesis. 
Interestingly, proliferation of stem cells has been associated with a more reducing 
environment (Halliwell and Gutteridge, 2015), while the redox status of 
differentiating cells tends to be more oxidized (Lewerenz et al., 2013). Differentiation 
is a highly energy demanding process and mitochondria are more active during this 
phase, and as a result more ROS are generated; it is also likely that ROS production at 
this stage is necessary for facilitating cellular maturation (Lewerenz et al., 2013). 
Available data provides strong reasons to believe that redox modulation functions as a 
central integrator of multiple processes related to self-renewal and differentiation, 
rather than as a controller of a single unique downstream effector pathway. Many 
different signalling pathways appear to converge on regulation of the redox state, and 
redox alterations can in turn modulate several different pathways of possible 
relevance in modulation of self-renewal and differentiation.  
Mine is the first study, to my knowledge, that examined the effects of redox shifts in 
human hippocampal progenitors on neurogenesis and proposed potential mechanisms 




4.3.1   Proliferation of the human hippocampal progenitor cells upon redox 
shifts in the system 
Treatment of cells with 25µM and 50µM of t-BHP caused a significant reduction in 
proliferation, with no difference at 1µM and 10µM as measured by Ki67 
immunolabeling. My observations are in good agreement with studies that provided 
evidence for a more reduced environment favouring cellular proliferation, however 
results are conflicting, as some studies reported increased cellular proliferation in 
response to mild OS insults (Le Belle et al., 2011; Pérez Estrada et al., 2014; Smith et 
al., 2000; Walton et al., 2012). It was demonstrated that treatment of dividing rat 
oligodendrocyte progenitor cells with 50nM of t-BHP was associated with diminished 
progenitor division, with one-half of the founder cells differentiated without dividing 
and the rest undergoing one to three divisions. In this study a reduced environment 
induced in these cells by 1mM of NAC led to enhanced self-renewal (Smith et al., 
2000). In contrast, another study showed increase proliferation of rat NPCs exposed 
to 100µM in H2O2 compared to controls (Pérez Estrada et al., 2014). The effects of a 
redox imbalance on cellular proliferation is likely to depend on the cell type as well as 
on experimental conditions. 
An enhanced proliferation in response to mild OS is usually interpreted as activation 
of compensatory mechanisms. The cell line HPC0A07/03C utilised in this thesis is a 
conditionally immortalised line transduced with the c-myc-ER gene that strongly 
promotes cell proliferation in the presence of 4-hydroxy-tamoxifen (4-OHT) (Dang et 
al., 1999) and directly regulates a variety of genes, including those that enhance 
glycolytic activity and oxidative phosphorylation, leading to increased energy 
production and increased levels of ROS (Dang, 2012; Vafa et al., 2002). Therefore, it 
is possible that in my experiments the redox-sensitive signalling pathways involved in 
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promotion of proliferation have reached a plateau, due to an already high proliferation 
rate and ROS levels induced by c-myc. Thus, shifting the redox status in the system 
towards more oxidised conditions (1µM and 10µM of t-BHP) did not cause an 
increased proliferation, whereas higher levels of OS (25µM and 50µM of t-BHP) 
halted cell proliferation.  
Another potential reason for not seeing increased proliferation in my model is the 
level of activation of NF-κB, which showed an increase at 10µM of t-BHP after 24 
hours. Both a decrease in the number of proliferating cells in the subgranular zone of 
the dentate gyrus of the hippocampus and depressive-like behaviour observed in a rat 
model of induced stress were completely abrogated when rats were pre-administered 
NF-κB inhibitors (JSH-23 and SC-514) before the stress (Koo et al., 2010). It is 
possible that activation of this transcription factor contributed to decreased 
proliferation of the hippocampal progenitors.  
The data obtained in my experiments on decreased proliferation of the human 
hippocampal progenitors by introducing a more oxidised environment may represent 
a potential link between the observations on decreased neurogenesis and increased OS 
observed in MDD.  
 
 
4.3.2   Differentiation of the human hippocampal progenitor cells upon redox 
shifts in the system 
In the present study human hippocampal progenitor cells exhibited an increased 
number of neuroblasts (+38% and +30%) and mature neurons (+34% and +33%) 
upon treatment with 1µM and 10µM of t-BHP, as measured by immunolabeling them 
with Dcx and MAP2 markers, respectively. It is important to note that the human 
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hippocampal progenitor cells differentiate in the absence of 4-OHT, meaning that the 
c-myc gene is not active, and its potential effect to increase ROS levels is therefore 
absent during this phase. My results support and augment the findings on enhanced 
neural differentiation induced by endogenous and exogenous pro-oxidant stimulus in 
vitro and in vivo (Le Belle et al., 2011; Pérez Estrada et al., 2014; Smith et al., 2000; 
Tsatmali et al., 2006). For example, when rat oligodendrocytes progenitor cells were 
exposed to 50nM of t-BHP for 5 days during differentiation, 83% of clones consisted 
wholly of oligodendrocytes, whereas in basal division conditions they reached only 
35% (Smith et al., 2000). In a different study, rat NPCs were treated with 100µM of 
H2O2 for 24h and then cells differentiated without any treatment for the next 7 days. 
As a result, cells exposed to peroxide generated significantly more neurons compared 
to unexposed controls (Pérez Estrada et al., 2014), suggesting that ROS can trigger 
differentiation without being present during the entire differentiation phase. 
Furthermore, murine primary brain-derived neural progenitors treated with H2O2 
during sphere formation produced significantly higher numbers of neurons as a 
percentage of total cells than when differentiated in the presence of standard media 
(Le Belle et al., 2011). Another study that specifically examined the level of ROS in 
proliferating and differentiating brain cells demonstrated that isolated rat cells that 
exhibited the lowest reactivity with the ROS-sensing dye were proliferative 
progenitor cells. When these cells were plated and differentiation was induced, low 
levels of ROS were detected at day 0 and 2, but after 7 days, fluorescence, indicative 
of ROS presence, filled the entire cell body and processes in neurons, 
oligodendrocytes and astrocytes, as detected by immunolabeling (Tsatmali et al., 
2006).  
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In line with my findings these observations provide evidence for physiological roles 
of ROS and their influence on the neuronal development, however molecular 
mechanisms were not fully elucidated in these studies. In this thesis I investigated 
particular signalling pathways that are potentially involved in redox regulation of 
neurogenesis which is discussed below in 4.3.3. 
Separate attention deserve the in vivo studies modelling brain ischaemia–reperfusion-
induced injury - a complex neuropathological condition arising after restoration of 
blood flow to the ischemic tissue accompanied by well-established increased levels 
of OS (Sanderson et al., 2013). Reperfusion injury is a potentially damaging condition 
for the brain, and ischemic insults have been reported to induce the formation of new 
neurons and increased differentiation into mature neurons in humans (Jin et al., 2006), 
nonhuman primates (Tonchev, 2011) and in the adult rodent brains (Kernie and 
Parent, 2010; Ruan et al., 2014). Of relevance to MDD, an animal study that 
investigated the effects of a combination of reperfusion injury with chronic mild 
stress (commonly used model for inducing depressive-like behaviour in rodents) on 
adult hippocampal neurogenesis revealed that ischemic rats exhibited increased levels 
of both new born and differentiated mature neurons in comparison to the control 
group. Interestingly, in the group with two stressors the number of new born and 
differentiated neurons was significantly lower than in the ischemic group. Also, the 
group subjected to reperfusion injury and chronic mild stress demonstrated 
depressive-like behaviour, with was alleviated by the SSRI citalopram, together with 
a decrease in neurogenesis (Wang et al., 2008). One can speculate that ischemia-
induced neurogenesis could be due to re-connection to the systemic environment 
through vasculature that intimately surrounds neural stem cells (Filippov et al., 2003) 
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and provides exposure to an abundance of factors, including ROS that can modulate 
proliferation, differentiation and survival of the cells (Palmer et al., 2000).  
Findings in this thesis provide evidence for ROS acting as secondary messengers and 
playing an essential role in neurogenesis. However, it is not clear whether ROS–
induced neurogenesis is necessarily beneficial, as increased levels of ROS can also 
lead to various stem cell dysfunctions, which can manifest in different forms such as 
failure to self-renew, aberrant differentiation or premature senescence and increased 
apoptosis (Jones and Rando, 2011). The maintenance of balance between self-renewal 
and differentiation is pivotal for neural stem cells function in development, tissue 
repair, and homeostasis. In particular, if too many cells are pushed towards 
differentiation this might lead to a gradual depletion of the stem cell pool. Another 
possibility is aberrant differentiation, when an abnormally skewed distribution of 
progeny towards one fate is observed. Furthermore, stem cells can accumulate 
oxidative cellular damage and reach premature senescence. Additionally, it is not 
clear whether all new born or maturated neurons are capable of appropriately 
integrating in the existing neural network. One in vitro study addressed some of the 
issues above and revealed a number of interesting facts. In particular, rat brain cells 
isolated from neurogenic niches with high levels of ROS did not reflect a population 
that is undergoing the massive cell death or apoptosis that was observed in the cortex 
under the same conditions. Additionally, using patch clamp analysis it was identified 
that high ROS-positive cells in neurogenic niches were functional neurons, with 
neuronal morphologies, normal membrane potentials, and fired repeated action 
potentials (Tsatmali et al., 2006). These observations provide evidence that increased 
ROS play a physiological role during neurogenesis, rather than solely being a toxic 
by-product of an energy-demanding process.  
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The in vitro findings on increased differentiation upon oxidative stimulus obtained in 
this thesis provide reasons to believe that ROS play a central role in the regulation of 
neurogenesis. However, the functionality of the neuroblasts and mature neurons 
differentiated from the human hippocampal progenitor cells upon OS stimulus needs 
to be further researched in vitro and in vivo to evaluate the formation of the 
connections of newly generated cells, stem cell pool renewal, cellular senescence 
markers and capability of these cells to contribute to cognitive domains. Presumably, 
ROS facilitated relevant signal transduction pathways which led to an increased 
differentiation and potential signalling pathways were further investigated in the 
present study and described below. 
 
 
4.3.3   MAPK modulation in the human hippocampal progenitor cells by t-BHP 
I investigated the activation by oxidative stimulus of three main MAPKs that exist in 
mammalian species: ERK1/2, p38 and JNK. In my experiments no significant 
increase was observed in the level of phosphorylated MAPKs in the hippocampal 
cells treated with 1µM, 10µM and 25µM of t-BHP during the proliferation and 
differentiation assay (10 days in total), although a trend towards increase was 
observed for pERK1/2 at 1µM. In order to examine a possible time-dependant 
activation of the kinases, I evaluated their phosphorylation upon treatment of cells 
with 1µM and 10µM of t-BHP for 24 hours during proliferation. Again, no significant 
increase was observed in the level of phosphorylated MAPKs, however a similar 
trend towards increase was observed for pERK1/2 at 1µM of t-BHP. 
Alterations in redox homeostasis have been reported to induce various signal 
transduction pathways, thus affecting cell division and/or differentiation. The MAPK 
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signalling cascades are one of the most ancient and evolutionarily conserved 
signalling pathways that transduce signal from the cell surface to the nucleus and play 
essential regulatory roles including cellular growth, differentiation, immune responses 
and cell death (Zhang and Dong, 2005). MAPKs can be activated by a wide variety of 
different stimuli, but in general, ERK1/2 is preferentially activated in response to 
growth factors, and p38 and JNK MAPKs are more responsive to stress stimuli. 
Interestingly, all these responses are redox-regulated and studies have demonstrated 
that ROS can induce or mediate the activation of the MAPK pathways along with a 
number of cellular stimuli that induce ROS production, whereas antioxidants applied 
after the oxidative insult block MAPK activation (Haddad, 2002; Son et al., 2013). 
Redox regulation of MAPKs is context specific and may be both upstream and 
downstream of ROS (Morgan and Kim, 2014). The mechanisms by which ROS can 
activate the MAPK pathways are not well defined, however plausible mechanisms 
include oxidation of redox-sensitive proteins in the MAPKs cascades and by directly 
activating them; another possibility is inhibiting MAPK phosphatases that remove a 
phosphate group from MAPKs, also resulting in activation of kinase pathways 
(Kamata et al., 2005).  
One of the explanations for not seeing differences in the levels of p38 and pJNK in 
my experiments across treatment conditions could be due to the fact that immune 
response is also necessary for triggering these pathways. Although ROS have been 
shown to be involved in p38 and pJNK initiation, these MAPKs cascades are 
primarily activated by cytokines such as TNF-α and IL-1β. As mentioned, no 
cytokines were detected in my cell model upon t-BHP treatment. Another possibility 
is that the level of oxidative stimulus inflicted to the cells was not sufficient to 
activate p38 and JNK MAPKs that are known to be mobilized in the stress conditions 
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for the cells. Furthermore, one of the main signalling pathways that intersects with 
JNK with regard to ROS and cellular stress is the extensive crosstalk that occurs in 
multiple ways between JNK and NF-κB. NF-κB activation, which was detected in my 
experiments, is known to prevent sustained JNK activation and thus prevent cell death 
through both apoptosis and necrosis (Morgan and Liu, 2011a). Therefore, considering 
the low doses of t-BHP that were used in these particular experiments, it is plausible 
that mostly cytoprotective mechanisms were triggered upon OS insult, resulting in 
inhibition of activation of stress kinases pathways. 
Due to the expenses of the assay, I did not perform more repeats at different doses or 
time points, and proceeded to evaluate neurogenesis, where I blocked the activation of 
pERK1/2 during proliferation and differentiation, as discussed in details below. 
 
 
4.3.4   ERK1/2 as a potential signalling pathway of t-BHP–induced neural 
maturation of the human hippocampal progenitor cells. 
In my experiments a trend towards an increase of pERK1/2 was observed when cells 
were challenged with oxidative stimulus during proliferation only or during both the 
proliferation and differentiation phases. My findings are consistent with results from 
other in vitro studies, showing ERK1/2 activation upon oxidative stimulus in both 
undifferentiated and differentiated cells (Ruffels et al., 2004). Interestingly, increased 
RNA and protein levels of MAPK phosphatase 1 (MKP1) (an enzyme that deactivates 
ERK1/2) in the postmortem samples of the hippocampus of human subjects diagnosed 
with depression was found by array-based transcriptome profiling. Furthermore, 
increased hippocampal MKP-1 expression as a result of stress was observed in the 
same study, in rat and mouse models of depression. Conversely, chronic 
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antidepressant treatment normalized both the stress-induced MKP-1 expression and 
behaviour, whereas mice lacking MKP-1 were resilient to stress (Duric et al., 2010). 
These observations suggest that a certain level of phosphorylated ERK1/2 is 
necessary for emotional regulation and my findings show that ERK1/2 can be 
activated by ROS. The ERK cascade is a major signalling pathway involved in 
neuronal plasticity, function and survival and thus I also investigated if neural 
development of the hippocampal progenitors induced by oxidative stimulus is 
mediated through activation of this pathway. I blocked ERK1/2 activation with the 
FR180204 inhibitor. My results indicate that the t-BHP–induced increase in MAP2-
positive neurons was abrogated by blocking this kinase upon redox shifts in the 
system. However, no effects were observed for Dcx-positive neuroblasts. Thus, these 
findings indicate that in the human hippocampal progenitor cells ERK pathway is 
involved in redox–induced neuronal maturation, whereas intermediate process of 
differentiation into neuroblasts is facilitated through different mechanisms.  
ERK phosphorylation is known to be involved in mood regulation, and the majority 
of in vivo studies demonstrate induction of depressive-like behaviour in animals upon 
inhibition of the ERK pathway (Duman et al., 2007; Réus et al., 2014; Wefers et al., 
2012). The mechanisms by which ROS activate the ERK cascade are unclear and the 
molecular targets are unknown. We know that the ERK pathway is activated by 
growth factors, such as epidermal growth factor (EGF) which is involved in the 
regulation of cell proliferation, survival, migration and differentiation, however it was 
also shown to be directly triggered by ROS (Son et al., 2013). Interestingly, it was 
suggested that ROS-mediated ERK activation may be an upstream event of the 
growth factors receptors, that have cysteine-rich motifs. Surprisingly, ROS were 
shown to affect epidermal growth factor receptor (EGFR) signalling by inhibition of 
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the receptor internalization, thus increasing the receptor's signalling potential (Verbon 
et al., 2012). Furthermore, ROS can also directly activate the EGFR in the absence of 
growth factor receptor ligands (León-Buitimea et al., 2012), which is now referred to 
as “receptor transactivation” (Son et al., 2013). In my experiments the trend for         
t-BHP–mediated increase in pERK1/2 was observed during both the proliferation and 
differentiation phases. It is plausible that in the human hippocampal progenitor cells 
ROS increased the receptor's signalling potential during proliferation, whereas during 
the differentiation phase, in the absence of EGF, ROS activated EGFR, which resulted 
in the initiation of the ERK cascade. 
Another possible molecular mechanism by which the activation of ERK cascade 
results in increased formation of mature neurons is through an increase in levels of the 
neurotrophic factor BDNF. BDNF is one of the downstream molecules of ERK 
pathway possessing pro-neurogenic, pro-survival and neuroprotective properties, and 
it is frequently reported to be downregulated in depressed patients (Molendijk et al., 
2014). Interestingly, mice with a heterozygous deletion of the BDNF gene showed a 
depressive phenotype when challenged with a low dose of ERK inhibitor or with a 
stressor. However, neither the gene deletion nor the low-level inhibitors alone resulted 
in observable behavioural changes, suggesting a role for intracellular signalling 
through ERK pathway in the regulation of behaviour in mouse models of depression 
(Duman et al., 2007). Remarkably, antidepressant treatment (Hunsberger et al., 2009) 
and non-pharmacological treatments, such as exercise and electroconvulsive therapy 
(Ruan et al., 2014) have been shown to upregulate the MAPK/ERK signalling 
pathway and promote neurogenesis in animal models of depression. Likewise, it was 
demonstrated in cultured cortical neurons that neuroprotective effects of BDNF rely 
on ERK activation (Sun et al., 2008). Considering these observations, it would be 
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instructive to measure the levels of BDNF in the differentiated human hippocampal 
progenitor cells and identify whether the redox-induced neurogenesis that is mediated 
through ERK pathway is due to an increase of this neurotrophic factor. It would also 
be of interest to measure other redox signalling pathways that have been shown to 
influence neurogenesis, such as the phosphatidylinositol-4,5-bisphosphate 3-
kinase/protein kinase B (PI3K/Akt) pathway. In combination with exogenous ROS 
stimulation, pharmacological inhibition of PI3K eliminated the increased 
differentiation of murine and human neural progenitors into mature neurons caused by 
H2O2 (Le Belle et al., 2011). It is possible that a redox induced PI3k/Akt pathway 
contributed to the increased neuroblast formation in my experiments. 
To conclude, redox regulation of neurogenesis is a tightly balanced complex process, 
which mainly depends on the cellular context. Further research is needed to identify 
potential strategies for targeting redox-mediated signalling pathways that are involved 
in neurogenesis modulation. 
 
 
4.4   Crosstalk between redox and inflammatory systems  
 
4.4.1   Activation of Nrf2 and NF-κB transcription factors with no signs of 
inflammation 
In my model I investigated whether the oxidative stimulus leads to activation of two 
transcription factors: NF-κB, which is a master regulator of immune response, and 
Nrf2, the major antioxidant defense transcription factor. Additionally, I examined if 
the redox-induced upregulation of NF-κB modulates the production of cytokines in 
the human hippocampal progenitor cells, considering that increased levels are 
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constantly detected in MDD patients as evidenced by several meta-analyses (Dowlati 
et al., 2010; Howren et al., 2009; Valkanova et al., 2013). In my experiments t-BHP 
treatment of the human hippocampal progenitor cells caused activation of both Nrf2 
and NF-κB transcription factors in a dose-dependent manner, however no signs of 
elevated cytokines across all conditions treated with a range of peroxide 
concentrations were detected. 
A significant increase in the amount of nuclear Nrf2 was observed in the hippocampal 
progenitors at 50µM (+46%) and at 100µM (+113%) of t-BHP after 1 hour. Induction 
of Nrf2 upon OS is a common finding (Dell’Orco et al., 2016; Haskew-Layton et al., 
2010). Interestingly, it was demonstrated in vitro that low and moderate doses 
(125µM, 250µM and 500µM) of hydrogen peroxide increased Nrf2 activation, 
whereas higher doses (1mM and 2mM) decreased its transcription activity (Ning et 
al., 2010). In my experiments I checked Nrf2 activation only when using doses of t-
BHP up to 100µM, because higher doses led to a significant decrease in cell viability, 
when antioxidative mechanisms were not capable of resisting the oxidative damage.  
More and more evidence suggests that Nrf2 contributes to the pathogenesis of MDD. 
A recent study reported that mice with a depression-like phenotype induced by 
repeated social defeat stress exhibited lower expression of Keap1 and Nrf2 proteins in 
the prefrontal cortex, CA3 and dentate gyrus of hippocampus, whereas pre-treatment 
of the animals with the Nrf2 activator sulforaphane prevented the depression-like 
behaviour (Yao et al., 2016). Importantly, the role of Nrf2 in mood regulation extends 
beyond its permutation of antioxidative defence system. It was demonstrated that 
Nrf2 deletion results in depressive-like behaviour in mice and also in altered levels of 
neurotransmitters, crucial for emotional processing (Martín-de-Saavedra et al., 2013; 
Wojnicz et al., 2016).  
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Furthermore, in addition to regulation of the antioxidant defence by Nrf2, recent 
evidence suggests crucial involvement of Nrf2 in the modulation of the inflammatory 
system (Ma, 2013). In particular, the immunosuppressive properties of Nrf2 were 
studied in human immature dendritic cells, where in the presence of low 
concentrations of the Nrf2 inducer inorganic arsenic, the ability of the cells to release 
key cytokines in response to different stimulating agents such as LPS was repressed 
(Macoch et al., 2013). Similarly, higher serum levels of proinflammatory cytokines 
were reported in Nrf2 knock-out mice than in wild-type mice (Yao et al., 2016). 
Contrary to the widely accepted view that Nrf2 suppresses inflammation through 
redox control, a recent study demonstrated that Nrf2 opposes the transcriptional 
upregulation of proinflammatory cytokine genes (Kobayashi et al., 2016). Both a 
microarray and Nrf2 chromatin immunoprecipitation (ChIP)-seq analyses revealed 
that Nrf2 binds to the proximity of proinflammatory cytokine genes, including IL-6 
and IL-1β, and inhibits their expression induced by LPS. Furthermore, the Nrf2-
mediated inhibition of proinflammatory cytokine genes was independent of ROS 
elimination, as NAC treatment alone without Nrf2 induction did not affect cytokine 
mRNA expression. Further in vivo imaging analysis revealed that Nrf2 activation 
inhibits IL-6 induction in a murine inflammation model and alleviates inflammatory 
phenotypes (Kobayashi et al., 2016).  
NF-κB is another critical transcription factor involved in the pathophysiology of 
MDD that has been reported to be both down- or up-regulated in OS conditions 
(Oliveira-Marques et al., 2009). In my experiments treatment of the cells with t-BHP 
for 1 hour caused a significant increase in NF-κB activation at 50µM (16%) and 
100µM (17%), the same concentrations that caused Nrf2 activation. The crosstalk 
mechanism between Nrf2 and NF-κB is complex and is still under elucidation 
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(Buelna-Chontal and Zazueta, 2013). Treatment of the cells with t-BHP for 24 hours 
caused a much smaller but significant increase in NF-κB activation at 10µM (4%) 
with no effect at 1µM. Since higher concentrations of t-BHP are toxic when applied 
for 24 hours, they were not tested in this experiment. Thus, these data suggest that 
redox NF-κB activation occurs at different levels and duration of oxidative 
stimulation. 
Opposite to my hypothesis that redox activation of NF-κB would lead to increased 
production of cytokines in the human hippocampal cells, no inflammatory proteins 
were detected in the cellular supernatant as measured by a 25-plex panel. There is a 
number of reasons for these observations. First of all, although NF-κB activation is 
mainly associated with promulgation of pro-inflammatory cascades, it is also known 
to regulate transcription of a variety of genes differentially affecting proliferation, 
maturation, and survival hugely depending on cell type, localization, conditions and 
stimulus applied (Koo et al., 2010; Morgan and Liu, 2011b). Once NF-κB is 
triggered, it is not clear to what extent it needs to be activated in terms of duration and 
degree of the effect to initiate an inflammatory response. Therefore, there is a 
possibility that in my experiments the activation of NF-κB was a transit event in 
response to the acute oxidative stimulus that did not lead to an immune reaction. 
Finally, given the immunosuppressive capacity of Nrf2, it is possible that in the 
human hippocampal progenitor cells challenged with OS, Nrf2 inhibited the 
production of cytokines via clearing up ROS and also by directly blocking gene 
transcription.  
While both increased OS and inflammatory biomarkers are frequently reported in 
depressed patients, it is still not clear what the initial event that triggers the 
downstream cascades is, and complex interactions between redox and inflammatory 
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systems are not fully elucidated. It has been hypothesised that OS is a key determinant 
of neuroinflammatory response, potentially critical to emotional wellbeing, as 
enhanced inflammation also leads to an increased ROS production (Salim, 2016). 
Considering that MDD has been associated with increased OS and activation of 
inflammatory pathways, studies that identify Nrf2 as the upstream regulator of 
antioxidant defences and cytokine production provide a molecular basis for an Nrf2-
mediated antioxidative and anti-inflammatory approach. 
 
 
4.4.2   Kynurenine pathway 
In this thesis I investigated if the oxidative challenge of the human hippocampal cells leads to 
perturbations in the kynurenine pathway. Quinolinic acid (QUINA), 3-hydroxyanthranilic 
acid (3-HANA), kynurenic acid (KYNA) and 3-hydroxykynurenine (3-HK) were not 
detected in neither the supernatants collected from cells treated with 200µM, 500µM and 
1000µM of t-BHP after one hour, or after subsequent 23 hours. Kynurenine (KYN), 
tryptophan (TRP) and anthranilic acid (ANA), were detected in all samples, however no 
significant differences across conditions were observed. 
Alterations in the kynurenine pathway have been implicated in the pathogenesis of 
depression, because catabolism via kynurenine pathway may divert tryptophan from the 
serotonin synthetic route, critical for emotional well-being (Maes et al., 2011b). The 
kynurenine pathway includes metabolism of KYN to either the potentially neuroprotective 
KYNA, or to the excitotoxic free radical generator compounds 3-HANA and QUINA. It was 
proposed that an imbalance between QUINA and KYNA resulting in increased neurotoxicity  
is key in mood disorders (Maes et al., 2011a; Savitz et al., 2015). Increased levels of 3-
HANA and QUINA, together with IDO, have been associated with MDD (Gabbay et al., 
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2010; Young et al., 2016). Nor KYNA, neither 3-HANA or QUINA have been detected in 
my samples, whilst ANA was present in all samples, suggesting that in my experiments 
kynurenine pathway went towards ANA, which was reported to have both pro-oxidant and 
scavenging as well as anti-inflammatory properties upon interaction with copper (Gaubert et 
al., 2000; Ocampo et al., 2014). 
Importantly, the kynurenine pathway is known to be affected by inflammation and OS (Tan 
et al., 2012; Lovelace et al., 2016). The pathway converts the serotonin precursor tryptophan 
to kynurenine, catalysed by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-
dioxygenase (TDO), potentially leading to less serotonin, a principal neurotransmitter in 
mood regulation (Myint et al., 2007). It has been identified that shifting the tryptophan 
metabolism towards kynurenine is mainly due to increased IDO activity that is triggered by 
pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-2 and IL-1β (Zunszain et al., 2012a), 
and also directly by ROS (M Maes et al., 2011b). Interestingly, tryptophan and kynurenine 
have been reported to possess scavenging properties and can be considered as potential 
antioxidants (Ocampo et al., 2014). Therefore, another possibility is that the tryptophan and 
kynurenine present in my samples counteracted the effect of t-BHP on the pathway 
activation.  
Both neuroprotective and neurotoxic properties of metabolites of the kynurenine pathway 
have been investigated in regards to the pathogenesis of MDD. Due to the dual effects of 
these metabolites and the high degree of modulation of the pathway by inflammatory 
cytokines, metals, pH and the redox environment, it is challenging to establish a precise 
mechanism by which cellular alterations can be produced. In particular, as OS and 
inflammation are intimately linked with each other in the pathophysiology of depression, 
studying the effects of both together, as happens in vivo, would be of interest.  
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4.5   Investigating the antioxidative properties of antidepressants and 
omega-3 fatty acids 
 
4.5.1   NAC and GSH, but not antidepressants exhibited antioxidative properties 
In this thesis I tested sertraline, venlafaxine and ketamine for their antioxidative 
properties in the human hippocampal progenitor cells treated with the doses of t-BHP 
that significantly reduced cell viability. I also validated the model by testing the 
antioxidants NAC and GSH, both of which exerted antioxidative characteristics and 
prevented the decrease in cell viability inflicted by the oxidative damage.  
Pre-treatment of the cells with 1mM or 10mM of NAC did not have a significant 
preventing effect on cell viability when compared to the cells treated with 100µM and 
500µM of t-BHP only. However, pre-treatment of the cells for 1 hour followed by co-
treatment with a higher dose of NAC, 100mM, and either 100µM or 500µM of t-BHP 
caused a reduction in cell viability to 85% and 76% respectively, being significantly 
different from the conditions where cells were treated with peroxide only, when cell 
viability was reduced to 52% at 100µM and 37% at 500µM. In this experimental 
paradigm sertraline, venlafaxine and ketamine did not prevent the decrease in cell 
viability caused by t-BHP.  
Following these results, I decided to increase the pre-treatment duration with all 
compounds under investigation to 24 hours and also to use cell permeable GSH 
instead of NAC, hypothesizing that GSH might be antioxidative at lower doses than 
its precursor. Cells were pre-treated for 24 hours with 1mM and 10mM of GSH, 
followed by 1 hour co-treatment with either 100µM or 500µM of t-BHP. In this 
situation 1mM and 10mM of GSH plus 100µM of t-BHP caused reductions in cell 
viability to 98% and 91% which presented a significant difference when compared to 
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the cells treated with 100µM of t-BHP only, reaching 75%. In the same experiment 
1mM and 10mM of GSH co-treated with 500µM of t-BHP caused changes in cell 
viability to 76% and 73%, which was also significantly different when compared to 
the cells treated with 500µM of t-BHP only reaching 46%. Sertraline, venlafaxine and 
ketamine again did not demonstrate the ability to prevent the decrease in cell viability 
caused by oxidative damage. 
The decision on testing antidepressants for their antioxidative properties in my model 
was prompted by numerous reports in the literature on the ability of these compounds 
to reduce OS in depressed patients or in animal models of depression. The molecular 
mechanisms of their antioxidant effects remain elusive, and I wished to generate 
insights on this phenomenon. To my knowledge, there are no previous studies 
investigating the antioxidative effects of sertraline, venlafaxine and ketamine in 
human brain cells. My in vitro model is especially useful for addressing these 
molecular mechanisms, because it eliminates a huge number of confounding factors 
present in in vivo models. A likely explanation of my negative findings on the ability 
of antidepressants to prevent the reduction in cell viability inflicted by the oxidative 
damage is that sertraline, venlafaxine and ketamine do not possess direct scavenging 
characteristics or affect pathways that are primarily involved in the antioxidant 
defence. Nevertheless, these antidepressants have been demonstrated to positively 
modulate OS biomarkers in vivo, and it is most probable that their effect is mediated 
through indirect mechanisms influencing other factors, such as the immune response. 
For example, venlafaxine was shown to reduce NF-κB and IL-6 protein secretion 
induced by IL-1β in the human hippocampal progenitor cells (Horowitz et al., 2015) 
utilised in this thesis. Possibly, antioxidative effect of venlafaxine in vivo could be 
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mediated through downregulation of NF-κB and proinflammatory cytokines that in 
turn determine the oxidative state. 
 
 
4.5.2   EPA, but not DHA, protected cells from oxidative damage  
Among all the compounds I investigated implementing 24 hours of pre-treatment 
(sertraline, venlafaxine, ketamine, EPA and DHA) only EPA exhibited antioxidative 
properties, by completely preventing the reduction in hippocampal cell viability 
caused by 100µM of t-BHP. No effect of EPA on viability of cells treated with 
500µM of t-BHP was observed, most likely because the oxidative damage was too 
severe.  
My findings are consistent with a number of in vivo and in vitro studies that have 
demonstrated antioxidant effects of omega-3 fatty acids (Giordano and Visioli, 2014). 
Positive effects of omega-3 fatty acids on systemic OS have been shown in various 
pathological conditions, including depression in humans and animals (Castillo et al., 
2014; Guermouche et al., 2014). However, there is widespread concern that intakes of 
long chain omega-3 fatty acids might increase circulating concentrations of 
lipoperoxides, potentially interfering with the immune system. Indeed, the 
oxidizability of the omega-3 fatty acids and DHA and EPA in particular (at least in 
vitro) is very high, due to their high number of double bonds (Halliwell and 
Gutteridge, 2015). Nevertheless, no evidence was found for pro-oxidant effects of 
omega-3 fatty acids on lipid peroxidation by a comprehensive review that summarised 
in vivo findings on the levels of F2-isoprostanes in patients receiving fish oil 
supplements (Mori, 2013). Consequently, it has been suggested that high doses of 
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omega-3 fatty acids might trigger OS, whereas lower doses could exert antioxidant 
activities (Guillot et al., 2009).  
A number of in vivo and in vitro studies that have demonstrated antioxidant effects of 
PUFAs proposed molecular mechanisms underlying its antioxidant activities, such as 
Nrf2 activation and NADPH oxidases inhibition (Giordano and Visioli, 2014; 
Kusunoki et al., 2013; Liu et al., 2014; Richard et al., 2008; Zhang et al., 2014). 
Contrary to my expectations based on reported antioxidative properties of DHA in 
vitro, in my model it did not prevent the oxidative cell damage. In particular, DHA 
activated Nrf2 and its downstream genes, protecting mouse neural progenitor cells 
from the oxidative injury induced by H2O2 (Liu et al., 2014). In endothelial cells, 
DHA was shown to inhibit one of the NADPH oxidases and hence decreased ROS 
production (Richard et al., 2009). The actions of different compounds hugely depend 
on their concentration, the experimental paradigm and the cell type. Interestingly, a 
combination of both DHA and EPA showed neuroprotective effects in mice neurons 
tested in a similar in vitro experimental paradigm as the one in this thesis. Following 
the initial observation that the fatty acids attenuated ischemic neuronal injury in mice 
via Nrf2 and heme oxygenase-1 (HO-1) activation, an in vitro experiment was set up 
where cortical neurons were pretreated with 10µM, 20µM, 40µM and 100µM of EPA 
or DHA for 24 hours, and then subjected to oxygen glucose deprivation for 1 hour to 
mimic in vitro ischemia. Cells were returned to normal culture media supplied with 
the same concentration of DHA or EPA for the following 24 hours. Both DHA and 
EPA reduced the percentage of dead neurons and the level of lactate 
dehydrogenase (LDH), an enzyme that is released when cells loose membrane 
integrity, in a dose-dependent manner between 10µM and 100µM, with the highest 
pronounced effect at 20µM, indicating a neuroprotective effect (Zhang et al., 2014). 
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Results suggest an optimal dose for the protective effects, which may not have been 
the one used for DHA in my experiments. Nevertheless, in my experiments EPA 
prevented the reduction in cell viability induced by t-BHP, which is in line with other 
in vitro data examining the antioxidative properties of this fatty acid (Sakata et al., 
2013). Similarly, EPA-enriched phospholipids exhibited neuroprotective effects 
against H2O2 or t-BHP-induced cytotoxicity in PC12 cells, as measured by MTS and 
LDH assays (Wu et al., 2014). Interestingly, it was demonstrated recently that MDD 
responds to EPA or EPA + DHA treatments, differentially or synergistically, being 
most effective with higher doses of EPA combined with lower doses of DHA (Song et 
al., 2016). Also, it was identified that chronic or severe MDD cognitive decline is 
associated with lower EPA but not DHA concentrations in erythrocyte membranes 
(Chiu et al., 2012). Moreover, findings coming from animal studies suggest that low 
levels of EPA compared to DHA in brain phospholipids may be the result of EPA 
rapid β-oxidation, that occurs quicker than DHA upon uptake by the brain (Chen et 
al., 2009). Thus, it is plausible that the brain requirement for EPA is higher than for 
DHA, as EPA gets oxidised more when the level of OS increases in pathological 
conditions, such as MDD.  
My results support the notion of EPA possessing cytoprotective characteristics against 
oxidative damage, which contributes to the pathophysiology of MDD and it is 
particularly pertinent in light of recent meta-analyses emphasising the importance of 
EPA over DHA in the antidepressant efficacy of fish oil preparations (Lin et al., 2010; 




4.6   Modulation of gene expression by EPA and GSH 
Following the results where EPA was shown to be cytoprotective against oxidative 
damage in my model, I wished to investigate some underlying molecular mechanisms 
of its effect. I hypothesized that the antioxidative properties of EPA could be 
mediated by antioxidative gene regulation. Thus, using the same experimental design 
as in assessing the capacity of compounds to prevent the reduction in cell viability 
induced by t-BHP, I tested the effect of t-BHP on its own, as well as that of EPA and 
GSH in the presence of the oxidative insult, on the regulation of the following genes: 
NQO1, SLC1A1, HMOX1, SLC7A11, GCLM, Keap1. I decided to test EPA and GSH 
in the presence of oxidative stimulus but not on their own, because I wanted to find 
out whether these drugs are capable of regulating these genes in the presence of 
oxidative stimulus, since I am interested if MDD patients who have an increased 
oxidative status and may benefit from the compounds under investigation. 
Considering that 500µM of t-BHP caused a dramatic decrease in cell viability (46%) 
and EPA was not effective at this dose of t-BHP, I chose to use 100µM of t-BHP for 
all gene expression experiments. 
 
 
4.6.1   Keap1 and HMOX1 
Treatment of the cells with t-BHP only, or EPA and GSH in the presence of t-BHP, 
led to downregulation of Keap1: t-BHP only of -20%, t-BHP plus EPA of -35% and t-
BHP plus GSH of -47%. Keap1 is the gene that codes for the protein that anchors 
Nrf2 to cytoplasm and thus keeps it inactivated (Figure 47). Downregulation of 
Keap1 by t-BHP is consistent with my results indicating increased levels of nuclear 
Nrf2 translocation upon 100µM of t-BHP treatment (section 3.4.1). Interestingly, 
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although EPA and GSH would potentially reduce OS due to their scavenging 
capacity, these molecules also promote an antioxidant defence by downregulating 
Keap1, which subsequently causes higher levels of Nrf2 being liberated from the 
cytoplasm and translocated to the nucleus, where it can initiate transcription of the 
antioxidative genes. It is plausible that both EPA and GSH positively modulate Nrf2 
activation by downregulating Keap1. In line with data obtained in this thesis, it was 
shown in brain endothelial cells challenged with hydrogen peroxide that GSH not 
only prevents cellular oxidative damage, but also increases the basal level of Nrf2 
proteins and upregulates Nrf2 protein levels decreased by H2O2 treatment (Song et al., 
2014). EPA as well as DHA have been previously demonstrated to upregulate the 
levels of Nrf2 in rats and in rat primary cortical neuron cultures (Zhang et al., 2014). 
However, to my knowledge, this is the first study showing in human hippocampal 
progenitor cells the ability of EPA and GSH to downregulate Keap1, potentially 





Figure 47. Release model of regulation of the Keap1–Nrf2 pathway. Dimeric 
Keap1 sequesters Nrf2 in the cytoplasm by binding to the actin cytoskeleton. Inducers 
react with specific cysteine residues in Keap1, leading to release of Nrf2, allowing the 
transcription factor to translocate to the nucleus and turn on the expression of 
cytoprotective genes (Baird and Dinkova-Kostova, 2011). 
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Treatment of the hippocampal cells with t-BHP upregulated HMOX1 gene by +62% 
and upon co-treatment with t-BHP plus EPA by +92%. HMOX1 is a downstream Nrf2 
gene, which is highly responsive to oxidative stimulus and codes for the enzyme 
heme oxygenase 1 (HO-1). HO-1 catalyzes the degradation of protein-unbound heme, 
that accelerates the production of ROS. HO-1 is one of the key players in the 
oxidative defence mechanism, and plays a fundamental role against the free heme 
mediated oxidative process (Morimatsu et al., 2012). While in my experiments EPA 
in the presence of t-BHP upregulated HMOX1 with a stronger signal, surprisingly, no 
difference for this gene expression was observed with GSH in the presence of t-BHP. 
In this case, since GSH is a strong free radical scavenger, it is possible that its 
addition to the cells attenuated levels of OS that induced the upregulation of HMOX1 
in other conditions. These results are in line with other studies that addressed the 
antioxidative mechanisms of fish oils. It was demonstrated in mice and in vitro that 
omega-3 PUFAs diminished ischemic neuronal injury by Nrf2 and HO-1 activation 
through generation of 4-HNE (Zhang et al., 2014). Furthermore, in adipocytes the 
supplementation with omega-3 PUFAs also led to activation of Nrf-2 and HO-1 
expression (Kusunoki et al., 2013).  
 
 
4.6.2   NQO1 and GCLM  
Data obtained in this thesis indicated no significant difference in the expression of 
NQO1 and GCLM genes across all experimental conditions. NQO1 gene codes for the 
redox-regulated flavoenzyme NADPH:quinone oxidoreductase 1 (NQO1), protecting 
against OS induced by detoxifying quinine derivatives. NQO1 functions as a two 
electron donor providing a substrate that competes with the formation of ROS. GCLM 
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gene codes for the glutamate cysteine ligase modifier (GCLM) subunit of the rate-
limiting protein of the GSH synthesis glutamate cysteine ligase (GCL). The GCL 
subunits are often coordinately induced in response to OS, hormones and growth 
factors, but distinct transcriptional and post-transcriptional mechanisms mediate their 
differential rates and levels of induction (Franklin et al., 2009). Out of two subunits I 
chose to measure GCLM, because it was demonstrated to be a limiting enzyme for 
GCL enzyme formation in most cell types and tissues (Chen et al., 2005; Lee et al., 
2006), and therefore an increased expression of GCLM alone is likely to be an 
effective mechanism for enhancing cellular GCL activity. Importantly, while neither 
NQO1 (Pae et al., 2007) nor GCLM (Berk et al., 2011) polymorphisms appear to be 
related to a susceptibility to depression, they appear to be associated with the response 
to antidepressant drugs (Mendez-David et al., 2015). Both NQO1 and GCLM genes 
are downstream targets of Nrf2, and have been also reported to be regulated by other 
transcription factors, including NF-κB (Lu, 2013). Perhaps in my experiments no 
induction of NQO1 and GCLM genes has been observed due to regulation of these 
genes by other than Nrf2 pathways influencing its expression. Furthermore, 
epigenetic modifications (heritable alterations in gene expression that occur without 
changes in the primary DNA sequence) have been reported to be profoundly involved 
in OS responses. ROS can cause serious DNA lesions and lead to mutagenesis. In 
addition, many Nrf2-activating compounds have been identified as epigenetic 
modulators, and the expression of several Nrf2-target genes has been found to be 
regulated epigenetically. Circumstantial evidence suggests that different epigenetic 
layers may be engaged in complex crosstalk to establish and maintain different 
chromatin states. Keap1 and Nrf2 expression could be regulated by methylation/ 
demethylation of CpGs in the promoter regions, acetylation/deacetylation and 
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methylation/demethylation of histones, or targeting of mRNAs by miRNAs. 
Moreover, the above-mentioned epigenetic modifications may not function alone, but 
they may be linked to each other and work in combination to regulate gene 
transcription (Guo et al., 2015). Finally, target genes can be also epigenetically 
modified. For example, it was demonstrated in vitro that hypermethylation of the CpG 
DNA island of the NQO1 gene leads to its downregulated transcription (Tada et al., 
2005). Another possible explanation of my findings is that the time point (1 hour after 
OS insult followed by 23 hours of incubation in fresh media) was not representative 
of upregulation of NQO1 and GCLM expression and an increase in gene expression 
occurred within 23 hours of incubation in fresh media. 
  
 
4.6.3   Modulation of system xc− and glutamate transport by the compounds 
under investigation via gene expression  
In my experiments t-BHP treatment of the human hippocampal progenitor cells 
caused a downregulation of SLC7A11 gene of -25%, whereas EPA in the presence of 
t-BHP prevented the downregulation of this gene caused by oxidative injury and 
upregulated it by +38% when compared with the peroxide treatment. In contrast, GSH 
did not demonstrate similar effects to EPA and downnregulated this gene even 
further, for -42% from the vehicle condition. Treatment with the peroxide alone, or 
with EPA in the presence of the oxidative stimulus, did not cause significant changes 
in SLC1A1 expression. Surprisingly, GSH plus t-BHP led to a downregulation of 
SLC1A1 gene of -35% when compared with vehicle. 
SLC7A11 gene codes for the determinant xCT subunit of the cystine/glutamate 
exchange system (system xc−), which is the main provider of cysteine for GSH 
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synthesis. System xc− plays a pivotal role in redox homeostasis as well as neuronal 
signalling by regulating the glutathione production which occurs via the exchange of 
intracellular glutamate with extracellular cystine at a 1:1 molar ratio. Dysregulation of 
GSH homeostasis and alterations in glutamate neurotransmission have been vastly 
implicated in the pathophysiology of MDD (Duffy et al., 2015; Lewerenz and Maher, 
2015). It was postulated that any perturbation in the system xc− system function may 
contribute, directly or indirectly, to the pathophysiology of a variety of CNS disorders 
including depression, making it a promising target for treating CNS disorders (Patel et 
al., 2015). Therefore, I wished to investigate how SLC7A11 gene expression is 
regulated in the human hippocampal cells by oxidative stimulus and potentially 
modulated by the antioxidative EPA and GSH. Generally, the xCT subunit can be 
induced by OS in both an Nrf2-dependent or -independent manner. Contrary to my 
expectations, SLC7A11 was downregulated by t-BHP treatment, presumably due to 
excessive release of glutamate into the extracellular space as a result of increased cell 
death inflicted by oxidative damage. Indeed, many in vitro studies demonstrated 
inhibition of system the xc− by glutamate concentrations greater than 20µM (Kritis et 
al., 2015). Also, xCT has been recently reported to be regulated by the activating 
transcription factor 4 (ATF4) and Nrf1 and the effect of t-BHP treatment on its 
activity is unclear (Massie et al., 2015). EPA, however, reversed the oxidative 
SLC7A11 downregulation, demonstrating another important determinant of its 
antioxidative effects.  
Interestingly, GSH downregulated SLC7A11 and the biological rational for this would 
be a self-regulation of the system via a negative feedback loop. Specifically, 
exogenously added GSH can inhibit SLC7A11 in order not to recruit more cystine for 
more GSH synthesis, since it may be already present in abundance. In line with this 
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notion GSH downregulated SLC1A1, the gene that codes for the EAAT3 transporter, 
whose main function is to regulate the extracellular glutamate concentration and 
maintain its concentration at low physiological levels to avoid toxic effects 
(Krzyżanowska et al., 2014). At excitotoxic concentrations, glutamate triggers the rise 
of intracellular Ca2+ levels, followed by upregulation of ROS production, dysfunction 
of mitochondria, and release of lysosomal enzymes, eventually leading to neuronal 
oxytosis (Tan, 2001). As such, glutamate accumulation also inhibits system xc− and 
depletes neurons of glutathione’s reducing potential, leading to free radical 
accumulation (Kritis et al., 2015). Thus, after release into the synaptic cleft in 
exchange for cystine, glutamate is rapidly removed through EAATs into glial cells 
and neurons. So, GSH inhibited the system xc− and potentially shifted the homeostasis 
towards less cystine being imported into the cell and concomitant decrease in 
extracellular glutamate release. These perturbations, in turn, required the adjustment 
of the rate of the glutamate clearance, which was decreased by downregulation of 
SLC1A1. This idea is supported by in vivo research in xCT knock-out mice, which 
exhibited a strong decrease in extracellular glutamate levels (De Bundel et al., 2011). 
Interestingly, a recent animal study indicated anxiolytic and antidepressant-like 
effects in system xc− deficient mice, suggesting that under physiological conditions 
glutamate release via xc− system mediates aspects of higher brain function related to 
mood regulation (Bentea et al., 2015). Data obtained in this thesis provide further 
evidence for system xc−  being responsive to changes in redox environment, possibly 
tightly regulating the balance between GSH synthesis and glutamate release, both 
implicated in the pathogenesis of MDD.  
 
 254 
4.6.4   Summary on gene expression modulation by EPA and GSH 
In this thesis I have demonstrated that EPA and GSH exert antioxidative properties in 
the presence of an oxidative injury via differentially regulating the expression of 
genes involved in an OS response. In particular, both EPA and GSH amplified the 
Keap1 gene downregulation that was inhibited by t-BHP, potentially leading to an 
increase in Nrf2 activation. EPA also upregulated HMOX1 and reversed the t-BHP–
induced downregulation of SLC7A11, suggesting that its antioxidative properties 
extend beyond being a mechanistic target for oxidation. 
Additionally, I provided evidence that GSH regulates the xc− system by 
downregulating SLC7A11 gene, potentially leading to a reduction of excessive 
extracellular glutamate, that is involved in almost every aspect of physiological brain 
functioning, including the control of emotion which has been implicated in the 
pathogenesis of MDD. Furthermore, GSH downregulated SLC1A1, possibly 
promoting a settling to equilibrium between extracellular glutamate and GSH 
synthesis de novo. 
Overall, data obtained in this thesis on the effects of EPA and GSH on gene 
expression considerably contribute to the existing knowledge on their cytoprotective 
properties. The present study also emphasises the role of system xc− and its redox 





4.7   Methodological considerations 
The findings obtained in this thesis have a number of possible limitations, regarding 
the cell and induced OS model that should be considered when interpreting the data.   
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4.7.1   The use of an in vitro system 
I have used a conditionally immortalised human embryonic hippocampal progenitor 
cell line to model exogenously-induced OS and to examine the effects of redox shifts 
on cell viability, neurogenesis, regulation of transcription factors and downstream 
molecular cascades, as well as the capability of various antidepressant compounds to 
prevent the inflicted oxidative damage.  
As with all in vitro models, the main limitation of the study lies in the challenge to 
extrapolate findings from cells to the whole organism. Isolated cells in culture are not 
embedded in their natural environment, therefore such a system necessarily provides a 
simplistic representation of the whole organism. Hence, data obtained from in vitro 
studies must be interpreted with caution in order not to draw erroneous conclusions 
about the more complex, entire organism. However, the cells used in the present study 
represent one of the only means to investigate the processes relevant to the 
pathogenesis of depression and the effects of antidepressant compounds in human 
brain cells, and, in particular, hippocampal progenitor cells that are capable of 
neurogenesis with pertinent relevance to depression. Furthermore, the simplicity of in 
vitro systems also has advantages, as it allows the targeted examination of specific 
molecular mechanisms such as redox-induced activation of transcription factors, 
without confounding influences which cannot be eliminated in vivo, but simply 
omitted in a cell culture system.  
Previously, studies that have looked at biomarkers of OS in depression and effects of 
antidepressants, antioxidants and fish oils on the oxidative status were mainly 
conducted in animal models of depression and in the peripheral samples from 
humans. In vitro studies that have researched similar parameters were performed in 
cellular models obtained from rodents. These approaches have been instructive, but 
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there are difficulties translating effects found in rodents (either in vivo or in vitro 
models) to humans, due to the possibility of species-specific effects. Findings from 
peripheral human samples are also difficult to extrapolate to the CNS, given that 
human neural cells might not be directly similarly affected. In contrast, the present 
model allows the investigation of molecular mechanisms potentially associated with 
MDD directly on human neural cells coming from the hippocampus - a brain area 
known to be affected in depression. What is more, this approach enables the 
comparison with findings in animal brains and peripheral human samples, providing a 
complementary set of observations.  
Previous findings from this cell model have been replicated in human samples, and 
conversely, effects thought to occur in depressed subjects have been recapitulated in 
this cell model, suggesting that the model possesses translational relevance and may 
be a useful system for generating insights into some molecular mechanisms of 
depression. For example, our laboratory had identified that antidepressants upregulate 
the pro-neurogenic gene p11 (Anacker et al., 2011) and this finding was then 
replicated in peripheral blood mRNA of depressed patients before and after eight 
weeks of treatment with antidepressants (Cattaneo et al., 2013). Additionally, it was 
also demonstrated that IL-1β (Zunszain et al., 2012a) and dexamethasone (Anacker et 
al., 2011) (both considered depressogenic insults) decrease neurogenesis in the 
present cell model. Furthermore, dexamethasone treatment of these cells demonstrate 
epigenetic and gene expression changes in the stress-regulated gene FKBP5, that are 
identical to those identified in peripheral blood mRNA of patients who have 
experienced childhood maltreatment, known to be a major risk factor for depression 
(Klengel et al., 2013).  
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Thus, this in vitro model offers means to investigate molecular processes pertinent to 
depression that could potentially be translated in an in vivo studies with species-
specific relevance and without the need for animals. Reduced usage of animals is an 
ethical imperative in the research community and therefore performing screening of 
various compounds for specific qualities which often requires a lot of modifications 
and steps is more appropriate in a cell culture. While it is difficult to be certain how 
readily translatable the findings in hippocampal progenitor cells are to processes in 
the human brain, studies continue to emphasise their importance in memory processes 
and other functions (Kropff et al., 2015). 
 
 
4.7.2   Cell type 
4.7.2.1   c-Myc construct is a potential confounder of the cellular model 
Another methodological consideration is the cell type used in the present study. 
Firstly, the human hippocampal progenitor cell line employed is of foetal origin and 
as such likely retains youthful molecular and epigenetic signatures (Horvath, 2013), 
presenting another challenge in extrapolating findings into adult humans, though cells 
express the same markers as adult hippocampal progenitor cells, and they also have 
the same potential to proliferate and to differentiate into neurons, astrocytes and 
oligodendrocytes. Secondly, these cells are transduced with the c-myc-ERTM gene 
construct (Johansson et al., 2008; Pollock et al., 2006), which could be a potential 
confounder of the model. This transgene generates a fusion protein that stimulates cell 
proliferation in the presence of the synthetic drug 4-hydroxy-tamoxifen (4-OHT). 
Removal of 4-OHT (and the growth factors EGF and FGF) induces differentiation of 
the hippocampal progenitors into neurons, astrocytes and oligodendrocytes. c-myc is 
 258 
a highly conserved transcriptional regulatory protein linked to developmental 
processes and functions as a proto-oncogene in a wide variety of cancers, and its 
increased expression strongly promotes cell proliferation (Dang et al., 1999). With 
respect to hippocampal neurogenesis, c-myc is expressed in both the adult dentate 
gyrus and in cultured adult mouse hippocampal progenitor cells, and is thought to 
maintain the adult neuronal progenitor cell state. Indeed, c-myc expression is 
downregulated upon differentiation, and consistent with this, knockdown of c-myc 
enhances differentiation, whereas overexpression leads to inhibition of differentiation 
(Denli, 2015). As such, the utilisation of the transgene technology to manipulate its 
activity enables the recapitulation of key molecular events that regulate adult 
hippocampal neurogenesis in vitro. However, c-myc has been estimated to directly 
regulate 15-20% of all genes, including those that play a role in cell cycle, cellular 
growth and proliferation, differentiation and stem cell maintenance, apoptosis, 
metabolism, ribosome biogenesis leading to elevated protein synthesis, glycolytic 
activity and oxidative phosphorylation leading to increased energy production and 
increased level of ROS (Dang, 2012). Importantly, while the overexpression of c-myc 
has been reported to elevate levels of ROS with concomitant increases in DNA 
damage (Vafa et al., 2002), a recent study using mice haplo insufficient for c-myc, 
where its expression was reduced by 50%, reported the same levels of OS markers as 
in their wild-type aged counterparts (Hofmann et al., 2015), suggesting that c-myc 
influence on the level of ROS is minimal. Notably, c-myc may also impact upon the 
immune responses owing to its direct regulation of cytokine expression (Eilers and 
Eisenman, 2008), however in my experiments cytokines were not detected, neither in 
vehicle conditions, nor in those treated with t-BHP. 
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Together, studies demonstrate that c-myc activity has a significant impact on the 
physiological cellular molecular events. As such, the utilisation of the c-myc-ERTM 
construct in the present study may have confounded some of the molecular measures 
undertaken, such as activation of transcription factors and gene expression. Despite 
this, the major part of this thesis was devoted to investigation of the effects of redox 
shifts in neurogenesis (section 4.3) and the changes assessed in these experiments 
occurred during the differentiation phase, in the absence of 4-OHT, thus limiting the 
influence of exogenous activation of c-myc on the pathways explored.  
 
 
4.7.2.2   Immune responses in this cellular model 
OS has been shown to trigger inflammation in vivo and there are a lot of potential 
mechanisms by which OS might cause inflammation, as discussed in the introduction 
of this thesis (section 1.2.6.) Conventionally, hippocampal progenitor cells have been 
generally considered to be affected by inflammation rather than to produce 
inflammatory molecules. However, they are known to respond to and produce 
inflammatory signalling (Horowitz et al., 2015; Johansson et al., 2008; Kokaia et al., 
2012; Zunszain et al., 2012a). With respect to immune responses in the brain, glia and 
in particular microglia have been regarded as the most relevant cell type to 
investigate. Microglia are known to show pronounced phenotypic changes in response 
to inflammatory stimuli and to produce inflammatory mediators (Nayak et al., 2014). 
Additionally, it has been assumed that antidepressants are immunomodulatory largely 
because of their effects on microglia (Lu et al., 2010; Tynan and Weidenhofer, 2012). 
However, our lab also demonstrated that monoaminergic antidepressants and omega-3 
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PUFAs are immunomodulatory directly to hippocampal progenitor cells, extending 
the scope of cells in which antidepressants can regulate immune processes (Horowitz 
et al., 2015).  
In this study I have shown that hippocampal progenitor cells do not respond to 
exogenously induced OS by producing pro- or anti-inflammatory cytokines, 
independently of the OS level being applied. It is possible that this cell line is able to 
produce immune markers only in response to a very specific stimulus, such as IL-1β 
as described above. The absence of inflammatory changes caused by OS in my model 
could also explain no differences being detected in the kynurenine pathway in cells 
subjected to oxidative insult, since both OS and inflammation are known to contribute 
to alterations of this pathway. 
 
 
4.7.3   Studying OS in vitro 
Modelling and studying OS in cell culture presents a number of challenges. Cell 
culture by itself imposes an OS to which cells adapt, changing their properties. In 
most studies, including those in this thesis, cells are cultured in hyperoxia under 
atmospheric oxygen concentrations in 1–10 mm Hg range (≈21%), whereas under 
physiological conditions in vivo brain oxygen fluctuates around 150 mm Hg (≈5%) 
(Erecińska and Silver, 2001), with O2 at around 1.3% in the regions with high cellular 
density such as the hippocampal dentate gyrus. The way to overcome this issue would 
be culturing cells in special equipment allowing to maintain appropriate O2 levels, 
which involves a chamber and a separate glove box set for performing manipulations 
with cells to avoid changing their exposure to different O2 levels. As this is an 
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expensive equipment that is not available in all laboratories (including ours), the 
majority of published in vitro studies have been carried out in standard culturing 
conditions.  
Generally, rates of ROS production increase as O2 level rises, so cells in culture are 
also likely to produce more ROS. Thus, it is recognized that cell culture can 
encourage mutations and genetic drifts, because as soon as cells are placed in culture 
they begin to adapt and become more resistant to various stimuli, with multiple 
changes in gene expression and protein levels triggered by the OS. Cellular adaptation 
to the OS of ‘culture shock’ is characterized by increased ROS production, altered 
cellular redox, inhibited cell growth, and enhanced antioxidant defences, such as 
upregulation of superoxide dismutases, GSH synthesis and downregulation of ROS-
generating enzymes (Halliwell and Gutteridge, 2015). Therefore, the metabolism of 
cells in culture is seriously perturbed and cells cultured under atmospheric 
concentrations of O2 are preconditioned to tolerate subsequent oxidative insults 
(Kumar et al., 2016). In addition, cells in culture may even further adapt to use ROS, 
e.g., for pro-proliferative or anti-death signalling purposes, in ways that might not be 
relevant in vivo (Halliwell, 2003).  
Despite the obstacles described above it must be noted that these problems are 
universal to most of the in vitro studies. However, enormous amount of valuable 
information about metabolic pathways, mechanisms involved in signal transduction, 
regulation of gene expression, cell proliferation and cell death obtained from cell 
culture research should not be underappreciated. Also, in this thesis all treatment 
conditions were always compared to vehicle condition, which existed in the same 
environment and yet demonstrate significant changes that might be relevant in vivo. 
 
 262 
4.8   Potential applications of the cellular model and future directions 
The cell line utilized in this thesis is a useful in vitro model for studying the role of 
OS in the pathogenesis of depression. It presents a convenient way for identifying 
specific molecular mechanisms involving redox shifts that could be 
pharmacologically targeted. It is also a convenient way of screening potential 
antidepressant compounds for their antioxidative properties. Therefore, following up 
the data obtained in this thesis, further expanding the exploration of the time course of 
action of oxidative insults and their effects on DNA and protein damage would be a 
good supplement to the available data. A huge number of antidepressants from 
different pharmacological classes available on the market and compounds with 
potential antidepressant, neuroprotective and antioxidative properties, such as 
minocycline and erythropoietin, could be tested and further investigated in the model 
employed in this thesis. 
To further study interactions between redox and inflammatory system, it would be 
interesting to build on the model used in this thesis to introduce more complex 
interactions and to explore the effect of exogenously-induced OS on microglial 
inflammatory profile and cytokines secretion. In addition, to the role of microglia in 
redox regulation, it also plays an important role in the immune cellular environment 
(Vilhardt et al., 2016). Following this, co-incubation of OS–activated microglia with 
the hippocampal progenitor cells could be useful. Additionally, a lot of useful 
information has been obtained from in vitro models possessing some of the properties 
of the blood-brain barrier by co-culturing endothelial cells with brain cells (Abbott et 
al., 2012; Hurst and Fritz, 1996), which could be also a possibility for studying OS in 
human hippocampal progenitor cells to investigate what metabolic relationships 
vascular and neural cell lines might have in OS conditions. Another line of research 
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could be developed by co-culturing progenitor cells with stem cells. For example, 
when co-cultured with primary cortical neurons mesenchymal stromal cells were 
found to protect neurons from damage after experimental stroke and in vitro using 
oxygen–glucose deprivation model of cerebral ischemia (Scheibe et al., 2012). 
With regards to the action of EPA, that is known to possess antidepressant properties 
and has exhibited antioxidative effects in my model, further exploration of the time 
course of action and specification of the oxidative damage it prevents (lipid, DNA and 
protein oxidative damage), as well as its ability to modulate transcription factors 
would be instructive. Additionally, EPA positively modulated system xc− that 
transports one molecule of cystine necessary for GSH synthesis into cells in exchange 
for one molecule of glutamate into the extracellular space through upregulation of the 
SLC7A11 gene. However, no effect of EPA on EAAT3, that clears up excitotoxic 
glutamate from the extracellular space, was observed. Thus, it would be instructive to 
investigate a combined effect of EPA and an EAAT3 enhancer in the presence of OS 
on the glutamate levels to test if such a combination can lead to both increased GSH 
synthesis and glutamate clearance. In contrast, GSH negatively modulated system xc−, 
potentially leading to decreased extracellular glutamate, which would be interesting to 
evaluate. Data obtained in this thesis suggest that OS-induced changes in 
neurogenesis might occur in biological systems with altered redox balance, and a 
potential ROS-dependent ERK1/2 signal transduction pathway has been identified in 
the human hippocampal progenitor cells. A next step would be testing and validating 
the EPA effects on redox-dependant pathways in animal models of depression. 
It would be a massive step forward to assess the efficacy of antidepressant drugs in 
ameliorating a signal indicative of OS in the brain in depressed versus non-depressed 
subjects using modern neuroimaging techniques, such as positron emission 
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tomography or magnetic resonance imaging. For example, GSH levels in the brain 
provide indirect information on oxidative stress of the brain. As such, in 
vivo detection of GSH from various brain regions (frontal cortex, parietal cortex, 
hippocampus and cerebellum) in bilateral hemispheres of healthy subjects and from 
bi-lateral frontal cortices in patients with mild cognitive impairment (MCI) and 
Alzheimer’s disease (AD) has been previously reported (Mandal et al., 2012). Similar 
studies could be conducted with depressed patients. 
The purpose of my whole research on the role of OS in MDD was to elucidate 
specific molecular mechanisms that could be targeted, with a longer term aim to help 
design more efficient treatments for patients who show only partial response to 
therapy or who remain treatment-resistant. To further advance this challenge, along 
with investigating the mechanisms of OS involvement in the pathogenesis of 
depression, it is crucial to find a reliable method to identify those MDD patients with 
increased redox status who might benefit from a therapy targeting pathways altered 
by increased OS. At the moment one of the major challenges in the field of redox 
biology remains an absence of a standard biomarker or reference levels for OS status 
in vivo and in vitro. This brings up a clear necessity to employ a robust OS biomarker, 
that would detect a major part of the total ongoing oxidative damage in vivo.  
Findings obtained in this thesis, proposed future research and potential implications 





Results obtained upon t-BHP 
treatment 














and its prevention 
•   Decrease in cell viability in 
a dose-dependent manner 
•   Increase in lipid 
peroxidation in a dose-
dependent manner 
•   Decrease in the number of 
cells in a dose-dependent 
manner  
•   No difference in the levels 
of CC3 expression  
•   Pre-treatment with GSH, 
NAC and EPA followed by 
co-treatment with t-BHP 
prevented decrease in cell 
viability 
•   No effect for sertraline, 
venlafaxine or DHA on 
cell viability in the 
presence of t-BHP 
•   Investigate different 
time-points and 
concentrations 
•   Add other OS damage 
assays, in particular 
DNA/RNA oxidation 
and protein carbonyl 
assays 
•   Further identify cell 
death mechanisms 
induce by t-BHP (e.g. 
cytochrome c release, 
mitochondria membrane 
potential) 
•   Measure intracellular 
GSH levels and 
GSH:GSSG ratio upon 
GSH treatment 
•   Use this model as a 
screening tool for 
antioxidative properties 






•   Increase in Nrf2 nuclear 
translocation 
•   Increase in NF-κB nuclear 
translocation 
•   Test the effects of EPA 
pre-treatment on 
expression of these 
transcription factors 
•   Identify particular 
downstream genes using 





•   No cytokines detected 
using two different 
methods (ELISA and 
Luminex platform) 
•   Test whether Nrf2 
mediates inhibition of 
proinflammatory 
cytokines independent of 
ROS elimination 
•   Co-culture human 
hippocampal progenitor 




•   No difference in 
tryptophan metabolites 
•   Co-culture human 
hippocampal progenitor 





•   Increase in ERK1/2 
phosphorylation 
•   No difference in JNK and 
p38 phosphorylation  
•   Investigate different 
time-points and 
concentrations of t-BHP 









•   Decrease in Ki-67 
expression, indicative of 
decreased proliferation  
•   Increase in Dcx and MAP2 
expression, indicative of 
increased neurogenesis 
•   Inhibition of the t-BHP–
induced ERK1/2 activation 
abrogated MAP2 but not 
Dcx increase 
•   Co-treatment with 
antidepressants and 
PUFAs to assess their 
effect on neurogenesis in 
the presence of OS 
stimulus 


















•   Decrease in SLC7A11and 
Keap1expression 
•   Increase in HMOX1 
expression 




Pre-treatment with GSH or EPA 
followed by co-treatment with 
t-BHP: 
•   EPA and GSH induced 
further decrease in 
Keap1expression 
•   EPA induced further 
increase in HMOX1 
expression 
•   EPA induced increase 
(compared with t-BHP 
treatment only), whereas 
GSH induced a further 
decrease in SLC7A11 
expression 
•   GSH, but not EPA, 
induced decrease in 
SLC1A1 expression 
•   No difference in NQO1 
and GCLM expression 
when pre-treated with GSH 
or EPA 
•   Investigate the effect of 
EPA and GSH on their 
own (without OS 
stimulus) on expression 
of the genes studied in 
this thesis  
•   Measure GSH and 
glutamate upon 
modulation of system xc− 
by EPA and GSH 
demonstrated in this 
thesis 
•   Investigate a combined 
effect of EPA and an 
EAAT3 enhancer in the 
presence of OS on the 
glutamate levels, to test 
if such a combination 
can lead to both 
increased GSH synthesis 
and glutamate clearance 
•   Measure expression of 
other OS relevant genes, 
e.g. genes coding for 
NOX isoforms, and 
study the effect of GSH 
and EPA on their 
expression in OS 
conditions 
 
Table 11. Summary of the findings obtained in this thesis, proposed future 
research and potential implications of the results.  
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4.9   Conclusion  
In this thesis, I have set up for the first time an experimental in vitro model of OS in 
human hippocampal progenitor cells, clinically-relevant to depression. In particular, I 
have established that t-BHP–induced OS caused significant reductions in cell viability 
and an increase in lipid peroxidation, indicative of oxidative damage, in a dose-
dependent manner. This model provided a platform to study potential molecular 
mechanisms thought to be involved in the pathogenesis of MDD, as well as to test the 
ability of antidepressant compounds to prevent detrimental changes caused by an 
oxidative damage. 
I have generated evidence on the influence of redox shifts on the human hippocampal 
neurogenesis, where a mild oxidative stimulus led to an increase in neuroblasts and 
mature neurons. I have also identified redox-regulated signal transduction pathways 
involved in these processes. Specifically, I have shown that blocking ERK1/2 
activation abrogated the peroxide-induced differentiation of the progenitor cells into 
mature neurons. The research community is still at the stage of acquiring knowledge 
on adult neurogenesis and my findings considerably contribute to the field and present 
a substrate for pharmacological targeting in MDD patients by regulation of redox 
imbalance in the neurogenic niches. 
I have detected OS-induced activation of the Nrf2-Keap1 pathway, which plays a 
major role in the antioxidant defence, as well as activation of the redox-sensitive 
transcription factor NF-κB, a master regulator of immune responses. Contrary to my 
expectations, NF-κB activation did not lead to the activation of inflammatory 
cascades and alterations in the kynurenine pathway, possibly due to the counteraction 
of Nrf2. Confirmation of this hypothesis by further research could provide a strong 
reason to believe that therapeutic approaches inducing the Nrf2-Keap1 pathway, 
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consequently causing an upregulation of antioxidative defences and inhibition of 
inflammatory responses, might advance existing treatment strategies for MDD. 
Finally, I have shown in this thesis for the first time that EPA, known to possess 
antidepressant properties, prevented oxidative damage in human hippocampal 
progenitors, in the same way as the conventional antioxidants NAC and GSH, 
extending findings in animals and peripheral human samples. However, sertraline, 
venlafaxine, ketamine and DHA, previously reported to modulate the oxidative status 
in several models, did not demonstrate cytoprotective properties in my model. 
Moreover, a significant step was taken towards understanding the regulation of gene 
expression underlying the antioxidative properties of EPA and GSH, which had 
common as well as differential effects. The revelation of positive modulation of genes 
involved in the OS response by EPA implies its profound influence on redox status 
and extends our understanding of reported positive effects of the compound in 
depression. These data suggest that the oxidative status may identify those patients 
who might benefit from fish oils consumption to improve depressive symptoms. 
Remarkably, GSH was identified as a negative regulator of the antioxidative system 
xc−, potentially inhibiting cystine recruitment for further GSH synthesis, which would 
result in the decrease of extracellular glutamate. Alongside, GSH downregulated 
EAAT3 expression potentially leading to decreased glutamate clearance from the 
synaptic cleft, suggestive of a tight balance between GSH synthesis and extracellular 
glutamate release, both of which have been implicated in the pathophysiology of 
depression. 
In conclusion, findings obtained in this thesis extend our current understanding of 
redox-related molecular mechanisms considered to underlie the pathophysiology of 
MDD, that could be potentially pharmacologically targeted, based on the oxidative 
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status of depressed patients. Also, this research provided further molecular evidence 
of the beneficial effects of EPA on counterbalancing OS, known to be increased in 
depressed patients, thus emphasizing that redox state is a defining factor of positive 
therapeutic response to omega-3 PUFAs supplementation in MDD. 
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